id	sid	tid	token	lemma	pos
dpc-1595	1	1	dermatology	dermatology	NOUN
dpc-1595	1	2	:	:	PUNCT
dpc-1595	1	3	practical	practical	ADJ
dpc-1595	1	4	and	and	CCONJ
dpc-1595	1	5	conceptual	conceptual	ADJ
dpc-1595	1	6	dermatology	dermatology	NOUN
dpc-1595	1	7	practical	practical	ADJ
dpc-1595	1	8	&	&	CCONJ
dpc-1595	1	9	conceptual	conceptual	ADJ
dpc-1595	1	10	research	research	NOUN
dpc-1595	1	11	|	|	ADV
dpc-1595	1	12	dermatol	dermatol	ADJ
dpc-1595	1	13	pract	pract	NOUN
dpc-1595	1	14	concept	concept	NOUN
dpc-1595	1	15	.	.	PUNCT
dpc-1595	2	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	2	2	1	1	NUM
dpc-1595	2	3	calcipotriol	calcipotriol	NOUN
dpc-1595	2	4	/	/	SYM
dpc-1595	2	5	betamethasone	betamethasone	PROPN
dpc-1595	2	6	dipropionate	dipropionate	NOUN
dpc-1595	2	7	aerosol	aerosol	NOUN
dpc-1595	2	8	foam	foam	NOUN
dpc-1595	2	9	for	for	ADP
dpc-1595	2	10	plaque	plaque	NOUN
dpc-1595	2	11	psoriasis	psoriasis	NOUN
dpc-1595	2	12	:	:	PUNCT
dpc-1595	2	13	a	a	DET
dpc-1595	2	14	prospective	prospective	ADJ
dpc-1595	2	15	,	,	PUNCT
dpc-1595	2	16	observational	observational	ADJ
dpc-1595	2	17	,	,	PUNCT
dpc-1595	2	18	non	non	ADJ
dpc-1595	2	19	-	-	ADJ
dpc-1595	2	20	interventional	interventional	ADJ
dpc-1595	2	21	,	,	PUNCT
dpc-1595	2	22	single	single	ADJ
dpc-1595	2	23	-	-	PUNCT
dpc-1595	2	24	center	center	NOUN
dpc-1595	2	25	study	study	NOUN
dpc-1595	2	26	of	of	ADP
dpc-1595	2	27	patient	patient	ADJ
dpc-1595	2	28	adherence	adherence	NOUN
dpc-1595	2	29	and	and	CCONJ
dpc-1595	2	30	satisfaction	satisfaction	NOUN
dpc-1595	2	31	in	in	ADP
dpc-1595	2	32	daily	daily	ADJ
dpc-1595	2	33	use	use	NOUN
dpc-1595	2	34	francisco	francisco	PROPN
dpc-1595	2	35	josé	josé	PROPN
dpc-1595	2	36	navarro	navarro	PROPN
dpc-1595	2	37	-	-	PUNCT
dpc-1595	2	38	triviño1	triviño1	PROPN
dpc-1595	2	39	,	,	PUNCT
dpc-1595	2	40	mario	mario	PROPN
dpc-1595	2	41	lozano	lozano	PROPN
dpc-1595	2	42	-	-	PUNCT
dpc-1595	2	43	lozano2	lozano2	PROPN
dpc-1595	2	44	,	,	PUNCT
dpc-1595	2	45	ricardo	ricardo	PROPN
dpc-1595	2	46	ruiz	ruiz	NOUN
dpc-1595	2	47	-	-	PUNCT
dpc-1595	2	48	villaverde3	villaverde3	VERB
dpc-1595	2	49	1	1	NUM
dpc-1595	2	50	department	department	NOUN
dpc-1595	2	51	of	of	ADP
dpc-1595	2	52	contact	contact	NOUN
dpc-1595	2	53	eczema	eczema	NOUN
dpc-1595	2	54	and	and	CCONJ
dpc-1595	2	55	immunoallergic	immunoallergic	ADJ
dpc-1595	2	56	diseases	disease	NOUN
dpc-1595	2	57	,	,	PUNCT
dpc-1595	2	58	hospital	hospital	NOUN
dpc-1595	2	59	universitario	universitario	NOUN
dpc-1595	2	60	san	san	PROPN
dpc-1595	2	61	cecilio	cecilio	PROPN
dpc-1595	2	62	,	,	PUNCT
dpc-1595	2	63	granada	granada	PROPN
dpc-1595	2	64	,	,	PUNCT
dpc-1595	2	65	spain	spain	PROPN
dpc-1595	2	66	2	2	NUM
dpc-1595	2	67	department	department	NOUN
dpc-1595	2	68	of	of	ADP
dpc-1595	2	69	physical	physical	ADJ
dpc-1595	2	70	therapy	therapy	NOUN
dpc-1595	2	71	,	,	PUNCT
dpc-1595	2	72	faculty	faculty	NOUN
dpc-1595	2	73	of	of	ADP
dpc-1595	2	74	health	health	NOUN
dpc-1595	2	75	sciences	science	NOUN
dpc-1595	2	76	,	,	PUNCT
dpc-1595	2	77	and	and	CCONJ
dpc-1595	2	78	university	university	NOUN
dpc-1595	2	79	of	of	ADP
dpc-1595	2	80	granada	granada	PROPN
dpc-1595	2	81	&	&	CCONJ
dpc-1595	2	82	sport	sport	PROPN
dpc-1595	2	83	and	and	CCONJ
dpc-1595	2	84	health	health	PROPN
dpc-1595	2	85	joint	joint	PROPN
dpc-1595	2	86	university	university	PROPN
dpc-1595	2	87	institute	institute	NOUN
dpc-1595	2	88	(	(	PUNCT
dpc-1595	2	89	imuds	imuds	PROPN
dpc-1595	2	90	)	)	PUNCT
dpc-1595	2	91	,	,	PUNCT
dpc-1595	2	92	granada	granada	PROPN
dpc-1595	2	93	,	,	PUNCT
dpc-1595	2	94	spain	spain	PROPN
dpc-1595	2	95	3	3	NUM
dpc-1595	2	96	department	department	NOUN
dpc-1595	2	97	of	of	ADP
dpc-1595	2	98	psoriasis	psoriasis	NOUN
dpc-1595	2	99	,	,	PUNCT
dpc-1595	2	100	dermatology	dermatology	NOUN
dpc-1595	2	101	,	,	PUNCT
dpc-1595	2	102	hospital	hospital	NOUN
dpc-1595	2	103	universitario	universitario	NOUN
dpc-1595	2	104	san	san	PROPN
dpc-1595	2	105	cecilio	cecilio	PROPN
dpc-1595	2	106	,	,	PUNCT
dpc-1595	2	107	granada	granada	PROPN
dpc-1595	2	108	,	,	PUNCT
dpc-1595	2	109	spain	spain	PROPN
dpc-1595	2	110	key	key	ADJ
dpc-1595	2	111	words	word	NOUN
dpc-1595	2	112	:	:	PUNCT
dpc-1595	2	113	adherence	adherence	NOUN
dpc-1595	2	114	,	,	PUNCT
dpc-1595	2	115	satisfaction	satisfaction	NOUN
dpc-1595	2	116	,	,	PUNCT
dpc-1595	2	117	calcipotriol	calcipotriol	PROPN
dpc-1595	2	118	/	/	SYM
dpc-1595	2	119	betamethasone	betamethasone	PROPN
dpc-1595	2	120	,	,	PUNCT
dpc-1595	2	121	aerosol	aerosol	NOUN
dpc-1595	2	122	foam	foam	NOUN
dpc-1595	2	123	,	,	PUNCT
dpc-1595	2	124	psoriasis	psoriasis	NOUN
dpc-1595	2	125	citation	citation	NOUN
dpc-1595	2	126	:	:	PUNCT
dpc-1595	2	127	navarro	navarro	PROPN
dpc-1595	2	128	-	-	PUNCT
dpc-1595	2	129	triviño	triviño	PROPN
dpc-1595	2	130	fj	fj	PROPN
dpc-1595	2	131	,	,	PUNCT
dpc-1595	2	132	lozano	lozano	PROPN
dpc-1595	2	133	-	-	PUNCT
dpc-1595	2	134	lozano	lozano	PROPN
dpc-1595	2	135	m	m	PROPN
dpc-1595	2	136	,	,	PUNCT
dpc-1595	2	137	ruiz	ruiz	NOUN
dpc-1595	2	138	-	-	PUNCT
dpc-1595	2	139	villaverde	villaverde	ADJ
dpc-1595	2	140	r.	r.	PROPN
dpc-1595	2	141	calcipotriol	calcipotriol	PROPN
dpc-1595	2	142	/	/	SYM
dpc-1595	2	143	betamethasone	betamethasone	PROPN
dpc-1595	2	144	aerosol	aerosol	NOUN
dpc-1595	2	145	foam	foam	NOUN
dpc-1595	2	146	for	for	ADP
dpc-1595	2	147	plaque	plaque	NOUN
dpc-1595	2	148	psoriasis	psoriasis	NOUN
dpc-1595	2	149	:	:	PUNCT
dpc-1595	2	150	a	a	DET
dpc-1595	2	151	prospective	prospective	ADJ
dpc-1595	2	152	,	,	PUNCT
dpc-1595	2	153	observational	observational	ADJ
dpc-1595	2	154	,	,	PUNCT
dpc-1595	2	155	non	non	ADJ
dpc-1595	2	156	-	-	ADJ
dpc-1595	2	157	interventional	interventional	ADJ
dpc-1595	2	158	,	,	PUNCT
dpc-1595	2	159	single	single	ADJ
dpc-1595	2	160	-	-	PUNCT
dpc-1595	2	161	center	center	NOUN
dpc-1595	2	162	study	study	NOUN
dpc-1595	2	163	on	on	ADP
dpc-1595	2	164	patient	patient	ADJ
dpc-1595	2	165	adherence	adherence	NOUN
dpc-1595	2	166	and	and	CCONJ
dpc-1595	2	167	satisfaction	satisfaction	NOUN
dpc-1595	2	168	in	in	ADP
dpc-1595	2	169	daily	daily	ADJ
dpc-1595	2	170	use	use	NOUN
dpc-1595	2	171	.	.	PUNCT
dpc-1595	3	1	dermatol	dermatol	NOUN
dpc-1595	3	2	pract	pract	PROPN
dpc-1595	3	3	concept	concept	NOUN
dpc-1595	3	4	.	.	PUNCT
dpc-1595	4	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	4	2	.	.	PUNCT
dpc-1595	4	3	doi	doi	PROPN
dpc-1595	4	4	:	:	PUNCT
dpc-1595	4	5	https://doi.org/10.5826/dpc.1103a56	https://doi.org/10.5826/dpc.1103a56	NOUN
dpc-1595	4	6	accepted	accept	VERB
dpc-1595	4	7	:	:	PUNCT
dpc-1595	4	8	december	december	PROPN
dpc-1595	4	9	29	29	NUM
dpc-1595	4	10	,	,	PUNCT
dpc-1595	4	11	2020	2020	NUM
dpc-1595	4	12	;	;	PUNCT
dpc-1595	4	13	published	publish	VERB
dpc-1595	4	14	:	:	PUNCT
dpc-1595	4	15	may	may	AUX
dpc-1595	4	16	20	20	NUM
dpc-1595	4	17	,	,	PUNCT
dpc-1595	4	18	2021	2021	NUM
dpc-1595	4	19	copyright	copyright	NOUN
dpc-1595	4	20	:	:	PUNCT
dpc-1595	4	21	©	©	PROPN
dpc-1595	4	22	2021	2021	NUM
dpc-1595	4	23	navarro	navarro	PROPN
dpc-1595	4	24	-	-	PUNCT
dpc-1595	4	25	triviño	triviño	NOUN
dpc-1595	4	26	et	et	PROPN
dpc-1595	4	27	al	al	PROPN
dpc-1595	4	28	.	.	PUNCT
dpc-1595	5	1	this	this	PRON
dpc-1595	5	2	is	be	AUX
dpc-1595	5	3	an	an	DET
dpc-1595	5	4	open	open	ADJ
dpc-1595	5	5	-	-	PUNCT
dpc-1595	5	6	access	access	NOUN
dpc-1595	5	7	article	article	NOUN
dpc-1595	5	8	distributed	distribute	VERB
dpc-1595	5	9	under	under	ADP
dpc-1595	5	10	the	the	DET
dpc-1595	5	11	terms	term	NOUN
dpc-1595	5	12	of	of	ADP
dpc-1595	5	13	the	the	DET
dpc-1595	5	14	creative	creative	ADJ
dpc-1595	5	15	commons	common	NOUN
dpc-1595	5	16	attribution	attribution	NOUN
dpc-1595	5	17	license	license	NOUN
dpc-1595	5	18	by	by	ADP
dpc-1595	5	19	-	-	PUNCT
dpc-1595	5	20	nc-4.0	nc-4.0	NOUN
dpc-1595	5	21	,	,	PUNCT
dpc-1595	5	22	which	which	PRON
dpc-1595	5	23	permits	permit	VERB
dpc-1595	5	24	unrestricted	unrestricted	ADJ
dpc-1595	5	25	noncommercial	noncommercial	ADJ
dpc-1595	5	26	use	use	NOUN
dpc-1595	5	27	,	,	PUNCT
dpc-1595	5	28	distribution	distribution	NOUN
dpc-1595	5	29	,	,	PUNCT
dpc-1595	5	30	and	and	CCONJ
dpc-1595	5	31	reproduction	reproduction	NOUN
dpc-1595	5	32	in	in	ADP
dpc-1595	5	33	any	any	DET
dpc-1595	5	34	medium	medium	NOUN
dpc-1595	5	35	,	,	PUNCT
dpc-1595	5	36	provided	provide	VERB
dpc-1595	5	37	the	the	DET
dpc-1595	5	38	original	original	ADJ
dpc-1595	5	39	authors	author	NOUN
dpc-1595	5	40	and	and	CCONJ
dpc-1595	5	41	source	source	NOUN
dpc-1595	5	42	are	be	AUX
dpc-1595	5	43	credited	credit	VERB
dpc-1595	5	44	.	.	PUNCT
dpc-1595	6	1	funding	funding	NOUN
dpc-1595	6	2	:	:	PUNCT
dpc-1595	6	3	this	this	DET
dpc-1595	6	4	research	research	NOUN
dpc-1595	6	5	was	be	AUX
dpc-1595	6	6	funded	fund	VERB
dpc-1595	6	7	by	by	ADP
dpc-1595	6	8	leo	leo	PROPN
dpc-1595	6	9	pharma	pharma	PROPN
dpc-1595	6	10	.	.	PUNCT
dpc-1595	7	1	competing	compete	VERB
dpc-1595	7	2	interests	interest	NOUN
dpc-1595	7	3	:	:	PUNCT
dpc-1595	7	4	the	the	DET
dpc-1595	7	5	authors	author	NOUN
dpc-1595	7	6	have	have	VERB
dpc-1595	7	7	no	no	DET
dpc-1595	7	8	conflicts	conflict	NOUN
dpc-1595	7	9	of	of	ADP
dpc-1595	7	10	interest	interest	NOUN
dpc-1595	7	11	to	to	PART
dpc-1595	7	12	disclose	disclose	VERB
dpc-1595	7	13	.	.	PUNCT
dpc-1595	8	1	authorship	authorship	NOUN
dpc-1595	8	2	:	:	PUNCT
dpc-1595	8	3	all	all	DET
dpc-1595	8	4	authors	author	NOUN
dpc-1595	8	5	have	have	AUX
dpc-1595	8	6	contributed	contribute	VERB
dpc-1595	8	7	significantly	significantly	ADV
dpc-1595	8	8	to	to	ADP
dpc-1595	8	9	this	this	DET
dpc-1595	8	10	publication	publication	NOUN
dpc-1595	8	11	.	.	PUNCT
dpc-1595	9	1	corresponding	correspond	VERB
dpc-1595	9	2	author	author	NOUN
dpc-1595	9	3	:	:	PUNCT
dpc-1595	9	4	francisco	francisco	PROPN
dpc-1595	9	5	josé	josé	PROPN
dpc-1595	9	6	navarro	navarro	PROPN
dpc-1595	9	7	-	-	PUNCT
dpc-1595	9	8	triviño	triviño	PROPN
dpc-1595	9	9	,	,	PUNCT
dpc-1595	9	10	md	md	PROPN
dpc-1595	9	11	,	,	PUNCT
dpc-1595	9	12	hospital	hospital	NOUN
dpc-1595	9	13	universitario	universitario	PROPN
dpc-1595	9	14	san	san	PROPN
dpc-1595	9	15	cecilio	cecilio	PROPN
dpc-1595	9	16	,	,	PUNCT
dpc-1595	9	17	avenida	avenida	PROPN
dpc-1595	9	18	de	de	PROPN
dpc-1595	9	19	la	la	PROPN
dpc-1595	9	20	investigación	investigación	PROPN
dpc-1595	9	21	s	s	PROPN
dpc-1595	9	22	/	/	SYM
dpc-1595	9	23	n	n	CCONJ
dpc-1595	9	24	,	,	PUNCT
dpc-1595	9	25	18016	18016	NUM
dpc-1595	9	26	granada	granada	PROPN
dpc-1595	9	27	,	,	PUNCT
dpc-1595	9	28	spain	spain	PROPN
dpc-1595	9	29	.	.	PUNCT
dpc-1595	10	1	email	email	NOUN
dpc-1595	10	2	:	:	PUNCT
dpc-1595	10	3	fntmed@gmail.com	fntmed@gmail.com	X
dpc-1595	10	4	background	background	NOUN
dpc-1595	10	5	:	:	PUNCT
dpc-1595	10	6	psoriasis	psoriasis	NOUN
dpc-1595	10	7	is	be	AUX
dpc-1595	10	8	a	a	DET
dpc-1595	10	9	chronic	chronic	ADJ
dpc-1595	10	10	inflammatory	inflammatory	ADJ
dpc-1595	10	11	disease	disease	NOUN
dpc-1595	10	12	that	that	PRON
dpc-1595	10	13	has	have	VERB
dpc-1595	10	14	a	a	DET
dpc-1595	10	15	negative	negative	ADJ
dpc-1595	10	16	impact	impact	NOUN
dpc-1595	10	17	on	on	ADP
dpc-1595	10	18	patients	patient	NOUN
dpc-1595	10	19	’	'	PUNCT
dpc-1595	10	20	quality	quality	NOUN
dpc-1595	10	21	of	of	ADP
dpc-1595	10	22	life	life	NOUN
dpc-1595	10	23	.	.	PUNCT
dpc-1595	11	1	patients	patient	NOUN
dpc-1595	11	2	with	with	ADP
dpc-1595	11	3	mild	mild	ADJ
dpc-1595	11	4	–	–	PUNCT
dpc-1595	11	5	moderate	moderate	ADJ
dpc-1595	11	6	psoriasis	psoriasis	NOUN
dpc-1595	11	7	can	can	AUX
dpc-1595	11	8	be	be	AUX
dpc-1595	11	9	treated	treat	VERB
dpc-1595	11	10	with	with	ADP
dpc-1595	11	11	topical	topical	ADJ
dpc-1595	11	12	medications	medication	NOUN
dpc-1595	11	13	,	,	PUNCT
dpc-1595	11	14	such	such	ADJ
dpc-1595	11	15	as	as	ADP
dpc-1595	11	16	the	the	DET
dpc-1595	11	17	combination	combination	NOUN
dpc-1595	11	18	drug	drug	NOUN
dpc-1595	11	19	calcipotriol	calcipotriol	PROPN
dpc-1595	11	20	/	/	SYM
dpc-1595	11	21	betamethasone	betamethasone	PROPN
dpc-1595	11	22	dipropionate	dipropionate	NOUN
dpc-1595	11	23	(	(	PUNCT
dpc-1595	11	24	cal	cal	PROPN
dpc-1595	11	25	/	/	SYM
dpc-1595	11	26	bd	bd	PROPN
dpc-1595	11	27	)	)	PUNCT
dpc-1595	11	28	.	.	PUNCT
dpc-1595	12	1	objectives	objective	NOUN
dpc-1595	12	2	:	:	PUNCT
dpc-1595	12	3	this	this	DET
dpc-1595	12	4	study	study	NOUN
dpc-1595	12	5	investigated	investigate	VERB
dpc-1595	12	6	the	the	DET
dpc-1595	12	7	adherence	adherence	NOUN
dpc-1595	12	8	of	of	ADP
dpc-1595	12	9	psoriasis	psoriasis	NOUN
dpc-1595	12	10	patients	patient	NOUN
dpc-1595	12	11	to	to	AUX
dpc-1595	12	12	therapy	therapy	NOUN
dpc-1595	12	13	with	with	ADP
dpc-1595	12	14	cal	cal	PROPN
dpc-1595	12	15	/	/	SYM
dpc-1595	12	16	bd	bd	PROPN
dpc-1595	12	17	aerosol	aerosol	NOUN
dpc-1595	12	18	foam	foam	NOUN
dpc-1595	12	19	,	,	PUNCT
dpc-1595	12	20	as	as	ADV
dpc-1595	12	21	well	well	ADV
dpc-1595	12	22	as	as	ADP
dpc-1595	12	23	their	their	PRON
dpc-1595	12	24	satisfaction	satisfaction	NOUN
dpc-1595	12	25	with	with	ADP
dpc-1595	12	26	the	the	DET
dpc-1595	12	27	treatment	treatment	NOUN
dpc-1595	12	28	’s	’s	PART
dpc-1595	12	29	efficacy	efficacy	NOUN
dpc-1595	12	30	,	,	PUNCT
dpc-1595	12	31	safety	safety	NOUN
dpc-1595	12	32	,	,	PUNCT
dpc-1595	12	33	and	and	CCONJ
dpc-1595	12	34	effect	effect	NOUN
dpc-1595	12	35	on	on	ADP
dpc-1595	12	36	their	their	PRON
dpc-1595	12	37	quality	quality	NOUN
dpc-1595	12	38	of	of	ADP
dpc-1595	12	39	life	life	NOUN
dpc-1595	12	40	.	.	PUNCT
dpc-1595	13	1	methods	method	NOUN
dpc-1595	13	2	:	:	PUNCT
dpc-1595	13	3	patients	patient	NOUN
dpc-1595	13	4	with	with	ADP
dpc-1595	13	5	mild	mild	ADJ
dpc-1595	13	6	–	–	PUNCT
dpc-1595	13	7	moderate	moderate	ADJ
dpc-1595	13	8	plaque	plaque	NOUN
dpc-1595	13	9	psoriasis	psoriasis	NOUN
dpc-1595	13	10	were	be	AUX
dpc-1595	13	11	eligible	eligible	ADJ
dpc-1595	13	12	to	to	PART
dpc-1595	13	13	participate	participate	VERB
dpc-1595	13	14	in	in	ADP
dpc-1595	13	15	this	this	DET
dpc-1595	13	16	open	open	ADJ
dpc-1595	13	17	-	-	PUNCT
dpc-1595	13	18	label	label	NOUN
dpc-1595	13	19	,	,	PUNCT
dpc-1595	13	20	non	non	ADJ
dpc-1595	13	21	-	-	ADJ
dpc-1595	13	22	placebo	placebo	NOUN
dpc-1595	13	23	controlled	control	VERB
dpc-1595	13	24	,	,	PUNCT
dpc-1595	13	25	prospective	prospective	ADJ
dpc-1595	13	26	single	single	ADJ
dpc-1595	13	27	-	-	PUNCT
dpc-1595	13	28	center	center	NOUN
dpc-1595	13	29	study	study	NOUN
dpc-1595	13	30	.	.	PUNCT
dpc-1595	14	1	adherence	adherence	NOUN
dpc-1595	14	2	to	to	ADP
dpc-1595	14	3	treatment	treatment	NOUN
dpc-1595	14	4	was	be	AUX
dpc-1595	14	5	assessed	assess	VERB
dpc-1595	14	6	using	use	VERB
dpc-1595	14	7	the	the	DET
dpc-1595	14	8	morisky	morisky	NOUN
dpc-1595	14	9	-	-	PUNCT
dpc-1595	14	10	green	green	ADJ
dpc-1595	14	11	scale	scale	NOUN
dpc-1595	14	12	4	4	NUM
dpc-1595	14	13	and	and	CCONJ
dpc-1595	14	14	12	12	NUM
dpc-1595	14	15	weeks	week	NOUN
dpc-1595	14	16	after	after	ADP
dpc-1595	14	17	the	the	DET
dpc-1595	14	18	start	start	NOUN
dpc-1595	14	19	of	of	ADP
dpc-1595	14	20	treatment	treatment	NOUN
dpc-1595	14	21	.	.	PUNCT
dpc-1595	15	1	satisfaction	satisfaction	NOUN
dpc-1595	15	2	with	with	ADP
dpc-1595	15	3	the	the	DET
dpc-1595	15	4	treatment	treatment	NOUN
dpc-1595	15	5	was	be	AUX
dpc-1595	15	6	assessed	assess	VERB
dpc-1595	15	7	using	use	VERB
dpc-1595	15	8	the	the	DET
dpc-1595	15	9	abbreviated	abbreviate	VERB
dpc-1595	15	10	treatment	treatment	NOUN
dpc-1595	15	11	satisfaction	satisfaction	NOUN
dpc-1595	15	12	questionnaire	questionnaire	NOUN
dpc-1595	15	13	for	for	ADP
dpc-1595	15	14	medication	medication	NOUN
dpc-1595	15	15	(	(	PUNCT
dpc-1595	15	16	tsqm-9	tsqm-9	PROPN
dpc-1595	15	17	)	)	PUNCT
dpc-1595	15	18	.	.	PUNCT
dpc-1595	16	1	the	the	DET
dpc-1595	16	2	severity	severity	NOUN
dpc-1595	16	3	of	of	ADP
dpc-1595	16	4	psoriasis	psoriasis	NOUN
dpc-1595	16	5	was	be	AUX
dpc-1595	16	6	assessed	assess	VERB
dpc-1595	16	7	on	on	ADP
dpc-1595	16	8	the	the	DET
dpc-1595	16	9	miga	miga	PROPN
dpc-1595	16	10	and	and	CCONJ
dpc-1595	16	11	pga	pga	PROPN
dpc-1595	16	12	scales	scale	NOUN
dpc-1595	16	13	,	,	PUNCT
dpc-1595	16	14	and	and	CCONJ
dpc-1595	16	15	the	the	DET
dpc-1595	16	16	impact	impact	NOUN
dpc-1595	16	17	on	on	ADP
dpc-1595	16	18	quality	quality	NOUN
dpc-1595	16	19	of	of	ADP
dpc-1595	16	20	life	life	NOUN
dpc-1595	16	21	was	be	AUX
dpc-1595	16	22	assessed	assess	VERB
dpc-1595	16	23	using	use	VERB
dpc-1595	16	24	the	the	DET
dpc-1595	16	25	pdi	pdi	NOUN
dpc-1595	16	26	and	and	CCONJ
dpc-1595	16	27	dlqi	dlqi	NOUN
dpc-1595	16	28	scales	scale	NOUN
dpc-1595	16	29	.	.	PUNCT
dpc-1595	17	1	results	result	NOUN
dpc-1595	17	2	:	:	PUNCT
dpc-1595	17	3	a	a	DET
dpc-1595	17	4	total	total	NOUN
dpc-1595	17	5	of	of	ADP
dpc-1595	17	6	65	65	NUM
dpc-1595	17	7	patients	patient	NOUN
dpc-1595	17	8	entered	enter	VERB
dpc-1595	17	9	the	the	DET
dpc-1595	17	10	study	study	NOUN
dpc-1595	17	11	.	.	PUNCT
dpc-1595	18	1	adherence	adherence	NOUN
dpc-1595	18	2	to	to	ADP
dpc-1595	18	3	treatment	treatment	NOUN
dpc-1595	18	4	was	be	AUX
dpc-1595	18	5	good	good	ADJ
dpc-1595	18	6	,	,	PUNCT
dpc-1595	18	7	with	with	ADP
dpc-1595	18	8	73.8	73.8	NUM
dpc-1595	18	9	%	%	NOUN
dpc-1595	18	10	of	of	ADP
dpc-1595	18	11	patients	patient	NOUN
dpc-1595	18	12	showing	show	VERB
dpc-1595	18	13	high	high	ADJ
dpc-1595	18	14	adherence	adherence	NOUN
dpc-1595	18	15	at	at	ADP
dpc-1595	18	16	12	12	NUM
dpc-1595	18	17	weeks	week	NOUN
dpc-1595	18	18	.	.	PUNCT
dpc-1595	19	1	satisfaction	satisfaction	NOUN
dpc-1595	19	2	was	be	AUX
dpc-1595	19	3	also	also	ADV
dpc-1595	19	4	good	good	ADJ
dpc-1595	19	5	,	,	PUNCT
dpc-1595	19	6	with	with	ADP
dpc-1595	19	7	46	46	NUM
dpc-1595	19	8	patients	patient	NOUN
dpc-1595	19	9	(	(	PUNCT
dpc-1595	19	10	70.8	70.8	NUM
dpc-1595	19	11	%	%	NOUN
dpc-1595	19	12	)	)	PUNCT
dpc-1595	19	13	being	be	AUX
dpc-1595	19	14	completely	completely	ADV
dpc-1595	19	15	satisfied	satisfied	ADJ
dpc-1595	19	16	.	.	PUNCT
dpc-1595	20	1	abstract	abstract	ADJ
dpc-1595	20	2	2	2	NUM
dpc-1595	20	3	research	research	NOUN
dpc-1595	20	4	|	|	ADV
dpc-1595	20	5	dermatol	dermatol	ADJ
dpc-1595	20	6	pract	pract	NOUN
dpc-1595	20	7	concept	concept	NOUN
dpc-1595	20	8	.	.	PUNCT
dpc-1595	21	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	21	2	introduction	introduction	NOUN
dpc-1595	21	3	psoriasis	psoriasis	NOUN
dpc-1595	21	4	is	be	AUX
dpc-1595	21	5	a	a	DET
dpc-1595	21	6	chronic	chronic	ADJ
dpc-1595	21	7	inflammatory	inflammatory	ADJ
dpc-1595	21	8	disease	disease	NOUN
dpc-1595	21	9	that	that	PRON
dpc-1595	21	10	affects	affect	VERB
dpc-1595	21	11	2%–4	2%–4	NUM
dpc-1595	21	12	%	%	NOUN
dpc-1595	21	13	of	of	ADP
dpc-1595	21	14	the	the	DET
dpc-1595	21	15	western	western	ADJ
dpc-1595	21	16	population	population	NOUN
dpc-1595	22	1	[	[	X
dpc-1595	22	2	1	1	NUM
dpc-1595	22	3	]	]	PUNCT
dpc-1595	22	4	.	.	PUNCT
dpc-1595	23	1	it	it	PRON
dpc-1595	23	2	is	be	AUX
dpc-1595	23	3	characterized	characterize	VERB
dpc-1595	23	4	by	by	ADP
dpc-1595	23	5	the	the	DET
dpc-1595	23	6	formation	formation	NOUN
dpc-1595	23	7	of	of	ADP
dpc-1595	23	8	well	well	ADV
dpc-1595	23	9	-	-	PUNCT
dpc-1595	23	10	defined	define	VERB
dpc-1595	23	11	erythematous	erythematous	ADJ
dpc-1595	23	12	-	-	PUNCT
dpc-1595	23	13	squamous	squamous	ADJ
dpc-1595	23	14	plaques	plaque	NOUN
dpc-1595	23	15	and	and	CCONJ
dpc-1595	23	16	a	a	DET
dpc-1595	23	17	complex	complex	ADJ
dpc-1595	23	18	immune	immune	ADJ
dpc-1595	23	19	mechanism	mechanism	NOUN
dpc-1595	23	20	[	[	X
dpc-1595	23	21	2	2	NUM
dpc-1595	23	22	]	]	PUNCT
dpc-1595	23	23	.	.	PUNCT
dpc-1595	24	1	psoriasis	psoriasis	NOUN
dpc-1595	24	2	is	be	AUX
dpc-1595	24	3	recognized	recognize	VERB
dpc-1595	24	4	by	by	ADP
dpc-1595	24	5	the	the	DET
dpc-1595	24	6	world	world	PROPN
dpc-1595	24	7	health	health	PROPN
dpc-1595	24	8	organization	organization	NOUN
dpc-1595	24	9	as	as	ADP
dpc-1595	24	10	a	a	DET
dpc-1595	24	11	debilitating	debilitating	ADJ
dpc-1595	24	12	,	,	PUNCT
dpc-1595	24	13	painful	painful	ADJ
dpc-1595	24	14	disease	disease	NOUN
dpc-1595	24	15	[	[	X
dpc-1595	24	16	3	3	NUM
dpc-1595	24	17	]	]	PUNCT
dpc-1595	24	18	.	.	PUNCT
dpc-1595	25	1	the	the	DET
dpc-1595	25	2	association	association	NOUN
dpc-1595	25	3	of	of	ADP
dpc-1595	25	4	comorbidities	comorbiditie	NOUN
dpc-1595	25	5	such	such	ADJ
dpc-1595	25	6	as	as	ADP
dpc-1595	25	7	psoriatic	psoriatic	ADJ
dpc-1595	25	8	arthropathy	arthropathy	ADJ
dpc-1595	25	9	and	and	CCONJ
dpc-1595	25	10	the	the	DET
dpc-1595	25	11	risk	risk	NOUN
dpc-1595	25	12	of	of	ADP
dpc-1595	25	13	cardiovascular	cardiovascular	ADJ
dpc-1595	25	14	disease	disease	NOUN
dpc-1595	25	15	make	make	VERB
dpc-1595	25	16	psoriasis	psoriasis	NOUN
dpc-1595	25	17	a	a	DET
dpc-1595	25	18	systemic	systemic	ADJ
dpc-1595	25	19	disease	disease	NOUN
dpc-1595	25	20	.	.	PUNCT
dpc-1595	26	1	the	the	DET
dpc-1595	26	2	disease	disease	NOUN
dpc-1595	26	3	has	have	VERB
dpc-1595	26	4	a	a	DET
dpc-1595	26	5	psychological	psychological	ADJ
dpc-1595	26	6	impact	impact	NOUN
dpc-1595	26	7	on	on	ADP
dpc-1595	26	8	patients	patient	NOUN
dpc-1595	26	9	,	,	PUNCT
dpc-1595	26	10	who	who	PRON
dpc-1595	26	11	have	have	VERB
dpc-1595	26	12	a	a	DET
dpc-1595	26	13	greater	great	ADJ
dpc-1595	26	14	risk	risk	NOUN
dpc-1595	26	15	of	of	ADP
dpc-1595	26	16	depression	depression	NOUN
dpc-1595	26	17	,	,	PUNCT
dpc-1595	26	18	anxiety	anxiety	NOUN
dpc-1595	26	19	,	,	PUNCT
dpc-1595	26	20	and	and	CCONJ
dpc-1595	26	21	even	even	ADV
dpc-1595	26	22	social	social	ADJ
dpc-1595	26	23	stigmatization	stigmatization	NOUN
dpc-1595	26	24	[	[	X
dpc-1595	26	25	4	4	NUM
dpc-1595	26	26	]	]	PUNCT
dpc-1595	26	27	.	.	PUNCT
dpc-1595	27	1	all	all	PRON
dpc-1595	27	2	of	of	ADP
dpc-1595	27	3	these	these	PRON
dpc-1595	27	4	have	have	VERB
dpc-1595	27	5	a	a	DET
dpc-1595	27	6	significant	significant	ADJ
dpc-1595	27	7	negative	negative	ADJ
dpc-1595	27	8	impact	impact	NOUN
dpc-1595	27	9	on	on	ADP
dpc-1595	27	10	the	the	DET
dpc-1595	27	11	patients	patient	NOUN
dpc-1595	27	12	’	'	PUNCT
dpc-1595	27	13	quality	quality	NOUN
dpc-1595	27	14	of	of	ADP
dpc-1595	27	15	life	life	NOUN
dpc-1595	27	16	.	.	PUNCT
dpc-1595	28	1	the	the	DET
dpc-1595	28	2	development	development	NOUN
dpc-1595	28	3	in	in	ADP
dpc-1595	28	4	recent	recent	ADJ
dpc-1595	28	5	years	year	NOUN
dpc-1595	28	6	of	of	ADP
dpc-1595	28	7	biological	biological	ADJ
dpc-1595	28	8	drugs	drug	NOUN
dpc-1595	28	9	has	have	AUX
dpc-1595	28	10	revolutionized	revolutionize	VERB
dpc-1595	28	11	the	the	DET
dpc-1595	28	12	treatment	treatment	NOUN
dpc-1595	28	13	of	of	ADP
dpc-1595	28	14	psoriasis	psoriasis	NOUN
dpc-1595	28	15	.	.	PUNCT
dpc-1595	29	1	however	however	ADV
dpc-1595	29	2	,	,	PUNCT
dpc-1595	29	3	topical	topical	ADJ
dpc-1595	29	4	medications	medication	NOUN
dpc-1595	29	5	are	be	AUX
dpc-1595	29	6	considered	consider	VERB
dpc-1595	29	7	the	the	DET
dpc-1595	29	8	cornerstone	cornerstone	NOUN
dpc-1595	29	9	of	of	ADP
dpc-1595	29	10	therapy	therapy	NOUN
dpc-1595	29	11	for	for	ADP
dpc-1595	29	12	many	many	ADJ
dpc-1595	29	13	patients	patient	NOUN
dpc-1595	29	14	[	[	X
dpc-1595	29	15	5	5	NUM
dpc-1595	29	16	]	]	PUNCT
dpc-1595	29	17	.	.	PUNCT
dpc-1595	30	1	patients	patient	NOUN
dpc-1595	30	2	with	with	ADP
dpc-1595	30	3	a	a	DET
dpc-1595	30	4	score	score	NOUN
dpc-1595	30	5	less	less	ADJ
dpc-1595	30	6	than	than	ADP
dpc-1595	30	7	10	10	NUM
dpc-1595	30	8	on	on	ADP
dpc-1595	30	9	a	a	DET
dpc-1595	30	10	psoriasis	psoriasis	NOUN
dpc-1595	30	11	severity	severity	NOUN
dpc-1595	30	12	index	index	NOUN
dpc-1595	30	13	(	(	PUNCT
dpc-1595	30	14	eg	eg	NOUN
dpc-1595	30	15	,	,	PUNCT
dpc-1595	30	16	pasi	pasi	PROPN
dpc-1595	30	17	,	,	PUNCT
dpc-1595	30	18	bsa	bsa	NOUN
dpc-1595	30	19	,	,	PUNCT
dpc-1595	30	20	or	or	CCONJ
dpc-1595	30	21	dlqi	dlqi	ADJ
dpc-1595	30	22	)	)	PUNCT
dpc-1595	30	23	can	can	AUX
dpc-1595	30	24	be	be	AUX
dpc-1595	30	25	treated	treat	VERB
dpc-1595	30	26	with	with	ADP
dpc-1595	30	27	topical	topical	ADJ
dpc-1595	30	28	monotherapy	monotherapy	NOUN
dpc-1595	30	29	.	.	PUNCT
dpc-1595	31	1	patients	patient	NOUN
dpc-1595	31	2	with	with	ADP
dpc-1595	31	3	moderate	moderate	ADJ
dpc-1595	31	4	plaque	plaque	NOUN
dpc-1595	31	5	psoriasis	psoriasis	NOUN
dpc-1595	31	6	who	who	PRON
dpc-1595	31	7	were	be	AUX
dpc-1595	31	8	treated	treat	VERB
dpc-1595	31	9	with	with	ADP
dpc-1595	31	10	calcipotriol	calcipotriol	PROPN
dpc-1595	31	11	/	/	SYM
dpc-1595	31	12	betamethasone	betamethasone	PROPN
dpc-1595	31	13	dipropionate	dipropionate	NOUN
dpc-1595	31	14	(	(	PUNCT
dpc-1595	31	15	cal	cal	PROPN
dpc-1595	31	16	/	/	SYM
dpc-1595	31	17	bd	bd	PROPN
dpc-1595	31	18	)	)	PUNCT
dpc-1595	31	19	aerosol	aerosol	NOUN
dpc-1595	31	20	foam	foam	NOUN
dpc-1595	31	21	for	for	ADP
dpc-1595	31	22	4	4	NUM
dpc-1595	31	23	weeks	week	NOUN
dpc-1595	31	24	achieved	achieve	VERB
dpc-1595	31	25	a	a	DET
dpc-1595	31	26	psoriasis	psoriasis	NOUN
dpc-1595	31	27	area	area	NOUN
dpc-1595	31	28	and	and	CCONJ
dpc-1595	31	29	severity	severity	NOUN
dpc-1595	31	30	index	index	NOUN
dpc-1595	31	31	(	(	PUNCT
dpc-1595	31	32	pasi	pasi	NOUN
dpc-1595	31	33	)	)	PUNCT
dpc-1595	31	34	score	score	NOUN
dpc-1595	31	35	of	of	ADP
dpc-1595	31	36	75	75	NUM
dpc-1595	31	37	,	,	PUNCT
dpc-1595	31	38	which	which	PRON
dpc-1595	31	39	was	be	AUX
dpc-1595	31	40	higher	high	ADJ
dpc-1595	31	41	than	than	ADP
dpc-1595	31	42	that	that	PRON
dpc-1595	31	43	achieved	achieve	VERB
dpc-1595	31	44	with	with	ADP
dpc-1595	31	45	12	12	NUM
dpc-1595	31	46	-	-	PUNCT
dpc-1595	31	47	week	week	NOUN
dpc-1595	31	48	methotrexate	methotrexate	NOUN
dpc-1595	31	49	and	and	CCONJ
dpc-1595	31	50	acitretin	acitretin	NOUN
dpc-1595	31	51	therapy	therapy	NOUN
dpc-1595	31	52	but	but	CCONJ
dpc-1595	31	53	similar	similar	ADJ
dpc-1595	31	54	to	to	ADP
dpc-1595	31	55	that	that	PRON
dpc-1595	31	56	with	with	ADP
dpc-1595	31	57	fumaric	fumaric	ADJ
dpc-1595	31	58	acid	acid	NOUN
dpc-1595	31	59	esters	ester	NOUN
dpc-1595	31	60	[	[	X
dpc-1595	31	61	6	6	NUM
dpc-1595	31	62	]	]	PUNCT
dpc-1595	31	63	.	.	PUNCT
dpc-1595	32	1	this	this	DET
dpc-1595	32	2	finding	finding	NOUN
dpc-1595	32	3	reaffirms	reaffirm	VERB
dpc-1595	32	4	the	the	DET
dpc-1595	32	5	indication	indication	NOUN
dpc-1595	32	6	for	for	ADP
dpc-1595	32	7	topical	topical	ADJ
dpc-1595	32	8	treatment	treatment	NOUN
dpc-1595	32	9	in	in	ADP
dpc-1595	32	10	patients	patient	NOUN
dpc-1595	32	11	with	with	ADP
dpc-1595	32	12	mild	mild	ADJ
dpc-1595	32	13	–	–	PUNCT
dpc-1595	32	14	moderate	moderate	ADJ
dpc-1595	32	15	plaque	plaque	NOUN
dpc-1595	32	16	psoriasis	psoriasis	NOUN
dpc-1595	32	17	.	.	PUNCT
dpc-1595	33	1	current	current	ADJ
dpc-1595	33	2	guidelines	guideline	NOUN
dpc-1595	33	3	recommend	recommend	VERB
dpc-1595	33	4	the	the	DET
dpc-1595	33	5	topical	topical	ADJ
dpc-1595	33	6	use	use	NOUN
dpc-1595	33	7	of	of	ADP
dpc-1595	33	8	a	a	DET
dpc-1595	33	9	vitamin	vitamin	NOUN
dpc-1595	33	10	d	d	NOUN
dpc-1595	33	11	analog	analog	NOUN
dpc-1595	33	12	(	(	PUNCT
dpc-1595	33	13	eg	eg	NOUN
dpc-1595	33	14	,	,	PUNCT
dpc-1595	33	15	calcipotriol	calcipotriol	PROPN
dpc-1595	33	16	)	)	PUNCT
dpc-1595	33	17	and	and	CCONJ
dpc-1595	33	18	a	a	DET
dpc-1595	33	19	corticosteroid	corticosteroid	ADJ
dpc-1595	33	20	(	(	PUNCT
dpc-1595	33	21	eg	eg	NOUN
dpc-1595	33	22	,	,	PUNCT
dpc-1595	33	23	betamethasone	betamethasone	NOUN
dpc-1595	33	24	dipropionate	dipropionate	PROPN
dpc-1595	33	25	)	)	PUNCT
dpc-1595	33	26	as	as	ADP
dpc-1595	33	27	the	the	DET
dpc-1595	33	28	first	first	ADJ
dpc-1595	33	29	-	-	PUNCT
dpc-1595	33	30	line	line	NOUN
dpc-1595	33	31	treatment	treatment	NOUN
dpc-1595	33	32	for	for	ADP
dpc-1595	33	33	plaque	plaque	NOUN
dpc-1595	33	34	psoriasis	psoriasis	NOUN
dpc-1595	33	35	.	.	PUNCT
dpc-1595	34	1	the	the	DET
dpc-1595	34	2	latest	late	ADJ
dpc-1595	34	3	cochrane	cochrane	NOUN
dpc-1595	34	4	review	review	NOUN
dpc-1595	34	5	on	on	ADP
dpc-1595	34	6	treatments	treatment	NOUN
dpc-1595	34	7	for	for	ADP
dpc-1595	34	8	psoriasis	psoriasis	NOUN
dpc-1595	34	9	[	[	X
dpc-1595	34	10	7	7	X
dpc-1595	34	11	]	]	PUNCT
dpc-1595	34	12	reported	report	VERB
dpc-1595	34	13	that	that	SCONJ
dpc-1595	34	14	the	the	DET
dpc-1595	34	15	combined	combined	ADJ
dpc-1595	34	16	use	use	NOUN
dpc-1595	34	17	of	of	ADP
dpc-1595	34	18	these	these	DET
dpc-1595	34	19	drugs	drug	NOUN
dpc-1595	34	20	from	from	ADP
dpc-1595	34	21	different	different	ADJ
dpc-1595	34	22	pharmacological	pharmacological	ADJ
dpc-1595	34	23	groups	group	NOUN
dpc-1595	34	24	is	be	AUX
dpc-1595	34	25	superior	superior	ADJ
dpc-1595	34	26	in	in	ADP
dpc-1595	34	27	efficacy	efficacy	NOUN
dpc-1595	34	28	and	and	CCONJ
dpc-1595	34	29	safety	safety	NOUN
dpc-1595	34	30	to	to	ADP
dpc-1595	34	31	their	their	PRON
dpc-1595	34	32	use	use	NOUN
dpc-1595	34	33	separately	separately	ADV
dpc-1595	34	34	.	.	PUNCT
dpc-1595	35	1	the	the	DET
dpc-1595	35	2	combination	combination	NOUN
dpc-1595	35	3	of	of	ADP
dpc-1595	35	4	0.005	0.005	NUM
dpc-1595	35	5	%	%	NOUN
dpc-1595	35	6	calcipotriol	calcipotriol	NOUN
dpc-1595	35	7	and	and	CCONJ
dpc-1595	35	8	0.064	0.064	NUM
dpc-1595	35	9	%	%	NOUN
dpc-1595	35	10	betamethasone	betamethasone	NOUN
dpc-1595	35	11	dipropionate	dipropionate	PROPN
dpc-1595	35	12	has	have	VERB
dpc-1595	35	13	a	a	DET
dpc-1595	35	14	lower	low	ADJ
dpc-1595	35	15	rate	rate	NOUN
dpc-1595	35	16	of	of	ADP
dpc-1595	35	17	side	side	NOUN
dpc-1595	35	18	effects	effect	NOUN
dpc-1595	35	19	than	than	SCONJ
dpc-1595	35	20	observed	observe	VERB
dpc-1595	35	21	with	with	ADP
dpc-1595	35	22	topical	topical	ADJ
dpc-1595	35	23	corticosteroids	corticosteroid	NOUN
dpc-1595	35	24	(	(	PUNCT
dpc-1595	35	25	mainly	mainly	ADV
dpc-1595	35	26	skin	skin	NOUN
dpc-1595	35	27	atrophy	atrophy	NOUN
dpc-1595	35	28	)	)	PUNCT
dpc-1595	35	29	and	and	CCONJ
dpc-1595	35	30	vitamin	vitamin	NOUN
dpc-1595	35	31	d	d	NOUN
dpc-1595	35	32	analogs	analog	NOUN
dpc-1595	35	33	(	(	PUNCT
dpc-1595	35	34	skin	skin	NOUN
dpc-1595	35	35	irritation	irritation	NOUN
dpc-1595	35	36	and	and	CCONJ
dpc-1595	35	37	hypercalcemia	hypercalcemia	NOUN
dpc-1595	35	38	)	)	PUNCT
dpc-1595	35	39	used	use	VERB
dpc-1595	35	40	separately	separately	ADV
dpc-1595	35	41	.	.	PUNCT
dpc-1595	36	1	a	a	DET
dpc-1595	36	2	new	new	ADJ
dpc-1595	36	3	aerosol	aerosol	NOUN
dpc-1595	36	4	foam	foam	NOUN
dpc-1595	36	5	formulation	formulation	NOUN
dpc-1595	36	6	of	of	ADP
dpc-1595	36	7	cal	cal	PROPN
dpc-1595	36	8	/	/	SYM
dpc-1595	36	9	bd	bd	PROPN
dpc-1595	36	10	(	(	PUNCT
dpc-1595	36	11	enstilar	enstilar	ADJ
dpc-1595	36	12	)	)	PUNCT
dpc-1595	36	13	for	for	ADP
dpc-1595	36	14	the	the	DET
dpc-1595	36	15	treatment	treatment	NOUN
dpc-1595	36	16	of	of	ADP
dpc-1595	36	17	plaque	plaque	NOUN
dpc-1595	36	18	psoriasis	psoriasis	NOUN
dpc-1595	36	19	was	be	AUX
dpc-1595	36	20	introduced	introduce	VERB
dpc-1595	36	21	in	in	ADP
dpc-1595	36	22	2017	2017	NUM
dpc-1595	36	23	.	.	PUNCT
dpc-1595	37	1	in	in	ADP
dpc-1595	37	2	an	an	DET
dpc-1595	37	3	in	in	ADP
dpc-1595	37	4	vitro	vitro	X
dpc-1595	37	5	model	model	NOUN
dpc-1595	37	6	of	of	ADP
dpc-1595	37	7	skin	skin	NOUN
dpc-1595	37	8	penetration	penetration	NOUN
dpc-1595	37	9	of	of	ADP
dpc-1595	37	10	cal	cal	PROPN
dpc-1595	37	11	/	/	SYM
dpc-1595	37	12	bd	bd	PROPN
dpc-1595	37	13	aerosol	aerosol	NOUN
dpc-1595	37	14	foam	foam	NOUN
dpc-1595	37	15	,	,	PUNCT
dpc-1595	37	16	greater	great	ADJ
dpc-1595	37	17	diffusion	diffusion	NOUN
dpc-1595	37	18	of	of	ADP
dpc-1595	37	19	both	both	DET
dpc-1595	37	20	drugs	drug	NOUN
dpc-1595	37	21	and	and	CCONJ
dpc-1595	37	22	more	more	ADV
dpc-1595	37	23	stable	stable	ADJ
dpc-1595	37	24	skin	skin	NOUN
dpc-1595	37	25	concentrations	concentration	NOUN
dpc-1595	37	26	were	be	AUX
dpc-1595	37	27	demonstrated	demonstrate	VERB
dpc-1595	37	28	[	[	X
dpc-1595	37	29	8	8	NUM
dpc-1595	37	30	]	]	PUNCT
dpc-1595	37	31	.	.	PUNCT
dpc-1595	38	1	the	the	DET
dpc-1595	38	2	anti	anti	ADJ
dpc-1595	38	3	-	-	ADJ
dpc-1595	38	4	psoriatic	psoriatic	ADJ
dpc-1595	38	5	effect	effect	NOUN
dpc-1595	38	6	of	of	ADP
dpc-1595	38	7	cal	cal	PROPN
dpc-1595	38	8	/	/	SYM
dpc-1595	38	9	bd	bd	PROPN
dpc-1595	38	10	aerosol	aerosol	NOUN
dpc-1595	38	11	foam	foam	NOUN
dpc-1595	38	12	was	be	AUX
dpc-1595	38	13	superior	superior	ADJ
dpc-1595	38	14	to	to	ADP
dpc-1595	38	15	that	that	PRON
dpc-1595	38	16	observed	observe	VERB
dpc-1595	38	17	with	with	ADP
dpc-1595	38	18	galenic	galenic	ADJ
dpc-1595	38	19	ointment	ointment	NOUN
dpc-1595	38	20	[	[	X
dpc-1595	38	21	9	9	NUM
dpc-1595	38	22	]	]	PUNCT
dpc-1595	38	23	.	.	PUNCT
dpc-1595	39	1	regarding	regard	VERB
dpc-1595	39	2	safety	safety	NOUN
dpc-1595	39	3	,	,	PUNCT
dpc-1595	39	4	the	the	DET
dpc-1595	39	5	muse	muse	NOUN
dpc-1595	39	6	study	study	NOUN
dpc-1595	39	7	[	[	X
dpc-1595	39	8	10	10	NUM
dpc-1595	39	9	]	]	PUNCT
dpc-1595	39	10	demonstrated	demonstrate	VERB
dpc-1595	39	11	a	a	DET
dpc-1595	39	12	good	good	ADJ
dpc-1595	39	13	safety	safety	NOUN
dpc-1595	39	14	profile	profile	NOUN
dpc-1595	39	15	,	,	PUNCT
dpc-1595	39	16	and	and	CCONJ
dpc-1595	39	17	the	the	DET
dpc-1595	39	18	pso	pso	NOUN
dpc-1595	39	19	-	-	PUNCT
dpc-1595	39	20	fast	fast	ADJ
dpc-1595	39	21	study	study	NOUN
dpc-1595	39	22	[	[	X
dpc-1595	39	23	11	11	NUM
dpc-1595	39	24	]	]	PUNCT
dpc-1595	39	25	demonstrated	demonstrate	VERB
dpc-1595	39	26	efficacy	efficacy	NOUN
dpc-1595	39	27	and	and	CCONJ
dpc-1595	39	28	tolerability	tolerability	NOUN
dpc-1595	39	29	in	in	ADP
dpc-1595	39	30	patients	patient	NOUN
dpc-1595	39	31	with	with	ADP
dpc-1595	39	32	psoriasis	psoriasis	NOUN
dpc-1595	39	33	of	of	ADP
dpc-1595	39	34	any	any	DET
dpc-1595	39	35	severity	severity	NOUN
dpc-1595	39	36	level	level	NOUN
dpc-1595	39	37	.	.	PUNCT
dpc-1595	40	1	adherence	adherence	NOUN
dpc-1595	40	2	to	to	ADP
dpc-1595	40	3	topical	topical	ADJ
dpc-1595	40	4	treatment	treatment	NOUN
dpc-1595	40	5	depends	depend	VERB
dpc-1595	40	6	on	on	ADP
dpc-1595	40	7	multiple	multiple	ADJ
dpc-1595	40	8	factors	factor	NOUN
dpc-1595	40	9	regarding	regard	VERB
dpc-1595	40	10	the	the	DET
dpc-1595	40	11	product	product	NOUN
dpc-1595	40	12	itself	itself	PRON
dpc-1595	40	13	and	and	CCONJ
dpc-1595	40	14	the	the	DET
dpc-1595	40	15	patient	patient	NOUN
dpc-1595	40	16	.	.	PUNCT
dpc-1595	41	1	cosmetics	cosmetic	NOUN
dpc-1595	41	2	and	and	CCONJ
dpc-1595	41	3	speed	speed	NOUN
dpc-1595	41	4	of	of	ADP
dpc-1595	41	5	action	action	NOUN
dpc-1595	41	6	are	be	AUX
dpc-1595	41	7	essential	essential	ADJ
dpc-1595	41	8	for	for	SCONJ
dpc-1595	41	9	the	the	DET
dpc-1595	41	10	patient	patient	NOUN
dpc-1595	41	11	to	to	PART
dpc-1595	41	12	correctly	correctly	ADV
dpc-1595	41	13	comply	comply	VERB
dpc-1595	41	14	with	with	ADP
dpc-1595	41	15	the	the	DET
dpc-1595	41	16	drug	drug	NOUN
dpc-1595	41	17	dosage	dosage	NOUN
dpc-1595	41	18	.	.	PUNCT
dpc-1595	42	1	however	however	ADV
dpc-1595	42	2	,	,	PUNCT
dpc-1595	42	3	other	other	ADJ
dpc-1595	42	4	social	social	ADJ
dpc-1595	42	5	and	and	CCONJ
dpc-1595	42	6	even	even	ADV
dpc-1595	42	7	occupational	occupational	ADJ
dpc-1595	42	8	factors	factor	NOUN
dpc-1595	42	9	can	can	AUX
dpc-1595	42	10	significantly	significantly	ADV
dpc-1595	42	11	influence	influence	VERB
dpc-1595	42	12	adherence	adherence	NOUN
dpc-1595	42	13	.	.	PUNCT
dpc-1595	43	1	the	the	DET
dpc-1595	43	2	main	main	ADJ
dpc-1595	43	3	objective	objective	NOUN
dpc-1595	43	4	of	of	ADP
dpc-1595	43	5	this	this	DET
dpc-1595	43	6	study	study	NOUN
dpc-1595	43	7	was	be	AUX
dpc-1595	43	8	to	to	PART
dpc-1595	43	9	determine	determine	VERB
dpc-1595	43	10	the	the	DET
dpc-1595	43	11	adherence	adherence	NOUN
dpc-1595	43	12	to	to	ADP
dpc-1595	43	13	treatment	treatment	NOUN
dpc-1595	43	14	with	with	ADP
dpc-1595	43	15	cal	cal	PROPN
dpc-1595	43	16	/	/	SYM
dpc-1595	43	17	bd	bd	PROPN
dpc-1595	43	18	aerosol	aerosol	NOUN
dpc-1595	43	19	foam	foam	NOUN
dpc-1595	43	20	in	in	ADP
dpc-1595	43	21	patients	patient	NOUN
dpc-1595	43	22	with	with	ADP
dpc-1595	43	23	mild	mild	ADJ
dpc-1595	43	24	–	–	PUNCT
dpc-1595	43	25	moderate	moderate	ADJ
dpc-1595	43	26	plaque	plaque	NOUN
dpc-1595	43	27	psoriasis	psoriasis	NOUN
dpc-1595	43	28	4	4	NUM
dpc-1595	43	29	weeks	week	NOUN
dpc-1595	43	30	after	after	ADP
dpc-1595	43	31	starting	start	VERB
dpc-1595	43	32	treatment	treatment	NOUN
dpc-1595	43	33	.	.	PUNCT
dpc-1595	44	1	the	the	DET
dpc-1595	44	2	secondary	secondary	ADJ
dpc-1595	44	3	objectives	objective	NOUN
dpc-1595	44	4	were	be	AUX
dpc-1595	44	5	to	to	PART
dpc-1595	44	6	evaluate	evaluate	VERB
dpc-1595	44	7	the	the	DET
dpc-1595	44	8	:	:	PUNCT
dpc-1595	44	9	(	(	PUNCT
dpc-1595	44	10	a	a	X
dpc-1595	44	11	)	)	PUNCT
dpc-1595	44	12	degree	degree	NOUN
dpc-1595	44	13	of	of	ADP
dpc-1595	44	14	patient	patient	ADJ
dpc-1595	44	15	satisfaction	satisfaction	NOUN
dpc-1595	44	16	during	during	ADP
dpc-1595	44	17	and	and	CCONJ
dpc-1595	44	18	after	after	ADP
dpc-1595	44	19	treatment	treatment	NOUN
dpc-1595	44	20	termination	termination	NOUN
dpc-1595	44	21	,	,	PUNCT
dpc-1595	44	22	and	and	CCONJ
dpc-1595	44	23	(	(	PUNCT
dpc-1595	44	24	b	b	NOUN
dpc-1595	44	25	)	)	PUNCT
dpc-1595	44	26	treatment	treatment	NOUN
dpc-1595	44	27	’	'	PUNCT
dpc-1595	44	28	efficacy	efficacy	NOUN
dpc-1595	44	29	,	,	PUNCT
dpc-1595	44	30	safety	safety	NOUN
dpc-1595	44	31	,	,	PUNCT
dpc-1595	44	32	and	and	CCONJ
dpc-1595	44	33	impact	impact	NOUN
dpc-1595	44	34	on	on	ADP
dpc-1595	44	35	the	the	DET
dpc-1595	44	36	patients	patient	NOUN
dpc-1595	44	37	’	'	PUNCT
dpc-1595	44	38	quality	quality	NOUN
dpc-1595	44	39	of	of	ADP
dpc-1595	44	40	life	life	NOUN
dpc-1595	44	41	.	.	PUNCT
dpc-1595	45	1	methods	method	NOUN
dpc-1595	45	2	patients	patient	NOUN
dpc-1595	45	3	from	from	ADP
dpc-1595	45	4	november	november	PROPN
dpc-1595	45	5	2017	2017	NUM
dpc-1595	45	6	to	to	ADP
dpc-1595	45	7	november	november	PROPN
dpc-1595	45	8	2019	2019	NUM
dpc-1595	45	9	,	,	PUNCT
dpc-1595	45	10	we	we	PRON
dpc-1595	45	11	recruited	recruit	VERB
dpc-1595	45	12	patients	patient	NOUN
dpc-1595	45	13	from	from	ADP
dpc-1595	45	14	the	the	DET
dpc-1595	45	15	dermatology	dermatology	NOUN
dpc-1595	45	16	department	department	NOUN
dpc-1595	45	17	at	at	ADP
dpc-1595	45	18	san	san	PROPN
dpc-1595	45	19	cecilio	cecilio	PROPN
dpc-1595	45	20	university	university	NOUN
dpc-1595	45	21	hospital	hospital	NOUN
dpc-1595	45	22	.	.	PUNCT
dpc-1595	46	1	patients	patient	NOUN
dpc-1595	46	2	were	be	AUX
dpc-1595	46	3	eligible	eligible	ADJ
dpc-1595	46	4	for	for	ADP
dpc-1595	46	5	the	the	DET
dpc-1595	46	6	study	study	NOUN
dpc-1595	46	7	if	if	SCONJ
dpc-1595	46	8	they	they	PRON
dpc-1595	46	9	were	be	AUX
dpc-1595	46	10	older	old	ADJ
dpc-1595	46	11	than	than	ADP
dpc-1595	46	12	18	18	NUM
dpc-1595	46	13	years	year	NOUN
dpc-1595	46	14	of	of	ADP
dpc-1595	46	15	age	age	NOUN
dpc-1595	46	16	and	and	CCONJ
dpc-1595	46	17	had	have	VERB
dpc-1595	46	18	a	a	DET
dpc-1595	46	19	clinical	clinical	ADJ
dpc-1595	46	20	diagnosis	diagnosis	NOUN
dpc-1595	46	21	of	of	ADP
dpc-1595	46	22	plaque	plaque	NOUN
dpc-1595	46	23	psoriasis	psoriasis	NOUN
dpc-1595	46	24	on	on	ADP
dpc-1595	46	25	the	the	DET
dpc-1595	46	26	trunk	trunk	NOUN
dpc-1595	46	27	and	and	CCONJ
dpc-1595	46	28	extremities	extremity	NOUN
dpc-1595	46	29	for	for	ADP
dpc-1595	46	30	at	at	ADV
dpc-1595	46	31	least	least	ADV
dpc-1595	46	32	6	6	NUM
dpc-1595	46	33	months	month	NOUN
dpc-1595	46	34	,	,	PUNCT
dpc-1595	46	35	with	with	ADP
dpc-1595	46	36	an	an	DET
dpc-1595	46	37	affected	affected	ADJ
dpc-1595	46	38	body	body	NOUN
dpc-1595	46	39	surface	surface	NOUN
dpc-1595	46	40	area	area	NOUN
dpc-1595	46	41	(	(	PUNCT
dpc-1595	46	42	bsa	bsa	PROPN
dpc-1595	46	43	)	)	PUNCT
dpc-1595	46	44	<	<	X
dpc-1595	46	45	10	10	NUM
dpc-1595	46	46	%	%	NOUN
dpc-1595	46	47	,	,	PUNCT
dpc-1595	46	48	a	a	DET
dpc-1595	46	49	pasi	pasi	NOUN
dpc-1595	46	50	<	<	X
dpc-1595	46	51	10	10	NUM
dpc-1595	46	52	,	,	PUNCT
dpc-1595	46	53	and	and	CCONJ
dpc-1595	46	54	a	a	DET
dpc-1595	46	55	dermatology	dermatology	NOUN
dpc-1595	46	56	life	life	NOUN
dpc-1595	46	57	quality	quality	NOUN
dpc-1595	46	58	index	index	NOUN
dpc-1595	46	59	(	(	PUNCT
dpc-1595	46	60	dlqi	dlqi	ADJ
dpc-1595	46	61	)	)	PUNCT
dpc-1595	46	62	score	score	NOUN
dpc-1595	46	63	<	<	X
dpc-1595	46	64	10	10	NUM
dpc-1595	46	65	.	.	PUNCT
dpc-1595	47	1	other	other	ADJ
dpc-1595	47	2	inclusion	inclusion	NOUN
dpc-1595	47	3	criteria	criterion	NOUN
dpc-1595	47	4	were	be	AUX
dpc-1595	47	5	the	the	DET
dpc-1595	47	6	ability	ability	NOUN
dpc-1595	47	7	to	to	PART
dpc-1595	47	8	apply	apply	VERB
dpc-1595	47	9	the	the	DET
dpc-1595	47	10	treatment	treatment	NOUN
dpc-1595	47	11	or	or	CCONJ
dpc-1595	47	12	,	,	PUNCT
dpc-1595	47	13	failing	fail	VERB
dpc-1595	47	14	that	that	SCONJ
dpc-1595	47	15	,	,	PUNCT
dpc-1595	47	16	to	to	PART
dpc-1595	47	17	be	be	AUX
dpc-1595	47	18	assisted	assist	VERB
dpc-1595	47	19	by	by	ADP
dpc-1595	47	20	personnel	personnel	NOUN
dpc-1595	47	21	who	who	PRON
dpc-1595	47	22	could	could	AUX
dpc-1595	47	23	apply	apply	VERB
dpc-1595	47	24	it	it	PRON
dpc-1595	47	25	.	.	PUNCT
dpc-1595	48	1	moreover	moreover	ADV
dpc-1595	48	2	,	,	PUNCT
dpc-1595	48	3	their	their	PRON
dpc-1595	48	4	scores	score	NOUN
dpc-1595	48	5	on	on	ADP
dpc-1595	48	6	the	the	DET
dpc-1595	48	7	physician	physician	NOUN
dpc-1595	48	8	global	global	ADJ
dpc-1595	48	9	assessment	assessment	NOUN
dpc-1595	48	10	(	(	PUNCT
dpc-1595	48	11	pga	pga	PROPN
dpc-1595	48	12	)	)	PUNCT
dpc-1595	48	13	,	,	PUNCT
dpc-1595	48	14	modified	modify	VERB
dpc-1595	48	15	investigator	investigator	NOUN
dpc-1595	48	16	’s	’s	PART
dpc-1595	48	17	global	global	ADJ
dpc-1595	48	18	assessment	assessment	NOUN
dpc-1595	48	19	(	(	PUNCT
dpc-1595	48	20	miga	miga	PROPN
dpc-1595	48	21	)	)	PUNCT
dpc-1595	48	22	,	,	PUNCT
dpc-1595	48	23	and	and	CCONJ
dpc-1595	48	24	modified	modify	VERB
dpc-1595	48	25	pasi	pasi	NOUN
dpc-1595	48	26	(	(	PUNCT
dpc-1595	48	27	excluding	exclude	VERB
dpc-1595	48	28	the	the	DET
dpc-1595	48	29	head	head	NOUN
dpc-1595	48	30	)	)	PUNCT
dpc-1595	48	31	had	have	VERB
dpc-1595	48	32	to	to	PART
dpc-1595	48	33	show	show	VERB
dpc-1595	48	34	at	at	ADP
dpc-1595	48	35	least	least	ADJ
dpc-1595	48	36	a	a	DET
dpc-1595	48	37	slight	slight	ADJ
dpc-1595	48	38	effect	effect	NOUN
dpc-1595	48	39	of	of	ADP
dpc-1595	48	40	improvement	improvement	NOUN
dpc-1595	48	41	.	.	PUNCT
dpc-1595	49	1	exclusion	exclusion	NOUN
dpc-1595	49	2	criteria	criterion	NOUN
dpc-1595	49	3	were	be	AUX
dpc-1595	49	4	psoriasis	psoriasis	NOUN
dpc-1595	49	5	in	in	ADP
dpc-1595	49	6	areas	area	NOUN
dpc-1595	49	7	other	other	ADJ
dpc-1595	49	8	than	than	ADP
dpc-1595	49	9	the	the	DET
dpc-1595	49	10	trunk	trunk	NOUN
dpc-1595	49	11	and	and	CCONJ
dpc-1595	49	12	extremities	extremity	NOUN
dpc-1595	49	13	(	(	PUNCT
dpc-1595	49	14	eg	eg	NOUN
dpc-1595	49	15	,	,	PUNCT
dpc-1595	49	16	scalp	scalp	NOUN
dpc-1595	49	17	,	,	PUNCT
dpc-1595	49	18	face	face	NOUN
dpc-1595	49	19	,	,	PUNCT
dpc-1595	49	20	genitals	genital	NOUN
dpc-1595	49	21	,	,	PUNCT
dpc-1595	49	22	and	and	CCONJ
dpc-1595	49	23	skin	skin	NOUN
dpc-1595	49	24	folds	fold	NOUN
dpc-1595	49	25	)	)	PUNCT
dpc-1595	49	26	,	,	PUNCT
dpc-1595	49	27	a	a	DET
dpc-1595	49	28	history	history	NOUN
dpc-1595	49	29	of	of	ADP
dpc-1595	49	30	allergy	allergy	NOUN
dpc-1595	49	31	to	to	ADP
dpc-1595	49	32	vitamin	vitamin	NOUN
dpc-1595	49	33	d	d	NOUN
dpc-1595	49	34	analogs	analog	NOUN
dpc-1595	49	35	or	or	CCONJ
dpc-1595	49	36	topical	topical	ADJ
dpc-1595	49	37	corticosteroids	corticosteroid	NOUN
dpc-1595	49	38	,	,	PUNCT
dpc-1595	49	39	and	and	CCONJ
dpc-1595	49	40	concurrent	concurrent	ADJ
dpc-1595	49	41	or	or	CCONJ
dpc-1595	49	42	previous	previous	ADJ
dpc-1595	49	43	treatment	treatment	NOUN
dpc-1595	49	44	with	with	ADP
dpc-1595	49	45	systemic	systemic	ADJ
dpc-1595	49	46	corticosteroids	corticosteroid	NOUN
dpc-1595	49	47	,	,	PUNCT
dpc-1595	49	48	retinoids	retinoid	NOUN
dpc-1595	49	49	(	(	PUNCT
dpc-1595	49	50	eg	eg	NOUN
dpc-1595	49	51	,	,	PUNCT
dpc-1595	49	52	acitretin	acitretin	NOUN
dpc-1595	49	53	)	)	PUNCT
dpc-1595	49	54	or	or	CCONJ
dpc-1595	49	55	immunosuppressants	immunosuppressant	NOUN
dpc-1595	49	56	(	(	PUNCT
dpc-1595	49	57	eg	eg	NOUN
dpc-1595	49	58	,	,	PUNCT
dpc-1595	49	59	methotrexate	methotrexate	NOUN
dpc-1595	49	60	,	,	PUNCT
dpc-1595	49	61	cyclosporine	cyclosporine	NOUN
dpc-1595	49	62	,	,	PUNCT
dpc-1595	49	63	fumaric	fumaric	ADJ
dpc-1595	49	64	acid	acid	PROPN
dpc-1595	49	65	esters	ester	NOUN
dpc-1595	49	66	)	)	PUNCT
dpc-1595	49	67	in	in	ADP
dpc-1595	49	68	the	the	DET
dpc-1595	49	69	past	past	ADJ
dpc-1595	49	70	4	4	NUM
dpc-1595	49	71	weeks	week	NOUN
dpc-1595	49	72	,	,	PUNCT
dpc-1595	49	73	etanercept	etanercept	NOUN
dpc-1595	49	74	(	(	PUNCT
dpc-1595	49	75	past	past	ADP
dpc-1595	49	76	4	4	NUM
dpc-1595	49	77	weeks	week	NOUN
dpc-1595	49	78	)	)	PUNCT
dpc-1595	49	79	,	,	PUNCT
dpc-1595	49	80	adalimumab	adalimumab	NOUN
dpc-1595	49	81	or	or	CCONJ
dpc-1595	49	82	infliximab	infliximab	NOUN
dpc-1595	49	83	(	(	PUNCT
dpc-1595	49	84	past	past	ADJ
dpc-1595	49	85	8	8	NUM
dpc-1595	49	86	weeks	week	NOUN
dpc-1595	49	87	)	)	PUNCT
dpc-1595	49	88	,	,	PUNCT
dpc-1595	49	89	ustekinumab	ustekinumab	NOUN
dpc-1595	49	90	(	(	PUNCT
dpc-1595	49	91	past	past	ADJ
dpc-1595	49	92	16	16	NUM
dpc-1595	49	93	weeks	week	NOUN
dpc-1595	49	94	)	)	PUNCT
dpc-1595	49	95	,	,	PUNCT
dpc-1595	49	96	other	other	ADJ
dpc-1595	49	97	biologics	biologic	NOUN
dpc-1595	49	98	(	(	PUNCT
dpc-1595	49	99	past	past	ADP
dpc-1595	49	100	4	4	NUM
dpc-1595	49	101	weeks	week	NOUN
dpc-1595	49	102	or	or	CCONJ
dpc-1595	49	103	5	5	NUM
dpc-1595	49	104	half	half	ADJ
dpc-1595	49	105	-	-	PUNCT
dpc-1595	49	106	lives	life	NOUN
dpc-1595	49	107	)	)	PUNCT
dpc-1595	49	108	,	,	PUNCT
dpc-1595	49	109	psoralen	psoralen	NOUN
dpc-1595	49	110	(	(	PUNCT
dpc-1595	49	111	past	past	ADJ
dpc-1595	49	112	4	4	NUM
dpc-1595	49	113	weeks	week	NOUN
dpc-1595	49	114	)	)	PUNCT
dpc-1595	49	115	,	,	PUNCT
dpc-1595	49	116	or	or	CCONJ
dpc-1595	49	117	uva	uva	PROPN
dpc-1595	49	118	or	or	CCONJ
dpc-1595	49	119	uvb	uvb	ADJ
dpc-1595	49	120	phototherapy	phototherapy	NOUN
dpc-1595	49	121	(	(	PUNCT
dpc-1595	49	122	past	past	ADJ
dpc-1595	49	123	2	2	NUM
dpc-1595	49	124	weeks	week	NOUN
dpc-1595	49	125	)	)	PUNCT
dpc-1595	49	126	.	.	PUNCT
dpc-1595	50	1	other	other	ADJ
dpc-1595	50	2	exclusion	exclusion	NOUN
dpc-1595	50	3	criteria	criterion	NOUN
dpc-1595	50	4	were	be	AUX
dpc-1595	50	5	:	:	PUNCT
dpc-1595	50	6	a	a	DET
dpc-1595	50	7	likelihood	likelihood	NOUN
dpc-1595	50	8	of	of	ADP
dpc-1595	50	9	excessive	excessive	ADJ
dpc-1595	50	10	sun	sun	NOUN
dpc-1595	50	11	exposure	exposure	NOUN
dpc-1595	50	12	during	during	ADP
dpc-1595	50	13	the	the	DET
dpc-1595	50	14	study	study	NOUN
dpc-1595	50	15	,	,	PUNCT
dpc-1595	50	16	disorders	disorder	NOUN
dpc-1595	50	17	of	of	ADP
dpc-1595	50	18	calcium	calcium	NOUN
dpc-1595	50	19	metabolism	metabolism	NOUN
dpc-1595	50	20	associated	associate	VERB
dpc-1595	50	21	with	with	ADP
dpc-1595	50	22	hypercalcemia	hypercalcemia	NOUN
dpc-1595	50	23	,	,	PUNCT
dpc-1595	50	24	skin	skin	NOUN
dpc-1595	50	25	infections	infection	NOUN
dpc-1595	50	26	,	,	PUNCT
dpc-1595	50	27	severe	severe	ADJ
dpc-1595	50	28	liver	liver	NOUN
dpc-1595	50	29	or	or	CCONJ
dpc-1595	50	30	kidney	kidney	NOUN
dpc-1595	50	31	disorders	disorder	NOUN
dpc-1595	50	32	,	,	PUNCT
dpc-1595	50	33	and	and	CCONJ
dpc-1595	50	34	a	a	DET
dpc-1595	50	35	recent	recent	ADJ
dpc-1595	50	36	diagnosis	diagnosis	NOUN
dpc-1595	50	37	of	of	ADP
dpc-1595	50	38	other	other	ADJ
dpc-1595	50	39	psoriasis	psoriasis	NOUN
dpc-1595	50	40	types	type	NOUN
dpc-1595	50	41	(	(	PUNCT
dpc-1595	50	42	eg	eg	NOUN
dpc-1595	50	43	,	,	PUNCT
dpc-1595	50	44	guttate	guttate	ADJ
dpc-1595	50	45	,	,	PUNCT
dpc-1595	50	46	erythrodermic	erythrodermic	ADJ
dpc-1595	50	47	,	,	PUNCT
dpc-1595	50	48	pustular	pustular	ADJ
dpc-1595	50	49	,	,	PUNCT
dpc-1595	50	50	or	or	CCONJ
dpc-1595	50	51	exfoliative	exfoliative	ADJ
dpc-1595	50	52	psoriasis	psoriasis	NOUN
dpc-1595	50	53	)	)	PUNCT
dpc-1595	50	54	.	.	PUNCT
dpc-1595	51	1	conclusions	conclusion	NOUN
dpc-1595	51	2	:	:	PUNCT
dpc-1595	51	3	over	over	ADP
dpc-1595	51	4	a	a	DET
dpc-1595	51	5	4	4	NUM
dpc-1595	51	6	-	-	PUNCT
dpc-1595	51	7	week	week	NOUN
dpc-1595	51	8	period	period	NOUN
dpc-1595	51	9	,	,	PUNCT
dpc-1595	51	10	patients	patient	NOUN
dpc-1595	51	11	treated	treat	VERB
dpc-1595	51	12	with	with	ADP
dpc-1595	51	13	cal	cal	PROPN
dpc-1595	51	14	/	/	SYM
dpc-1595	51	15	bd	bd	PROPN
dpc-1595	51	16	aerosol	aerosol	NOUN
dpc-1595	51	17	foam	foam	NOUN
dpc-1595	51	18	had	have	VERB
dpc-1595	51	19	significant	significant	ADJ
dpc-1595	51	20	improvement	improvement	NOUN
dpc-1595	51	21	in	in	ADP
dpc-1595	51	22	disease	disease	NOUN
dpc-1595	51	23	severity	severity	NOUN
dpc-1595	51	24	that	that	PRON
dpc-1595	51	25	was	be	AUX
dpc-1595	51	26	directly	directly	ADV
dpc-1595	51	27	related	relate	VERB
dpc-1595	51	28	to	to	ADP
dpc-1595	51	29	treatment	treatment	NOUN
dpc-1595	51	30	adherence	adherence	NOUN
dpc-1595	51	31	.	.	PUNCT
dpc-1595	52	1	research	research	NOUN
dpc-1595	52	2	|	|	ADV
dpc-1595	52	3	dermatol	dermatol	ADJ
dpc-1595	52	4	pract	pract	NOUN
dpc-1595	52	5	concept	concept	NOUN
dpc-1595	52	6	.	.	PUNCT
dpc-1595	53	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	53	2	3	3	NUM
dpc-1595	53	3	study	study	NOUN
dpc-1595	53	4	design	design	NOUN
dpc-1595	53	5	this	this	PRON
dpc-1595	53	6	was	be	AUX
dpc-1595	53	7	an	an	DET
dpc-1595	53	8	open	open	ADJ
dpc-1595	53	9	-	-	PUNCT
dpc-1595	53	10	label	label	NOUN
dpc-1595	53	11	,	,	PUNCT
dpc-1595	53	12	non	non	ADJ
dpc-1595	53	13	-	-	ADJ
dpc-1595	53	14	placebo	placebo	NOUN
dpc-1595	53	15	controlled	control	VERB
dpc-1595	53	16	,	,	PUNCT
dpc-1595	53	17	prospective	prospective	ADJ
dpc-1595	53	18	single	single	ADJ
dpc-1595	53	19	-	-	PUNCT
dpc-1595	53	20	center	center	NOUN
dpc-1595	53	21	study	study	NOUN
dpc-1595	53	22	.	.	PUNCT
dpc-1595	54	1	the	the	DET
dpc-1595	54	2	study	study	NOUN
dpc-1595	54	3	protocol	protocol	NOUN
dpc-1595	54	4	was	be	AUX
dpc-1595	54	5	approved	approve	VERB
dpc-1595	54	6	by	by	ADP
dpc-1595	54	7	the	the	DET
dpc-1595	54	8	ethics	ethic	NOUN
dpc-1595	54	9	committee	committee	PROPN
dpc-1595	54	10	of	of	ADP
dpc-1595	54	11	our	our	PRON
dpc-1595	54	12	hospital	hospital	NOUN
dpc-1595	54	13	on	on	ADP
dpc-1595	54	14	19	19	NUM
dpc-1595	54	15	oct	oct	NOUN
dpc-1595	54	16	2019	2019	NUM
dpc-1595	54	17	,	,	PUNCT
dpc-1595	54	18	with	with	ADP
dpc-1595	54	19	the	the	DET
dpc-1595	54	20	code	code	NOUN
dpc-1595	54	21	derm_003_2019	derm_003_2019	NOUN
dpc-1595	54	22	.	.	PUNCT
dpc-1595	55	1	the	the	DET
dpc-1595	55	2	study	study	NOUN
dpc-1595	55	3	was	be	AUX
dpc-1595	55	4	carried	carry	VERB
dpc-1595	55	5	out	out	ADP
dpc-1595	55	6	in	in	ADP
dpc-1595	55	7	compliance	compliance	NOUN
dpc-1595	55	8	with	with	ADP
dpc-1595	55	9	the	the	DET
dpc-1595	55	10	principles	principle	NOUN
dpc-1595	55	11	of	of	ADP
dpc-1595	55	12	the	the	DET
dpc-1595	55	13	declaration	declaration	NOUN
dpc-1595	55	14	of	of	ADP
dpc-1595	55	15	helsinki	helsinki	PROPN
dpc-1595	55	16	and	and	CCONJ
dpc-1595	55	17	good	good	ADJ
dpc-1595	55	18	clinical	clinical	ADJ
dpc-1595	55	19	practice	practice	NOUN
dpc-1595	55	20	.	.	PUNCT
dpc-1595	56	1	all	all	DET
dpc-1595	56	2	patients	patient	NOUN
dpc-1595	56	3	gave	give	VERB
dpc-1595	56	4	written	write	VERB
dpc-1595	56	5	informed	informed	ADJ
dpc-1595	56	6	consent	consent	NOUN
dpc-1595	56	7	.	.	PUNCT
dpc-1595	57	1	patients	patient	NOUN
dpc-1595	57	2	who	who	PRON
dpc-1595	57	3	had	have	AUX
dpc-1595	57	4	previously	previously	ADV
dpc-1595	57	5	used	use	VERB
dpc-1595	57	6	antipsoriatic	antipsoriatic	ADJ
dpc-1595	57	7	or	or	CCONJ
dpc-1595	57	8	other	other	ADJ
dpc-1595	57	9	relevant	relevant	ADJ
dpc-1595	57	10	treatments	treatment	NOUN
dpc-1595	57	11	underwent	undergo	VERB
dpc-1595	57	12	a	a	DET
dpc-1595	57	13	pharmacological	pharmacological	NOUN
dpc-1595	57	14	“	"	PUNCT
dpc-1595	57	15	washout	washout	NOUN
dpc-1595	57	16	period	period	NOUN
dpc-1595	57	17	”	"	PUNCT
dpc-1595	57	18	of	of	ADP
dpc-1595	57	19	at	at	ADV
dpc-1595	57	20	least	least	ADV
dpc-1595	57	21	4	4	NUM
dpc-1595	57	22	weeks	week	NOUN
dpc-1595	57	23	before	before	ADP
dpc-1595	57	24	starting	start	VERB
dpc-1595	57	25	the	the	DET
dpc-1595	57	26	study	study	NOUN
dpc-1595	57	27	.	.	PUNCT
dpc-1595	58	1	all	all	DET
dpc-1595	58	2	patients	patient	NOUN
dpc-1595	58	3	were	be	AUX
dpc-1595	58	4	educated	educate	VERB
dpc-1595	58	5	on	on	ADP
dpc-1595	58	6	how	how	SCONJ
dpc-1595	58	7	to	to	PART
dpc-1595	58	8	apply	apply	VERB
dpc-1595	58	9	cal	cal	PROPN
dpc-1595	58	10	/	/	SYM
dpc-1595	58	11	bd	bd	PROPN
dpc-1595	58	12	aerosol	aerosol	NOUN
dpc-1595	58	13	foam	foam	NOUN
dpc-1595	58	14	,	,	PUNCT
dpc-1595	58	15	with	with	ADP
dpc-1595	58	16	the	the	DET
dpc-1595	58	17	first	first	ADJ
dpc-1595	58	18	application	application	NOUN
dpc-1595	58	19	directly	directly	ADV
dpc-1595	58	20	observed	observe	VERB
dpc-1595	58	21	by	by	ADP
dpc-1595	58	22	an	an	DET
dpc-1595	58	23	investigator	investigator	NOUN
dpc-1595	58	24	.	.	PUNCT
dpc-1595	59	1	the	the	DET
dpc-1595	59	2	medication	medication	NOUN
dpc-1595	59	3	was	be	AUX
dpc-1595	59	4	applied	apply	VERB
dpc-1595	59	5	only	only	ADV
dpc-1595	59	6	to	to	ADP
dpc-1595	59	7	the	the	DET
dpc-1595	59	8	psoriasis	psoriasis	NOUN
dpc-1595	59	9	plaques	plaque	NOUN
dpc-1595	59	10	of	of	ADP
dpc-1595	59	11	the	the	DET
dpc-1595	59	12	trunk	trunk	NOUN
dpc-1595	59	13	and	and	CCONJ
dpc-1595	59	14	extremities	extremity	NOUN
dpc-1595	59	15	,	,	PUNCT
dpc-1595	59	16	avoiding	avoid	VERB
dpc-1595	59	17	its	its	PRON
dpc-1595	59	18	use	use	NOUN
dpc-1595	59	19	in	in	ADP
dpc-1595	59	20	areas	area	NOUN
dpc-1595	59	21	such	such	ADJ
dpc-1595	59	22	as	as	ADP
dpc-1595	59	23	the	the	DET
dpc-1595	59	24	scalp	scalp	NOUN
dpc-1595	59	25	,	,	PUNCT
dpc-1595	59	26	face	face	NOUN
dpc-1595	59	27	,	,	PUNCT
dpc-1595	59	28	genitals	genital	NOUN
dpc-1595	59	29	,	,	PUNCT
dpc-1595	59	30	and	and	CCONJ
dpc-1595	59	31	skin	skin	NOUN
dpc-1595	59	32	folds	fold	NOUN
dpc-1595	59	33	.	.	PUNCT
dpc-1595	60	1	cal	cal	PROPN
dpc-1595	60	2	/	/	SYM
dpc-1595	60	3	bd	bd	PROPN
dpc-1595	60	4	aerosol	aerosol	NOUN
dpc-1595	60	5	foam	foam	NOUN
dpc-1595	60	6	was	be	AUX
dpc-1595	60	7	applied	apply	VERB
dpc-1595	60	8	once	once	ADV
dpc-1595	60	9	a	a	DET
dpc-1595	60	10	day	day	NOUN
dpc-1595	60	11	according	accord	VERB
dpc-1595	60	12	to	to	ADP
dpc-1595	60	13	the	the	DET
dpc-1595	60	14	technical	technical	ADJ
dpc-1595	60	15	datasheet	datasheet	PROPN
dpc-1595	60	16	.	.	PUNCT
dpc-1595	61	1	complete	complete	ADJ
dpc-1595	61	2	resolution	resolution	NOUN
dpc-1595	61	3	of	of	ADP
dpc-1595	61	4	the	the	DET
dpc-1595	61	5	lesions	lesion	NOUN
dpc-1595	61	6	was	be	AUX
dpc-1595	61	7	considered	consider	VERB
dpc-1595	61	8	a	a	DET
dpc-1595	61	9	reason	reason	NOUN
dpc-1595	61	10	for	for	ADP
dpc-1595	61	11	discontinuation	discontinuation	NOUN
dpc-1595	61	12	of	of	ADP
dpc-1595	61	13	the	the	DET
dpc-1595	61	14	treatment	treatment	NOUN
dpc-1595	61	15	,	,	PUNCT
dpc-1595	61	16	while	while	SCONJ
dpc-1595	61	17	the	the	DET
dpc-1595	61	18	reappearance	reappearance	NOUN
dpc-1595	61	19	of	of	ADP
dpc-1595	61	20	lesions	lesion	NOUN
dpc-1595	61	21	allowed	allow	VERB
dpc-1595	61	22	the	the	DET
dpc-1595	61	23	resumption	resumption	NOUN
dpc-1595	61	24	of	of	ADP
dpc-1595	61	25	treatment	treatment	NOUN
dpc-1595	61	26	.	.	PUNCT
dpc-1595	62	1	continuous	continuous	ADJ
dpc-1595	62	2	,	,	PUNCT
dpc-1595	62	3	uninterrupted	uninterrupted	ADJ
dpc-1595	62	4	use	use	NOUN
dpc-1595	62	5	of	of	ADP
dpc-1595	62	6	cal	cal	PROPN
dpc-1595	62	7	/	/	SYM
dpc-1595	62	8	bd	bd	PROPN
dpc-1595	62	9	(	(	PUNCT
dpc-1595	62	10	once	once	ADV
dpc-1595	62	11	per	per	ADP
dpc-1595	62	12	day	day	NOUN
dpc-1595	62	13	)	)	PUNCT
dpc-1595	62	14	was	be	AUX
dpc-1595	62	15	permitted	permit	VERB
dpc-1595	62	16	for	for	ADP
dpc-1595	62	17	a	a	DET
dpc-1595	62	18	maximum	maximum	ADJ
dpc-1595	62	19	period	period	NOUN
dpc-1595	62	20	of	of	ADP
dpc-1595	62	21	4	4	NUM
dpc-1595	62	22	weeks	week	NOUN
dpc-1595	62	23	.	.	PUNCT
dpc-1595	63	1	evaluations	evaluation	NOUN
dpc-1595	63	2	were	be	AUX
dpc-1595	63	3	performed	perform	VERB
dpc-1595	63	4	at	at	ADP
dpc-1595	63	5	baseline	baseline	PROPN
dpc-1595	63	6	(	(	PUNCT
dpc-1595	63	7	visit	visit	VERB
dpc-1595	63	8	0	0	NUM
dpc-1595	63	9	)	)	PUNCT
dpc-1595	63	10	and	and	CCONJ
dpc-1595	63	11	at	at	ADP
dpc-1595	63	12	each	each	DET
dpc-1595	63	13	study	study	NOUN
dpc-1595	63	14	visit	visit	NOUN
dpc-1595	63	15	(	(	PUNCT
dpc-1595	63	16	week	week	NOUN
dpc-1595	63	17	4	4	NUM
dpc-1595	63	18	and	and	CCONJ
dpc-1595	63	19	week	week	NOUN
dpc-1595	63	20	12	12	NUM
dpc-1595	63	21	)	)	PUNCT
dpc-1595	63	22	.	.	PUNCT
dpc-1595	64	1	adherence	adherence	NOUN
dpc-1595	64	2	to	to	ADP
dpc-1595	64	3	treatment	treatment	NOUN
dpc-1595	64	4	was	be	AUX
dpc-1595	64	5	assessed	assess	VERB
dpc-1595	64	6	using	use	VERB
dpc-1595	64	7	the	the	DET
dpc-1595	64	8	morisky	morisky	NOUN
dpc-1595	64	9	-	-	PUNCT
dpc-1595	64	10	green	green	ADJ
dpc-1595	64	11	-	-	PUNCT
dpc-1595	64	12	levine	levine	NOUN
dpc-1595	64	13	scale	scale	NOUN
dpc-1595	64	14	,	,	PUNCT
dpc-1595	64	15	4	4	NUM
dpc-1595	64	16	weeks	week	NOUN
dpc-1595	64	17	and	and	CCONJ
dpc-1595	64	18	12	12	NUM
dpc-1595	64	19	weeks	week	NOUN
dpc-1595	64	20	after	after	ADP
dpc-1595	64	21	the	the	DET
dpc-1595	64	22	start	start	NOUN
dpc-1595	64	23	of	of	ADP
dpc-1595	64	24	treatment	treatment	NOUN
dpc-1595	64	25	.	.	PUNCT
dpc-1595	65	1	the	the	DET
dpc-1595	65	2	number	number	NOUN
dpc-1595	65	3	of	of	ADP
dpc-1595	65	4	cans	can	NOUN
dpc-1595	65	5	used	use	VERB
dpc-1595	65	6	by	by	ADP
dpc-1595	65	7	each	each	DET
dpc-1595	65	8	patient	patient	NOUN
dpc-1595	65	9	was	be	AUX
dpc-1595	65	10	quantified	quantify	VERB
dpc-1595	65	11	.	.	PUNCT
dpc-1595	66	1	the	the	DET
dpc-1595	66	2	degree	degree	NOUN
dpc-1595	66	3	of	of	ADP
dpc-1595	66	4	patient	patient	ADJ
dpc-1595	66	5	satisfaction	satisfaction	NOUN
dpc-1595	66	6	with	with	ADP
dpc-1595	66	7	the	the	DET
dpc-1595	66	8	treatment	treatment	NOUN
dpc-1595	66	9	was	be	AUX
dpc-1595	66	10	assessed	assess	VERB
dpc-1595	66	11	using	use	VERB
dpc-1595	66	12	the	the	DET
dpc-1595	66	13	abbreviated	abbreviate	VERB
dpc-1595	66	14	treatment	treatment	NOUN
dpc-1595	66	15	satisfaction	satisfaction	NOUN
dpc-1595	66	16	questionnaire	questionnaire	NOUN
dpc-1595	66	17	for	for	ADP
dpc-1595	66	18	medication	medication	NOUN
dpc-1595	66	19	(	(	PUNCT
dpc-1595	66	20	tsqm-9	tsqm-9	NOUN
dpc-1595	66	21	)	)	PUNCT
dpc-1595	66	22	scale	scale	NOUN
dpc-1595	66	23	at	at	ADP
dpc-1595	66	24	4	4	NUM
dpc-1595	66	25	weeks	week	NOUN
dpc-1595	66	26	,	,	PUNCT
dpc-1595	66	27	and	and	CCONJ
dpc-1595	66	28	at	at	ADP
dpc-1595	66	29	12	12	NUM
dpc-1595	66	30	weeks	week	NOUN
dpc-1595	66	31	in	in	ADP
dpc-1595	66	32	those	those	DET
dpc-1595	66	33	patients	patient	NOUN
dpc-1595	66	34	who	who	PRON
dpc-1595	66	35	restarted	restart	VERB
dpc-1595	66	36	treatment	treatment	NOUN
dpc-1595	66	37	due	due	ADP
dpc-1595	66	38	to	to	ADP
dpc-1595	66	39	regrowth	regrowth	NOUN
dpc-1595	66	40	of	of	ADP
dpc-1595	66	41	lesions	lesion	NOUN
dpc-1595	66	42	.	.	PUNCT
dpc-1595	67	1	the	the	DET
dpc-1595	67	2	severity	severity	NOUN
dpc-1595	67	3	of	of	ADP
dpc-1595	67	4	psoriasis	psoriasis	NOUN
dpc-1595	67	5	was	be	AUX
dpc-1595	67	6	assessed	assess	VERB
dpc-1595	67	7	using	use	VERB
dpc-1595	67	8	the	the	DET
dpc-1595	67	9	miga	miga	PROPN
dpc-1595	67	10	and	and	CCONJ
dpc-1595	67	11	pga	pga	PROPN
dpc-1595	67	12	scales	scale	NOUN
dpc-1595	67	13	,	,	PUNCT
dpc-1595	67	14	and	and	CCONJ
dpc-1595	67	15	the	the	DET
dpc-1595	67	16	impact	impact	NOUN
dpc-1595	67	17	on	on	ADP
dpc-1595	67	18	quality	quality	NOUN
dpc-1595	67	19	of	of	ADP
dpc-1595	67	20	life	life	NOUN
dpc-1595	67	21	was	be	AUX
dpc-1595	67	22	assessed	assess	VERB
dpc-1595	67	23	using	use	VERB
dpc-1595	67	24	the	the	DET
dpc-1595	67	25	psoriasis	psoriasis	NOUN
dpc-1595	67	26	disability	disability	NOUN
dpc-1595	67	27	index	index	NOUN
dpc-1595	67	28	(	(	PUNCT
dpc-1595	67	29	pdi	pdi	PROPN
dpc-1595	67	30	)	)	PUNCT
dpc-1595	67	31	and	and	CCONJ
dpc-1595	67	32	the	the	DET
dpc-1595	67	33	dlqi	dlqi	NOUN
dpc-1595	67	34	.	.	PUNCT
dpc-1595	68	1	the	the	DET
dpc-1595	68	2	extent	extent	NOUN
dpc-1595	68	3	and	and	CCONJ
dpc-1595	68	4	severity	severity	NOUN
dpc-1595	68	5	of	of	ADP
dpc-1595	68	6	clinical	clinical	ADJ
dpc-1595	68	7	signs	sign	NOUN
dpc-1595	68	8	of	of	ADP
dpc-1595	68	9	psoriasis	psoriasis	NOUN
dpc-1595	68	10	lesions	lesion	NOUN
dpc-1595	68	11	were	be	AUX
dpc-1595	68	12	evaluated	evaluate	VERB
dpc-1595	68	13	using	use	VERB
dpc-1595	68	14	the	the	DET
dpc-1595	68	15	mpasi	mpasi	NOUN
dpc-1595	68	16	.	.	PUNCT
dpc-1595	69	1	the	the	DET
dpc-1595	69	2	extent	extent	NOUN
dpc-1595	69	3	of	of	ADP
dpc-1595	69	4	psoriasis	psoriasis	NOUN
dpc-1595	69	5	involvement	involvement	NOUN
dpc-1595	69	6	was	be	AUX
dpc-1595	69	7	recorded	record	VERB
dpc-1595	69	8	as	as	ADP
dpc-1595	69	9	a	a	DET
dpc-1595	69	10	function	function	NOUN
dpc-1595	69	11	of	of	ADP
dpc-1595	69	12	the	the	DET
dpc-1595	69	13	affected	affected	ADJ
dpc-1595	69	14	body	body	NOUN
dpc-1595	69	15	surface	surface	NOUN
dpc-1595	69	16	area	area	NOUN
dpc-1595	69	17	(	(	PUNCT
dpc-1595	69	18	bsa	bsa	PROPN
dpc-1595	69	19	)	)	PUNCT
dpc-1595	69	20	.	.	PUNCT
dpc-1595	70	1	safety	safety	NOUN
dpc-1595	70	2	and	and	CCONJ
dpc-1595	70	3	tolerability	tolerability	NOUN
dpc-1595	70	4	were	be	AUX
dpc-1595	70	5	evaluated	evaluate	VERB
dpc-1595	70	6	after	after	ADP
dpc-1595	70	7	4	4	NUM
dpc-1595	70	8	weeks	week	NOUN
dpc-1595	70	9	of	of	ADP
dpc-1595	70	10	treatment	treatment	NOUN
dpc-1595	70	11	with	with	ADP
dpc-1595	70	12	cal	cal	PROPN
dpc-1595	70	13	/	/	SYM
dpc-1595	70	14	bd	bd	PROPN
dpc-1595	70	15	aerosol	aerosol	NOUN
dpc-1595	70	16	foam	foam	NOUN
dpc-1595	70	17	,	,	PUNCT
dpc-1595	70	18	and	and	CCONJ
dpc-1595	70	19	again	again	ADV
dpc-1595	70	20	at	at	ADP
dpc-1595	70	21	12	12	NUM
dpc-1595	70	22	weeks	week	NOUN
dpc-1595	70	23	in	in	ADP
dpc-1595	70	24	patients	patient	NOUN
dpc-1595	70	25	who	who	PRON
dpc-1595	70	26	restarted	restart	VERB
dpc-1595	70	27	topical	topical	ADJ
dpc-1595	70	28	treatment	treatment	NOUN
dpc-1595	70	29	due	due	ADP
dpc-1595	70	30	to	to	ADP
dpc-1595	70	31	the	the	DET
dpc-1595	70	32	regrowth	regrowth	NOUN
dpc-1595	70	33	of	of	ADP
dpc-1595	70	34	psoriasis	psoriasis	NOUN
dpc-1595	70	35	plaques	plaque	NOUN
dpc-1595	70	36	.	.	PUNCT
dpc-1595	71	1	serious	serious	ADJ
dpc-1595	71	2	adverse	adverse	ADJ
dpc-1595	71	3	events	event	NOUN
dpc-1595	71	4	and	and	CCONJ
dpc-1595	71	5	adverse	adverse	ADJ
dpc-1595	71	6	drug	drug	NOUN
dpc-1595	71	7	reactions	reaction	NOUN
dpc-1595	71	8	were	be	AUX
dpc-1595	71	9	recorded	record	VERB
dpc-1595	71	10	.	.	PUNCT
dpc-1595	72	1	statistical	statistical	ADJ
dpc-1595	72	2	analysis	analysis	NOUN
dpc-1595	72	3	all	all	DET
dpc-1595	72	4	analyses	analysis	NOUN
dpc-1595	72	5	were	be	AUX
dpc-1595	72	6	performed	perform	VERB
dpc-1595	72	7	using	use	VERB
dpc-1595	72	8	the	the	DET
dpc-1595	72	9	stata	stata	ADJ
dpc-1595	72	10	statistical	statistical	ADJ
dpc-1595	72	11	program	program	NOUN
dpc-1595	72	12	version	version	NOUN
dpc-1595	72	13	16.0	16.0	NUM
dpc-1595	72	14	for	for	ADP
dpc-1595	72	15	macos	macos	NOUN
dpc-1595	72	16	(	(	PUNCT
dpc-1595	72	17	statacorp	statacorp	PROPN
dpc-1595	72	18	)	)	PUNCT
dpc-1595	72	19	and	and	CCONJ
dpc-1595	72	20	the	the	DET
dpc-1595	72	21	level	level	NOUN
dpc-1595	72	22	of	of	ADP
dpc-1595	72	23	significance	significance	NOUN
dpc-1595	72	24	was	be	AUX
dpc-1595	72	25	set	set	VERB
dpc-1595	72	26	at	at	ADP
dpc-1595	72	27	p	p	NOUN
dpc-1595	72	28	<	<	X
dpc-1595	72	29	0.05	0.05	NUM
dpc-1595	72	30	.	.	PUNCT
dpc-1595	73	1	graphics	graphic	NOUN
dpc-1595	73	2	were	be	AUX
dpc-1595	73	3	made	make	VERB
dpc-1595	73	4	using	use	VERB
dpc-1595	73	5	graphpad	graphpad	NOUN
dpc-1595	73	6	prism	prism	NOUN
dpc-1595	73	7	version	version	NOUN
dpc-1595	73	8	8.0.0	8.0.0	NUM
dpc-1595	73	9	for	for	ADP
dpc-1595	73	10	macos	macos	NOUN
dpc-1595	73	11	(	(	PUNCT
dpc-1595	73	12	graphpad	graphpad	NOUN
dpc-1595	73	13	software	software	NOUN
dpc-1595	73	14	)	)	PUNCT
dpc-1595	73	15	.	.	PUNCT
dpc-1595	73	16	  	  	SPACE
dpc-1595	74	1	results	result	VERB
dpc-1595	74	2	the	the	DET
dpc-1595	74	3	study	study	NOUN
dpc-1595	74	4	enrolled	enrol	VERB
dpc-1595	74	5	65	65	NUM
dpc-1595	74	6	patients	patient	NOUN
dpc-1595	74	7	with	with	ADP
dpc-1595	74	8	plaque	plaque	NOUN
dpc-1595	74	9	psoriasis	psoriasis	NOUN
dpc-1595	74	10	,	,	PUNCT
dpc-1595	74	11	including	include	VERB
dpc-1595	74	12	33	33	NUM
dpc-1595	74	13	men	man	NOUN
dpc-1595	74	14	and	and	CCONJ
dpc-1595	74	15	32	32	NUM
dpc-1595	74	16	women	woman	NOUN
dpc-1595	74	17	,	,	PUNCT
dpc-1595	74	18	with	with	ADP
dpc-1595	74	19	a	a	DET
dpc-1595	74	20	mean	mean	ADJ
dpc-1595	74	21	age	age	NOUN
dpc-1595	74	22	of	of	ADP
dpc-1595	74	23	39.7	39.7	NUM
dpc-1595	74	24	years	year	NOUN
dpc-1595	74	25	(	(	PUNCT
dpc-1595	74	26	range	range	NOUN
dpc-1595	74	27	,	,	PUNCT
dpc-1595	74	28	18–70	18–70	NUM
dpc-1595	74	29	years	year	NOUN
dpc-1595	74	30	)	)	PUNCT
dpc-1595	74	31	.	.	PUNCT
dpc-1595	75	1	regarding	regard	VERB
dpc-1595	75	2	the	the	DET
dpc-1595	75	3	duration	duration	NOUN
dpc-1595	75	4	of	of	ADP
dpc-1595	75	5	psoriasis	psoriasis	NOUN
dpc-1595	75	6	,	,	PUNCT
dpc-1595	75	7	for	for	ADP
dpc-1595	75	8	36	36	NUM
dpc-1595	75	9	patients	patient	NOUN
dpc-1595	75	10	it	it	PRON
dpc-1595	75	11	was	be	AUX
dpc-1595	75	12	less	less	ADJ
dpc-1595	75	13	than	than	ADP
dpc-1595	75	14	5	5	NUM
dpc-1595	75	15	years	year	NOUN
dpc-1595	75	16	,	,	PUNCT
dpc-1595	75	17	for	for	ADP
dpc-1595	75	18	9	9	NUM
dpc-1595	75	19	patients	patient	NOUN
dpc-1595	75	20	it	it	PRON
dpc-1595	75	21	was	be	AUX
dpc-1595	75	22	between	between	ADP
dpc-1595	75	23	5	5	NUM
dpc-1595	75	24	and	and	CCONJ
dpc-1595	75	25	10	10	NUM
dpc-1595	75	26	years	year	NOUN
dpc-1595	75	27	,	,	PUNCT
dpc-1595	75	28	and	and	CCONJ
dpc-1595	75	29	for	for	ADP
dpc-1595	75	30	20	20	NUM
dpc-1595	75	31	patients	patient	NOUN
dpc-1595	75	32	it	it	PRON
dpc-1595	75	33	was	be	AUX
dpc-1595	75	34	greater	great	ADJ
dpc-1595	75	35	than	than	ADP
dpc-1595	75	36	10	10	NUM
dpc-1595	75	37	years	year	NOUN
dpc-1595	75	38	.	.	PUNCT
dpc-1595	76	1	no	no	DET
dpc-1595	76	2	patient	patient	NOUN
dpc-1595	76	3	had	have	AUX
dpc-1595	76	4	previously	previously	ADV
dpc-1595	76	5	undergone	undergo	VERB
dpc-1595	76	6	treatment	treatment	NOUN
dpc-1595	76	7	with	with	ADP
dpc-1595	76	8	acitretin	acitretin	NOUN
dpc-1595	76	9	,	,	PUNCT
dpc-1595	76	10	22	22	NUM
dpc-1595	76	11	patients	patient	NOUN
dpc-1595	76	12	(	(	PUNCT
dpc-1595	76	13	33.8	33.8	NUM
dpc-1595	76	14	%	%	NOUN
dpc-1595	76	15	)	)	PUNCT
dpc-1595	76	16	had	have	AUX
dpc-1595	76	17	used	use	VERB
dpc-1595	76	18	methotrexate	methotrexate	NOUN
dpc-1595	76	19	,	,	PUNCT
dpc-1595	76	20	12	12	NUM
dpc-1595	76	21	had	have	AUX
dpc-1595	76	22	used	use	VERB
dpc-1595	76	23	cyclosporine	cyclosporine	NOUN
dpc-1595	76	24	,	,	PUNCT
dpc-1595	76	25	and	and	CCONJ
dpc-1595	76	26	only	only	ADV
dpc-1595	76	27	1	1	NUM
dpc-1595	76	28	patient	patient	NOUN
dpc-1595	76	29	had	have	AUX
dpc-1595	76	30	undergone	undergo	VERB
dpc-1595	76	31	biological	biological	ADJ
dpc-1595	76	32	treatment	treatment	NOUN
dpc-1595	76	33	with	with	ADP
dpc-1595	76	34	etanercept	etanercept	NOUN
dpc-1595	76	35	(	(	PUNCT
dpc-1595	76	36	suspended	suspend	VERB
dpc-1595	76	37	in	in	ADP
dpc-1595	76	38	2016	2016	NUM
dpc-1595	76	39	by	by	ADP
dpc-1595	76	40	personal	personal	ADJ
dpc-1595	76	41	decision	decision	NOUN
dpc-1595	76	42	)	)	PUNCT
dpc-1595	76	43	.	.	PUNCT
dpc-1595	77	1	regarding	regard	VERB
dpc-1595	77	2	previous	previous	ADJ
dpc-1595	77	3	treatments	treatment	NOUN
dpc-1595	77	4	for	for	ADP
dpc-1595	77	5	psoriasis	psoriasis	NOUN
dpc-1595	77	6	,	,	PUNCT
dpc-1595	77	7	40	40	NUM
dpc-1595	77	8	patients	patient	NOUN
dpc-1595	77	9	(	(	PUNCT
dpc-1595	77	10	61.5	61.5	NUM
dpc-1595	77	11	%	%	NOUN
dpc-1595	77	12	)	)	PUNCT
dpc-1595	77	13	had	have	AUX
dpc-1595	77	14	previously	previously	ADV
dpc-1595	77	15	used	use	VERB
dpc-1595	77	16	topical	topical	ADJ
dpc-1595	77	17	corticosteroids	corticosteroid	NOUN
dpc-1595	77	18	and	and	CCONJ
dpc-1595	77	19	39	39	NUM
dpc-1595	77	20	patients	patient	NOUN
dpc-1595	77	21	(	(	PUNCT
dpc-1595	77	22	60	60	NUM
dpc-1595	77	23	%	%	NOUN
dpc-1595	77	24	)	)	PUNCT
dpc-1595	77	25	had	have	AUX
dpc-1595	77	26	previously	previously	ADV
dpc-1595	77	27	used	use	VERB
dpc-1595	77	28	cal	cal	PROPN
dpc-1595	77	29	/	/	SYM
dpc-1595	77	30	bd	bd	PROPN
dpc-1595	77	31	gel	gel	PROPN
dpc-1595	77	32	.	.	PUNCT
dpc-1595	78	1	treatment	treatment	NOUN
dpc-1595	78	2	adherence	adherence	NOUN
dpc-1595	78	3	and	and	CCONJ
dpc-1595	78	4	satisfaction	satisfaction	NOUN
dpc-1595	78	5	at	at	ADP
dpc-1595	78	6	4	4	NUM
dpc-1595	78	7	weeks	week	NOUN
dpc-1595	78	8	(	(	PUNCT
dpc-1595	78	9	visit	visit	VERB
dpc-1595	78	10	1	1	NUM
dpc-1595	78	11	)	)	PUNCT
dpc-1595	78	12	,	,	PUNCT
dpc-1595	78	13	adherence	adherence	NOUN
dpc-1595	78	14	to	to	ADP
dpc-1595	78	15	treatment	treatment	NOUN
dpc-1595	78	16	with	with	ADP
dpc-1595	78	17	cal	cal	PROPN
dpc-1595	78	18	/	/	SYM
dpc-1595	78	19	bd	bd	PROPN
dpc-1595	78	20	aerosol	aerosol	NOUN
dpc-1595	78	21	foam	foam	NOUN
dpc-1595	78	22	was	be	AUX
dpc-1595	78	23	high	high	ADJ
dpc-1595	78	24	on	on	ADP
dpc-1595	78	25	the	the	DET
dpc-1595	78	26	morisky	morisky	NOUN
dpc-1595	78	27	-	-	PUNCT
dpc-1595	78	28	green	green	ADJ
dpc-1595	78	29	-	-	PUNCT
dpc-1595	78	30	levine	levine	NOUN
dpc-1595	78	31	scale	scale	NOUN
dpc-1595	78	32	in	in	ADP
dpc-1595	78	33	100	100	NUM
dpc-1595	78	34	%	%	NOUN
dpc-1595	78	35	of	of	ADP
dpc-1595	78	36	the	the	DET
dpc-1595	78	37	participants	participant	NOUN
dpc-1595	78	38	.	.	PUNCT
dpc-1595	79	1	at	at	ADP
dpc-1595	79	2	12	12	NUM
dpc-1595	79	3	weeks	week	NOUN
dpc-1595	79	4	(	(	PUNCT
dpc-1595	79	5	visit	visit	VERB
dpc-1595	79	6	2	2	NUM
dpc-1595	79	7	)	)	PUNCT
dpc-1595	79	8	,	,	PUNCT
dpc-1595	79	9	48	48	NUM
dpc-1595	79	10	patients	patient	NOUN
dpc-1595	79	11	(	(	PUNCT
dpc-1595	79	12	73.8	73.8	NUM
dpc-1595	79	13	%	%	NOUN
dpc-1595	79	14	)	)	PUNCT
dpc-1595	79	15	showed	show	VERB
dpc-1595	79	16	high	high	ADJ
dpc-1595	79	17	adherence	adherence	NOUN
dpc-1595	79	18	,	,	PUNCT
dpc-1595	79	19	14	14	NUM
dpc-1595	79	20	patients	patient	NOUN
dpc-1595	79	21	(	(	PUNCT
dpc-1595	79	22	21.5	21.5	NUM
dpc-1595	79	23	%	%	NOUN
dpc-1595	79	24	)	)	PUNCT
dpc-1595	79	25	had	have	VERB
dpc-1595	79	26	moderate	moderate	ADJ
dpc-1595	79	27	adherence	adherence	NOUN
dpc-1595	79	28	,	,	PUNCT
dpc-1595	79	29	2	2	NUM
dpc-1595	79	30	patients	patient	NOUN
dpc-1595	79	31	had	have	VERB
dpc-1595	79	32	poor	poor	ADJ
dpc-1595	79	33	adherence	adherence	NOUN
dpc-1595	79	34	,	,	PUNCT
dpc-1595	79	35	and	and	CCONJ
dpc-1595	79	36	1	1	NUM
dpc-1595	79	37	patient	patient	NOUN
dpc-1595	79	38	was	be	AUX
dpc-1595	79	39	not	not	PART
dpc-1595	79	40	adhering	adhere	VERB
dpc-1595	79	41	to	to	ADP
dpc-1595	79	42	the	the	DET
dpc-1595	79	43	treatment	treatment	NOUN
dpc-1595	79	44	(	(	PUNCT
dpc-1595	79	45	figure	figure	NOUN
dpc-1595	79	46	1	1	NUM
dpc-1595	79	47	)	)	PUNCT
dpc-1595	79	48	.	.	PUNCT
dpc-1595	80	1	patient	patient	NOUN
dpc-1595	80	2	-	-	PUNCT
dpc-1595	80	3	reported	report	VERB
dpc-1595	80	4	satisfaction	satisfaction	NOUN
dpc-1595	80	5	was	be	AUX
dpc-1595	80	6	evaluated	evaluate	VERB
dpc-1595	80	7	using	use	VERB
dpc-1595	80	8	the	the	DET
dpc-1595	80	9	validated	validate	VERB
dpc-1595	80	10	tsqm-9	tsqm-9	NUM
dpc-1595	80	11	scale	scale	NOUN
dpc-1595	80	12	at	at	ADP
dpc-1595	80	13	4	4	NUM
dpc-1595	80	14	weeks	week	NOUN
dpc-1595	80	15	(	(	PUNCT
dpc-1595	80	16	visit	visit	VERB
dpc-1595	80	17	1	1	NUM
dpc-1595	80	18	):	):	PUNCT
dpc-1595	80	19	46	46	NUM
dpc-1595	80	20	patients	patient	NOUN
dpc-1595	80	21	(	(	PUNCT
dpc-1595	80	22	70.8	70.8	NUM
dpc-1595	80	23	%	%	NOUN
dpc-1595	80	24	)	)	PUNCT
dpc-1595	80	25	were	be	AUX
dpc-1595	80	26	completely	completely	ADV
dpc-1595	80	27	satisfied	satisfied	ADJ
dpc-1595	80	28	with	with	ADP
dpc-1595	80	29	the	the	DET
dpc-1595	80	30	treatment	treatment	NOUN
dpc-1595	80	31	,	,	PUNCT
dpc-1595	80	32	8	8	NUM
dpc-1595	80	33	patients	patient	NOUN
dpc-1595	80	34	(	(	PUNCT
dpc-1595	80	35	12.3	12.3	NUM
dpc-1595	80	36	%	%	NOUN
dpc-1595	80	37	)	)	PUNCT
dpc-1595	80	38	were	be	AUX
dpc-1595	80	39	moderately	moderately	ADV
dpc-1595	80	40	satisfied	satisfied	ADJ
dpc-1595	80	41	,	,	PUNCT
dpc-1595	80	42	and	and	CCONJ
dpc-1595	80	43	11	11	NUM
dpc-1595	80	44	patients	patient	NOUN
dpc-1595	80	45	(	(	PUNCT
dpc-1595	80	46	16.9	16.9	NUM
dpc-1595	80	47	%	%	NOUN
dpc-1595	80	48	)	)	PUNCT
dpc-1595	80	49	were	be	AUX
dpc-1595	80	50	mildly	mildly	ADV
dpc-1595	80	51	satisfied	satisfied	ADJ
dpc-1595	80	52	.	.	PUNCT
dpc-1595	81	1	the	the	DET
dpc-1595	81	2	12	12	NUM
dpc-1595	81	3	-	-	PUNCT
dpc-1595	81	4	week	week	NOUN
dpc-1595	81	5	score	score	NOUN
dpc-1595	81	6	(	(	PUNCT
dpc-1595	81	7	visit	visit	VERB
dpc-1595	81	8	2	2	NUM
dpc-1595	81	9	)	)	PUNCT
dpc-1595	81	10	on	on	ADP
dpc-1595	81	11	the	the	DET
dpc-1595	81	12	tsqm-9	tsqm-9	NUM
dpc-1595	81	13	scale	scale	NOUN
dpc-1595	81	14	showed	show	VERB
dpc-1595	81	15	that	that	SCONJ
dpc-1595	81	16	55	55	NUM
dpc-1595	81	17	patients	patient	NOUN
dpc-1595	81	18	(	(	PUNCT
dpc-1595	81	19	84.6	84.6	NUM
dpc-1595	81	20	%	%	NOUN
dpc-1595	81	21	)	)	PUNCT
dpc-1595	81	22	were	be	AUX
dpc-1595	81	23	completely	completely	ADV
dpc-1595	81	24	satisfied	satisfied	ADJ
dpc-1595	81	25	with	with	ADP
dpc-1595	81	26	the	the	DET
dpc-1595	81	27	treatment	treatment	NOUN
dpc-1595	81	28	,	,	PUNCT
dpc-1595	81	29	1	1	NUM
dpc-1595	81	30	patient	patient	NOUN
dpc-1595	81	31	was	be	AUX
dpc-1595	81	32	moderately	moderately	ADV
dpc-1595	81	33	satisfied	satisfied	ADJ
dpc-1595	81	34	,	,	PUNCT
dpc-1595	81	35	and	and	CCONJ
dpc-1595	81	36	9	9	NUM
dpc-1595	81	37	patients	patient	NOUN
dpc-1595	81	38	(	(	PUNCT
dpc-1595	81	39	13,9	13,9	NUM
dpc-1595	81	40	%	%	NOUN
dpc-1595	81	41	)	)	PUNCT
dpc-1595	81	42	were	be	AUX
dpc-1595	81	43	mildly	mildly	ADV
dpc-1595	81	44	satisfied	satisfied	ADJ
dpc-1595	81	45	.	.	PUNCT
dpc-1595	82	1	patients	patient	NOUN
dpc-1595	82	2	were	be	AUX
dpc-1595	82	3	divided	divide	VERB
dpc-1595	82	4	into	into	ADP
dpc-1595	82	5	3	3	NUM
dpc-1595	82	6	groups	group	NOUN
dpc-1595	82	7	on	on	ADP
dpc-1595	82	8	the	the	DET
dpc-1595	82	9	basis	basis	NOUN
dpc-1595	82	10	of	of	ADP
dpc-1595	82	11	their	their	PRON
dpc-1595	82	12	treatment	treatment	NOUN
dpc-1595	82	13	adherence	adherence	NOUN
dpc-1595	82	14	,	,	PUNCT
dpc-1595	82	15	and	and	CCONJ
dpc-1595	82	16	the	the	DET
dpc-1595	82	17	mean	mean	NOUN
dpc-1595	82	18	tsqm-9	tsqm-9	NUM
dpc-1595	82	19	score	score	NOUN
dpc-1595	82	20	was	be	AUX
dpc-1595	82	21	calculated	calculate	VERB
dpc-1595	82	22	for	for	ADP
dpc-1595	82	23	each	each	DET
dpc-1595	82	24	group	group	NOUN
dpc-1595	82	25	(	(	PUNCT
dpc-1595	82	26	figure	figure	NOUN
dpc-1595	82	27	2	2	NUM
dpc-1595	82	28	)	)	PUNCT
dpc-1595	82	29	.	.	PUNCT
dpc-1595	83	1	there	there	PRON
dpc-1595	83	2	was	be	VERB
dpc-1595	83	3	a	a	DET
dpc-1595	83	4	significant	significant	ADJ
dpc-1595	83	5	difference	difference	NOUN
dpc-1595	83	6	in	in	ADP
dpc-1595	83	7	tsqm-9	tsqm-9	NOUN
dpc-1595	83	8	scores	score	NOUN
dpc-1595	83	9	between	between	ADP
dpc-1595	83	10	patients	patient	NOUN
dpc-1595	83	11	who	who	PRON
dpc-1595	83	12	had	have	VERB
dpc-1595	83	13	high	high	ADJ
dpc-1595	83	14	adherence	adherence	NOUN
dpc-1595	83	15	to	to	ADP
dpc-1595	83	16	treatment	treatment	NOUN
dpc-1595	83	17	and	and	CCONJ
dpc-1595	83	18	those	those	PRON
dpc-1595	83	19	who	who	PRON
dpc-1595	83	20	had	have	VERB
dpc-1595	83	21	low	low	ADJ
dpc-1595	83	22	or	or	CCONJ
dpc-1595	83	23	no	no	PRON
dpc-1595	83	24	adherence	adherence	NOUN
dpc-1595	83	25	(	(	PUNCT
dpc-1595	83	26	t	t	NOUN
dpc-1595	83	27	=	=	SYM
dpc-1595	83	28	32,573	32,573	NUM
dpc-1595	83	29	;	;	PUNCT
dpc-1595	83	30	p	p	X
dpc-1595	83	31	=	=	NOUN
dpc-1595	83	32	0.007	0.007	NUM
dpc-1595	83	33	)	)	PUNCT
dpc-1595	83	34	.	.	PUNCT
dpc-1595	84	1	a	a	DET
dpc-1595	84	2	kruskal	kruskal	PROPN
dpc-1595	84	3	-	-	PUNCT
dpc-1595	84	4	wallis	wallis	PROPN
dpc-1595	84	5	test	test	NOUN
dpc-1595	84	6	was	be	AUX
dpc-1595	84	7	performed	perform	VERB
dpc-1595	84	8	to	to	PART
dpc-1595	84	9	check	check	VERB
dpc-1595	84	10	for	for	ADP
dpc-1595	84	11	significant	significant	ADJ
dpc-1595	84	12	intergroup	intergroup	NOUN
dpc-1595	84	13	differences	difference	NOUN
dpc-1595	84	14	.	.	PUNCT
dpc-1595	85	1	a	a	DET
dpc-1595	85	2	significant	significant	ADJ
dpc-1595	85	3	relationship	relationship	NOUN
dpc-1595	85	4	between	between	ADP
dpc-1595	85	5	adherence	adherence	NOUN
dpc-1595	85	6	and	and	CCONJ
dpc-1595	85	7	efficacy	efficacy	NOUN
dpc-1595	85	8	was	be	AUX
dpc-1595	85	9	evident	evident	ADJ
dpc-1595	85	10	,	,	PUNCT
dpc-1595	85	11	and	and	CCONJ
dpc-1595	85	12	there	there	PRON
dpc-1595	85	13	were	be	VERB
dpc-1595	85	14	also	also	ADV
dpc-1595	85	15	significant	significant	ADJ
dpc-1595	85	16	intergroup	intergroup	ADJ
dpc-1595	85	17	differences	difference	NOUN
dpc-1595	85	18	in	in	ADP
dpc-1595	85	19	favor	favor	NOUN
dpc-1595	85	20	of	of	ADP
dpc-1595	85	21	high	high	ADJ
dpc-1595	85	22	adherence	adherence	NOUN
dpc-1595	85	23	in	in	ADP
dpc-1595	85	24	all	all	DET
dpc-1595	85	25	comparisons	comparison	NOUN
dpc-1595	85	26	.	.	PUNCT
dpc-1595	86	1	the	the	DET
dpc-1595	86	2	results	result	NOUN
dpc-1595	86	3	are	be	AUX
dpc-1595	86	4	reported	report	VERB
dpc-1595	86	5	in	in	ADP
dpc-1595	86	6	table	table	NOUN
dpc-1595	86	7	2	2	NUM
dpc-1595	86	8	.	.	PUNCT
dpc-1595	87	1	efficacy	efficacy	VERB
dpc-1595	87	2	the	the	DET
dpc-1595	87	3	evolution	evolution	NOUN
dpc-1595	87	4	of	of	ADP
dpc-1595	87	5	psoriasis	psoriasis	NOUN
dpc-1595	87	6	severity	severity	NOUN
dpc-1595	87	7	(	(	PUNCT
dpc-1595	87	8	assessed	assess	VERB
dpc-1595	87	9	with	with	ADP
dpc-1595	87	10	pasi	pasi	PROPN
dpc-1595	87	11	,	,	PUNCT
dpc-1595	87	12	bsa	bsa	PROPN
dpc-1595	87	13	)	)	PUNCT
dpc-1595	87	14	is	be	AUX
dpc-1595	87	15	shown	show	VERB
dpc-1595	87	16	in	in	ADP
dpc-1595	87	17	figure	figure	NOUN
dpc-1595	87	18	3	3	NUM
dpc-1595	87	19	.	.	PUNCT
dpc-1595	88	1	the	the	DET
dpc-1595	88	2	evolution	evolution	NOUN
dpc-1595	88	3	of	of	ADP
dpc-1595	88	4	psoriasis	psoriasis	NOUN
dpc-1595	88	5	severity	severity	NOUN
dpc-1595	88	6	(	(	PUNCT
dpc-1595	88	7	assessed	assess	VERB
dpc-1595	88	8	with	with	ADP
dpc-1595	88	9	bsa	bsa	PROPN
dpc-1595	88	10	)	)	PUNCT
dpc-1595	88	11	according	accord	VERB
dpc-1595	88	12	to	to	ADP
dpc-1595	88	13	treatment	treatment	NOUN
dpc-1595	88	14	adherence	adherence	NOUN
dpc-1595	88	15	is	be	AUX
dpc-1595	88	16	shown	show	VERB
dpc-1595	88	17	in	in	ADP
dpc-1595	88	18	figure	figure	NOUN
dpc-1595	88	19	4	4	NUM
dpc-1595	88	20	.	.	PUNCT
dpc-1595	89	1	the	the	DET
dpc-1595	89	2	mean	mean	PROPN
dpc-1595	89	3	iga	iga	PROPN
dpc-1595	89	4	score	score	NOUN
dpc-1595	89	5	was	be	AUX
dpc-1595	89	6	1.954	1.954	NUM
dpc-1595	89	7	(	(	PUNCT
dpc-1595	89	8	sd	sd	NOUN
dpc-1595	89	9	=	=	SYM
dpc-1595	89	10	0.891	0.891	NUM
dpc-1595	89	11	)	)	PUNCT
dpc-1595	89	12	at	at	ADP
dpc-1595	89	13	the	the	DET
dpc-1595	89	14	baseline	baseline	PROPN
dpc-1595	89	15	visit	visit	NOUN
dpc-1595	89	16	,	,	PUNCT
dpc-1595	89	17	0.94	0.94	NUM
dpc-1595	89	18	(	(	PUNCT
dpc-1595	89	19	sd	sd	NOUN
dpc-1595	89	20	=	=	SYM
dpc-1595	89	21	0.982	0.982	NUM
dpc-1595	89	22	)	)	PUNCT
dpc-1595	89	23	at	at	ADP
dpc-1595	89	24	visit	visit	NOUN
dpc-1595	89	25	1	1	NUM
dpc-1595	89	26	,	,	PUNCT
dpc-1595	89	27	and	and	CCONJ
dpc-1595	89	28	0.62	0.62	NUM
dpc-1595	89	29	(	(	PUNCT
dpc-1595	89	30	sd	sd	NOUN
dpc-1595	89	31	=	=	SYM
dpc-1595	89	32	1.128	1.128	NUM
dpc-1595	89	33	)	)	PUNCT
dpc-1595	89	34	at	at	ADP
dpc-1595	89	35	visit	visit	NOUN
dpc-1595	89	36	2	2	NUM
dpc-1595	89	37	.	.	PUNCT
dpc-1595	90	1	the	the	DET
dpc-1595	90	2	mean	mean	ADJ
dpc-1595	90	3	pga	pga	NOUN
dpc-1595	90	4	score	score	NOUN
dpc-1595	90	5	was	be	AUX
dpc-1595	90	6	2.8	2.8	NUM
dpc-1595	90	7	(	(	PUNCT
dpc-1595	90	8	sd	sd	NOUN
dpc-1595	90	9	=	=	PUNCT
dpc-1595	90	10	0.905	0.905	NUM
dpc-1595	90	11	)	)	PUNCT
dpc-1595	90	12	at	at	ADP
dpc-1595	90	13	the	the	DET
dpc-1595	90	14	baseline	baseline	PROPN
dpc-1595	90	15	visit	visit	NOUN
dpc-1595	90	16	,	,	PUNCT
dpc-1595	90	17	1.19	1.19	NUM
dpc-1595	90	18	(	(	PUNCT
dpc-1595	90	19	sd	sd	NOUN
dpc-1595	90	20	=	=	SYM
dpc-1595	90	21	1.211	1.211	NUM
dpc-1595	90	22	)	)	PUNCT
dpc-1595	90	23	at	at	ADP
dpc-1595	90	24	visit	visit	NOUN
dpc-1595	90	25	1	1	NUM
dpc-1595	90	26	,	,	PUNCT
dpc-1595	90	27	and	and	CCONJ
dpc-1595	90	28	0.77	0.77	NUM
dpc-1595	90	29	(	(	PUNCT
dpc-1595	90	30	sd	sd	NOUN
dpc-1595	90	31	=	=	SYM
dpc-1595	90	32	1.1487	1.1487	NUM
dpc-1595	90	33	)	)	PUNCT
dpc-1595	90	34	at	at	ADP
dpc-1595	90	35	visit	visit	NOUN
dpc-1595	90	36	2	2	NUM
dpc-1595	90	37	.	.	PUNCT
dpc-1595	90	38	patients	patient	NOUN
dpc-1595	90	39	with	with	ADP
dpc-1595	90	40	psoriasis	psoriasis	NOUN
dpc-1595	90	41	of	of	ADP
dpc-1595	90	42	less	less	ADJ
dpc-1595	90	43	than	than	ADP
dpc-1595	90	44	5	5	NUM
dpc-1595	90	45	years	year	NOUN
dpc-1595	90	46	’	'	PUNCT
dpc-1595	90	47	duration	duration	NOUN
dpc-1595	90	48	had	have	VERB
dpc-1595	90	49	a	a	DET
dpc-1595	90	50	good	good	ADJ
dpc-1595	90	51	response	response	NOUN
dpc-1595	90	52	to	to	ADP
dpc-1595	90	53	topical	topical	ADJ
dpc-1595	90	54	treatment	treatment	NOUN
dpc-1595	90	55	with	with	ADP
dpc-1595	90	56	cal	cal	PROPN
dpc-1595	90	57	/	/	SYM
dpc-1595	90	58	bd	bd	PROPN
dpc-1595	90	59	aerosol	aerosol	NOUN
dpc-1595	90	60	foam	foam	NOUN
dpc-1595	90	61	,	,	PUNCT
dpc-1595	90	62	with	with	ADP
dpc-1595	90	63	a	a	DET
dpc-1595	90	64	mean	mean	ADJ
dpc-1595	90	65	pasi	pasi	NOUN
dpc-1595	90	66	score	score	NOUN
dpc-1595	90	67	at	at	ADP
dpc-1595	90	68	week	week	NOUN
dpc-1595	90	69	4	4	NUM
dpc-1595	90	70	of	of	ADP
dpc-1595	90	71	0.49	0.49	NUM
dpc-1595	90	72	(	(	PUNCT
dpc-1595	90	73	sd	sd	NOUN
dpc-1595	90	74	=	=	SYM
dpc-1595	90	75	0.70	0.70	NUM
dpc-1595	90	76	)	)	PUNCT
dpc-1595	90	77	and	and	CCONJ
dpc-1595	90	78	at	at	ADP
dpc-1595	90	79	week	week	NOUN
dpc-1595	90	80	12	12	NUM
dpc-1595	90	81	of	of	ADP
dpc-1595	90	82	0.13	0.13	NUM
dpc-1595	90	83	(	(	PUNCT
dpc-1595	90	84	sd	sd	NOUN
dpc-1595	90	85	0.30	0.30	NUM
dpc-1595	90	86	)	)	PUNCT
dpc-1595	90	87	(	(	PUNCT
dpc-1595	90	88	p	p	X
dpc-1595	90	89	<	<	X
dpc-1595	90	90	0.01	0.01	NUM
dpc-1595	90	91	)	)	PUNCT
dpc-1595	90	92	.	.	PUNCT
dpc-1595	91	1	patients	patient	NOUN
dpc-1595	91	2	with	with	ADP
dpc-1595	91	3	psoriasis	psoriasis	NOUN
dpc-1595	91	4	4	4	NUM
dpc-1595	91	5	research	research	NOUN
dpc-1595	91	6	|	|	ADV
dpc-1595	91	7	dermatol	dermatol	ADJ
dpc-1595	91	8	pract	pract	NOUN
dpc-1595	91	9	concept	concept	NOUN
dpc-1595	91	10	.	.	PUNCT
dpc-1595	92	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	92	2	table	table	NOUN
dpc-1595	92	3	1	1	NUM
dpc-1595	92	4	.	.	PUNCT
dpc-1595	92	5	characteristics	characteristic	NOUN
dpc-1595	92	6	of	of	ADP
dpc-1595	92	7	the	the	DET
dpc-1595	92	8	65	65	NUM
dpc-1595	92	9	patients	patient	NOUN
dpc-1595	92	10	with	with	ADP
dpc-1595	92	11	plaque	plaque	NOUN
dpc-1595	92	12	psoriasis	psoriasis	NOUN
dpc-1595	92	13	,	,	PUNCT
dpc-1595	92	14	at	at	ADP
dpc-1595	92	15	inclusion	inclusion	NOUN
dpc-1595	92	16	characteristic	characteristic	ADJ
dpc-1595	92	17	value	value	NOUN
dpc-1595	92	18	age	age	NOUN
dpc-1595	92	19	,	,	PUNCT
dpc-1595	92	20	years	year	NOUN
dpc-1595	92	21	,	,	PUNCT
dpc-1595	92	22	mean	mean	INTJ
dpc-1595	92	23	(	(	PUNCT
dpc-1595	92	24	sd	sd	NOUN
dpc-1595	92	25	)	)	PUNCT
dpc-1595	92	26	39.7	39.7	NUM
dpc-1595	92	27	(	(	PUNCT
dpc-1595	92	28	12.9	12.9	NUM
dpc-1595	92	29	)	)	PUNCT
dpc-1595	92	30	sex	sex	NOUN
dpc-1595	92	31	,	,	PUNCT
dpc-1595	92	32	n	n	PRON
dpc-1595	92	33	male	male	NOUN
dpc-1595	92	34	33	33	NUM
dpc-1595	92	35	female	female	ADJ
dpc-1595	92	36	32	32	NUM
dpc-1595	92	37	marital	marital	ADJ
dpc-1595	92	38	status	status	NOUN
dpc-1595	92	39	,	,	PUNCT
dpc-1595	92	40	n	n	PROPN
dpc-1595	92	41	(	(	PUNCT
dpc-1595	92	42	%	%	INTJ
dpc-1595	92	43	)	)	PUNCT
dpc-1595	92	44	single	single	ADJ
dpc-1595	92	45	21(32.3	21(32.3	NOUN
dpc-1595	92	46	)	)	PUNCT
dpc-1595	92	47	married	marry	VERB
dpc-1595	92	48	43	43	NUM
dpc-1595	92	49	(	(	PUNCT
dpc-1595	92	50	66.2	66.2	NUM
dpc-1595	92	51	)	)	PUNCT
dpc-1595	92	52	widowed	widow	VERB
dpc-1595	92	53	1	1	NUM
dpc-1595	92	54	(	(	PUNCT
dpc-1595	92	55	1.5	1.5	NUM
dpc-1595	92	56	)	)	PUNCT
dpc-1595	92	57	education	education	NOUN
dpc-1595	92	58	,	,	PUNCT
dpc-1595	92	59	n	n	CCONJ
dpc-1595	92	60	(	(	PUNCT
dpc-1595	92	61	%	%	INTJ
dpc-1595	92	62	)	)	PUNCT
dpc-1595	92	63	secondary	secondary	ADJ
dpc-1595	92	64	school	school	NOUN
dpc-1595	92	65	20	20	NUM
dpc-1595	92	66	(	(	PUNCT
dpc-1595	92	67	30.8	30.8	NUM
dpc-1595	92	68	)	)	PUNCT
dpc-1595	92	69	high	high	ADJ
dpc-1595	92	70	school	school	NOUN
dpc-1595	92	71	certificate	certificate	NOUN
dpc-1595	92	72	28	28	NUM
dpc-1595	92	73	(	(	PUNCT
dpc-1595	92	74	43.1	43.1	NUM
dpc-1595	92	75	)	)	PUNCT
dpc-1595	92	76	tertiary	tertiary	ADJ
dpc-1595	92	77	17(26.2	17(26.2	NOUN
dpc-1595	92	78	)	)	PUNCT
dpc-1595	92	79	occupational	occupational	ADJ
dpc-1595	92	80	status	status	NOUN
dpc-1595	92	81	,	,	PUNCT
dpc-1595	92	82	n	n	PROPN
dpc-1595	92	83	(	(	PUNCT
dpc-1595	92	84	%	%	INTJ
dpc-1595	92	85	)	)	PUNCT
dpc-1595	92	86	working	work	VERB
dpc-1595	92	87	or	or	CCONJ
dpc-1595	92	88	studying	study	VERB
dpc-1595	92	89	13	13	NUM
dpc-1595	92	90	(	(	PUNCT
dpc-1595	92	91	20.0	20.0	NUM
dpc-1595	92	92	)	)	PUNCT
dpc-1595	92	93	unemployed	unemployed	ADJ
dpc-1595	92	94	or	or	CCONJ
dpc-1595	92	95	disabled	disabled	ADJ
dpc-1595	92	96	42	42	NUM
dpc-1595	92	97	(	(	PUNCT
dpc-1595	92	98	64.6	64.6	NUM
dpc-1595	92	99	)	)	PUNCT
dpc-1595	92	100	retired	retire	VERB
dpc-1595	92	101	10	10	NUM
dpc-1595	92	102	(	(	PUNCT
dpc-1595	92	103	15.4	15.4	NUM
dpc-1595	92	104	)	)	PUNCT
dpc-1595	92	105	duration	duration	NOUN
dpc-1595	92	106	of	of	ADP
dpc-1595	92	107	psoriasis	psoriasis	NOUN
dpc-1595	92	108	,	,	PUNCT
dpc-1595	92	109	years	year	NOUN
dpc-1595	92	110	mean	mean	VERB
dpc-1595	92	111	(	(	PUNCT
dpc-1595	92	112	sd	sd	NOUN
dpc-1595	92	113	)	)	PUNCT
dpc-1595	92	114	9.5	9.5	NUM
dpc-1595	92	115	(	(	PUNCT
dpc-1595	92	116	9.5	9.5	NUM
dpc-1595	92	117	)	)	PUNCT
dpc-1595	92	118	previous	previous	ADJ
dpc-1595	92	119	therapy	therapy	NOUN
dpc-1595	92	120	with	with	ADP
dpc-1595	92	121	topical	topical	ADJ
dpc-1595	92	122	drugs	drug	NOUN
dpc-1595	92	123	,	,	PUNCT
dpc-1595	92	124	n	n	PROPN
dpc-1595	92	125	(	(	PUNCT
dpc-1595	92	126	%	%	INTJ
dpc-1595	92	127	)	)	PUNCT
dpc-1595	92	128	topical	topical	ADJ
dpc-1595	92	129	corticosteroids	corticosteroid	NOUN
dpc-1595	92	130	40	40	NUM
dpc-1595	92	131	(	(	PUNCT
dpc-1595	92	132	61.5	61.5	NUM
dpc-1595	92	133	)	)	PUNCT
dpc-1595	92	134	vitamin	vitamin	NOUN
dpc-1595	92	135	d3	d3	PROPN
dpc-1595	92	136	analogs	analog	NOUN
dpc-1595	92	137	8	8	NUM
dpc-1595	92	138	(	(	PUNCT
dpc-1595	92	139	12.0	12.0	NUM
dpc-1595	92	140	)	)	PUNCT
dpc-1595	92	141	cal	cal	PROPN
dpc-1595	92	142	/	/	SYM
dpc-1595	92	143	bd	bd	PROPN
dpc-1595	92	144	gel	gel	NOUN
dpc-1595	92	145	(	(	PUNCT
dpc-1595	92	146	daivobet	daivobet	NOUN
dpc-1595	92	147	)	)	PUNCT
dpc-1595	92	148	39	39	NUM
dpc-1595	92	149	(	(	PUNCT
dpc-1595	92	150	60.0	60.0	NUM
dpc-1595	92	151	)	)	PUNCT
dpc-1595	92	152	previous	previous	ADJ
dpc-1595	92	153	therapy	therapy	NOUN
dpc-1595	92	154	with	with	ADP
dpc-1595	92	155	systemic	systemic	ADJ
dpc-1595	92	156	drugs	drug	NOUN
dpc-1595	92	157	,	,	PUNCT
dpc-1595	92	158	n	n	PROPN
dpc-1595	92	159	(	(	PUNCT
dpc-1595	92	160	%	%	INTJ
dpc-1595	92	161	)	)	PUNCT
dpc-1595	92	162	methotrexate	methotrexate	NOUN
dpc-1595	92	163	22	22	NUM
dpc-1595	92	164	(	(	PUNCT
dpc-1595	92	165	33.8	33.8	NUM
dpc-1595	92	166	)	)	PUNCT
dpc-1595	92	167	cyclosporine	cyclosporine	NOUN
dpc-1595	92	168	12	12	NUM
dpc-1595	92	169	(	(	PUNCT
dpc-1595	92	170	18.5	18.5	NUM
dpc-1595	92	171	)	)	PUNCT
dpc-1595	92	172	acitretin	acitretin	NOUN
dpc-1595	92	173	0	0	NUM
dpc-1595	93	1	(	(	PUNCT
dpc-1595	93	2	0	0	NUM
dpc-1595	93	3	)	)	PUNCT
dpc-1595	93	4	fumaric	fumaric	ADJ
dpc-1595	93	5	acid	acid	NOUN
dpc-1595	93	6	ester	ester	NOUN
dpc-1595	93	7	0	0	NUM
dpc-1595	94	1	(	(	PUNCT
dpc-1595	94	2	0	0	NUM
dpc-1595	94	3	)	)	PUNCT
dpc-1595	94	4	biological	biological	ADJ
dpc-1595	94	5	drugs	drug	NOUN
dpc-1595	94	6	1	1	NUM
dpc-1595	94	7	(	(	PUNCT
dpc-1595	94	8	1.5	1.5	NUM
dpc-1595	94	9	)	)	PUNCT
dpc-1595	94	10	none	none	NOUN
dpc-1595	94	11	(	(	PUNCT
dpc-1595	94	12	46.2	46.2	NUM
dpc-1595	94	13	)	)	PUNCT
dpc-1595	94	14	sd	sd	NOUN
dpc-1595	94	15	=	=	SYM
dpc-1595	94	16	standard	standard	ADJ
dpc-1595	94	17	deviation	deviation	NOUN
dpc-1595	94	18	.	.	PUNCT
dpc-1595	95	1	figure	figure	NOUN
dpc-1595	95	2	1	1	NUM
dpc-1595	95	3	.	.	PUNCT
dpc-1595	96	1	morisky	morisky	NOUN
dpc-1595	96	2	-	-	PUNCT
dpc-1595	96	3	green	green	NOUN
dpc-1595	96	4	scores	score	NOUN
dpc-1595	96	5	for	for	ADP
dpc-1595	96	6	adherence	adherence	NOUN
dpc-1595	96	7	to	to	ADP
dpc-1595	96	8	cal	cal	PROPN
dpc-1595	96	9	/	/	SYM
dpc-1595	96	10	bd	bd	PROPN
dpc-1595	96	11	treatment	treatment	NOUN
dpc-1595	96	12	at	at	ADP
dpc-1595	96	13	12	12	NUM
dpc-1595	96	14	weeks	week	NOUN
dpc-1595	96	15	(	(	PUNCT
dpc-1595	96	16	visit	visit	VERB
dpc-1595	96	17	2	2	NUM
dpc-1595	96	18	)	)	PUNCT
dpc-1595	96	19	.	.	PUNCT
dpc-1595	97	1	high	high	ADJ
dpc-1595	97	2	adherence	adherence	NOUN
dpc-1595	97	3	was	be	AUX
dpc-1595	97	4	observed	observe	VERB
dpc-1595	97	5	in	in	ADP
dpc-1595	97	6	73.8	73.8	NUM
dpc-1595	97	7	%	%	NOUN
dpc-1595	97	8	.	.	PUNCT
dpc-1595	98	1	only	only	ADV
dpc-1595	98	2	4.6	4.6	NUM
dpc-1595	98	3	%	%	NOUN
dpc-1595	98	4	was	be	AUX
dpc-1595	98	5	reported	report	VERB
dpc-1595	98	6	as	as	ADP
dpc-1595	98	7	a	a	DET
dpc-1595	98	8	non	non	ADJ
dpc-1595	98	9	-	-	ADJ
dpc-1595	98	10	adherence	adherence	ADJ
dpc-1595	98	11	treatment	treatment	NOUN
dpc-1595	98	12	.	.	PUNCT
dpc-1595	99	1	morisky	morisky	ADJ
dpc-1595	99	2	–	–	PUNCT
dpc-1595	99	3	green	green	ADJ
dpc-1595	99	4	scale	scale	NOUN
dpc-1595	99	5	3	3	NUM
dpc-1595	99	6	month	month	NOUN
dpc-1595	99	7	73.8	73.8	NUM
dpc-1595	99	8	%	%	NOUN
dpc-1595	99	9	1.5	1.5	NUM
dpc-1595	99	10	%	%	NOUN
dpc-1595	99	11	3.1	3.1	NUM
dpc-1595	99	12	%	%	NOUN
dpc-1595	99	13	21.5	21.5	NUM
dpc-1595	99	14	%	%	NOUN
dpc-1595	99	15	high	high	ADJ
dpc-1595	99	16	adherence	adherence	NOUN
dpc-1595	99	17	moderate	moderate	ADJ
dpc-1595	99	18	adherence	adherence	NOUN
dpc-1595	99	19	bad	bad	ADJ
dpc-1595	99	20	adherence	adherence	NOUN
dpc-1595	99	21	no	no	DET
dpc-1595	99	22	adherence	adherence	NOUN
dpc-1595	99	23	of	of	ADP
dpc-1595	99	24	more	more	ADJ
dpc-1595	99	25	than	than	ADP
dpc-1595	99	26	10	10	NUM
dpc-1595	99	27	years	year	NOUN
dpc-1595	99	28	’	'	PUNCT
dpc-1595	99	29	evolution	evolution	NOUN
dpc-1595	99	30	had	have	VERB
dpc-1595	99	31	a	a	DET
dpc-1595	99	32	poor	poor	ADJ
dpc-1595	99	33	response	response	NOUN
dpc-1595	99	34	to	to	ADP
dpc-1595	99	35	cal/	cal/	PROPN
dpc-1595	99	36	bd	bd	PROPN
dpc-1595	99	37	aerosol	aerosol	VERB
dpc-1595	99	38	foam	foam	NOUN
dpc-1595	99	39	,	,	PUNCT
dpc-1595	99	40	with	with	ADP
dpc-1595	99	41	no	no	DET
dpc-1595	99	42	significant	significant	ADJ
dpc-1595	99	43	change	change	NOUN
dpc-1595	99	44	in	in	ADP
dpc-1595	99	45	pasi	pasi	NOUN
dpc-1595	99	46	scores	score	NOUN
dpc-1595	99	47	from	from	ADP
dpc-1595	99	48	week	week	NOUN
dpc-1595	99	49	4	4	NUM
dpc-1595	99	50	(	(	PUNCT
dpc-1595	99	51	mean	mean	NOUN
dpc-1595	99	52	=	=	SYM
dpc-1595	99	53	2.45	2.45	NUM
dpc-1595	99	54	;	;	PUNCT
dpc-1595	99	55	sd	sd	ADP
dpc-1595	99	56	=	=	SYM
dpc-1595	99	57	1.71	1.71	NUM
dpc-1595	99	58	)	)	PUNCT
dpc-1595	99	59	to	to	ADP
dpc-1595	99	60	week	week	NOUN
dpc-1595	99	61	12	12	NUM
dpc-1595	99	62	(	(	PUNCT
dpc-1595	99	63	mean	mean	NOUN
dpc-1595	99	64	=	=	SYM
dpc-1595	99	65	2.15	2.15	NUM
dpc-1595	99	66	;	;	PUNCT
dpc-1595	99	67	sd	sd	ADP
dpc-1595	99	68	=	=	NUM
dpc-1595	99	69	2.41	2.41	NUM
dpc-1595	99	70	;	;	PUNCT
dpc-1595	99	71	p	p	NOUN
dpc-1595	99	72	=	=	NOUN
dpc-1595	99	73	1	1	NUM
dpc-1595	99	74	)	)	PUNCT
dpc-1595	99	75	.	.	PUNCT
dpc-1595	100	1	quality	quality	NOUN
dpc-1595	100	2	of	of	ADP
dpc-1595	100	3	life	life	NOUN
dpc-1595	100	4	,	,	PUNCT
dpc-1595	100	5	safety	safety	NOUN
dpc-1595	100	6	and	and	CCONJ
dpc-1595	100	7	satisfaction	satisfaction	NOUN
dpc-1595	100	8	the	the	DET
dpc-1595	100	9	mean	mean	ADJ
dpc-1595	100	10	dlqi	dlqi	ADJ
dpc-1595	100	11	score	score	NOUN
dpc-1595	100	12	was	be	AUX
dpc-1595	100	13	10.67	10.67	NUM
dpc-1595	100	14	(	(	PUNCT
dpc-1595	100	15	sd	sd	NOUN
dpc-1595	100	16	=	=	SYM
dpc-1595	100	17	4.96	4.96	NUM
dpc-1595	100	18	)	)	PUNCT
dpc-1595	100	19	at	at	ADP
dpc-1595	100	20	the	the	DET
dpc-1595	100	21	baseline	baseline	PROPN
dpc-1595	100	22	visit	visit	NOUN
dpc-1595	100	23	,	,	PUNCT
dpc-1595	100	24	2.41	2.41	NUM
dpc-1595	100	25	(	(	PUNCT
dpc-1595	100	26	sd	sd	NOUN
dpc-1595	100	27	=	=	SYM
dpc-1595	100	28	3.87	3.87	NUM
dpc-1595	100	29	)	)	PUNCT
dpc-1595	100	30	at	at	ADP
dpc-1595	100	31	visit	visit	NOUN
dpc-1595	100	32	1	1	NUM
dpc-1595	100	33	,	,	PUNCT
dpc-1595	100	34	and	and	CCONJ
dpc-1595	100	35	2.24	2.24	NUM
dpc-1595	100	36	(	(	PUNCT
dpc-1595	100	37	sd	sd	NOUN
dpc-1595	100	38	=	=	PUNCT
dpc-1595	100	39	research	research	NOUN
dpc-1595	100	40	|	|	ADV
dpc-1595	100	41	dermatol	dermatol	ADJ
dpc-1595	100	42	pract	pract	NOUN
dpc-1595	100	43	concept	concept	NOUN
dpc-1595	100	44	.	.	PUNCT
dpc-1595	101	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	101	2	5	5	NUM
dpc-1595	101	3	5.25	5.25	NUM
dpc-1595	101	4	)	)	PUNCT
dpc-1595	101	5	at	at	ADP
dpc-1595	101	6	visit	visit	NOUN
dpc-1595	101	7	2	2	NUM
dpc-1595	101	8	.	.	PUNCT
dpc-1595	102	1	the	the	DET
dpc-1595	102	2	mean	mean	ADJ
dpc-1595	102	3	pdi	pdi	PROPN
dpc-1595	102	4	score	score	NOUN
dpc-1595	102	5	was	be	AUX
dpc-1595	102	6	21.37	21.37	NUM
dpc-1595	102	7	(	(	PUNCT
dpc-1595	102	8	sd	sd	NOUN
dpc-1595	102	9	=	=	SYM
dpc-1595	102	10	9.63	9.63	NUM
dpc-1595	102	11	)	)	PUNCT
dpc-1595	102	12	at	at	ADP
dpc-1595	102	13	the	the	DET
dpc-1595	102	14	baseline	baseline	PROPN
dpc-1595	102	15	visit	visit	NOUN
dpc-1595	102	16	,	,	PUNCT
dpc-1595	102	17	5.94	5.94	NUM
dpc-1595	102	18	(	(	PUNCT
dpc-1595	102	19	sd	sd	NOUN
dpc-1595	102	20	=	=	NOUN
dpc-1595	102	21	7.64	7.64	NUM
dpc-1595	102	22	)	)	PUNCT
dpc-1595	102	23	at	at	ADP
dpc-1595	102	24	visit	visit	NOUN
dpc-1595	102	25	1	1	NUM
dpc-1595	102	26	,	,	PUNCT
dpc-1595	102	27	and	and	CCONJ
dpc-1595	102	28	4.41	4.41	NUM
dpc-1595	102	29	(	(	PUNCT
dpc-1595	102	30	sd	sd	NOUN
dpc-1595	102	31	=	=	SYM
dpc-1595	102	32	9.92	9.92	NUM
dpc-1595	102	33	)	)	PUNCT
dpc-1595	102	34	at	at	ADP
dpc-1595	102	35	visit	visit	NOUN
dpc-1595	102	36	2	2	NUM
dpc-1595	102	37	.	.	PUNCT
dpc-1595	103	1	no	no	DET
dpc-1595	103	2	patient	patient	NOUN
dpc-1595	103	3	had	have	VERB
dpc-1595	103	4	side	side	ADJ
dpc-1595	103	5	effects	effect	NOUN
dpc-1595	103	6	related	relate	VERB
dpc-1595	103	7	to	to	ADP
dpc-1595	103	8	application	application	NOUN
dpc-1595	103	9	of	of	ADP
dpc-1595	103	10	cal/	cal/	PROPN
dpc-1595	103	11	bd	bd	PROPN
dpc-1595	103	12	aerosol	aerosol	VERB
dpc-1595	103	13	foam	foam	NOUN
dpc-1595	103	14	.	.	PUNCT
dpc-1595	104	1	regarding	regard	VERB
dpc-1595	104	2	its	its	PRON
dpc-1595	104	3	cosmetic	cosmetic	ADJ
dpc-1595	104	4	properties	property	NOUN
dpc-1595	104	5	,	,	PUNCT
dpc-1595	104	6	15.4	15.4	NUM
dpc-1595	104	7	%	%	NOUN
dpc-1595	104	8	responded	respond	VERB
dpc-1595	104	9	that	that	SCONJ
dpc-1595	104	10	the	the	DET
dpc-1595	104	11	product	product	NOUN
dpc-1595	104	12	’s	’s	PART
dpc-1595	104	13	most	most	ADV
dpc-1595	104	14	important	important	ADJ
dpc-1595	104	15	attribute	attribute	NOUN
dpc-1595	104	16	was	be	AUX
dpc-1595	104	17	that	that	SCONJ
dpc-1595	104	18	it	it	PRON
dpc-1595	104	19	did	do	AUX
dpc-1595	104	20	not	not	PART
dpc-1595	104	21	leave	leave	VERB
dpc-1595	104	22	residues	residue	NOUN
dpc-1595	104	23	or	or	CCONJ
dpc-1595	104	24	spots	spot	NOUN
dpc-1595	104	25	on	on	ADP
dpc-1595	104	26	the	the	DET
dpc-1595	104	27	skin	skin	NOUN
dpc-1595	104	28	,	,	PUNCT
dpc-1595	104	29	7.7	7.7	NUM
dpc-1595	104	30	%	%	NOUN
dpc-1595	104	31	valued	value	VERB
dpc-1595	104	32	the	the	DET
dpc-1595	104	33	absence	absence	NOUN
dpc-1595	104	34	of	of	ADP
dpc-1595	104	35	odor	odor	NOUN
dpc-1595	104	36	,	,	PUNCT
dpc-1595	104	37	and	and	CCONJ
dpc-1595	104	38	76.9	76.9	NUM
dpc-1595	104	39	%	%	NOUN
dpc-1595	104	40	rated	rate	VERB
dpc-1595	104	41	it	it	PRON
dpc-1595	104	42	as	as	ADP
dpc-1595	104	43	without	without	ADP
dpc-1595	104	44	data	datum	NOUN
dpc-1595	104	45	.	.	PUNCT
dpc-1595	105	1	patients	patient	NOUN
dpc-1595	105	2	reported	report	VERB
dpc-1595	105	3	as	as	ADP
dpc-1595	105	4	the	the	DET
dpc-1595	105	5	most	most	ADV
dpc-1595	105	6	important	important	ADJ
dpc-1595	105	7	interest	interest	NOUN
dpc-1595	105	8	the	the	DET
dpc-1595	105	9	easy	easy	ADJ
dpc-1595	105	10	application	application	NOUN
dpc-1595	105	11	of	of	ADP
dpc-1595	105	12	the	the	DET
dpc-1595	105	13	drug	drug	NOUN
dpc-1595	105	14	to	to	ADP
dpc-1595	105	15	the	the	DET
dpc-1595	105	16	skin	skin	NOUN
dpc-1595	105	17	.	.	PUNCT
dpc-1595	106	1	the	the	DET
dpc-1595	106	2	overall	overall	ADJ
dpc-1595	106	3	cosmetic	cosmetic	ADJ
dpc-1595	106	4	quality	quality	NOUN
dpc-1595	106	5	of	of	ADP
dpc-1595	106	6	cal	cal	PROPN
dpc-1595	106	7	/	/	SYM
dpc-1595	106	8	bd	bd	PROPN
dpc-1595	106	9	aerosol	aerosol	NOUN
dpc-1595	106	10	foam	foam	NOUN
dpc-1595	106	11	was	be	AUX
dpc-1595	106	12	rated	rate	VERB
dpc-1595	106	13	“	"	PUNCT
dpc-1595	106	14	good	good	ADJ
dpc-1595	106	15	”	"	PUNCT
dpc-1595	106	16	by	by	ADP
dpc-1595	106	17	90.8	90.8	NUM
dpc-1595	106	18	%	%	NOUN
dpc-1595	106	19	of	of	ADP
dpc-1595	106	20	the	the	DET
dpc-1595	106	21	participants	participant	NOUN
dpc-1595	106	22	.	.	PUNCT
dpc-1595	107	1	in	in	ADP
dpc-1595	107	2	terms	term	NOUN
dpc-1595	107	3	of	of	ADP
dpc-1595	107	4	general	general	ADJ
dpc-1595	107	5	satisfaction	satisfaction	NOUN
dpc-1595	107	6	with	with	ADP
dpc-1595	107	7	cal	cal	PROPN
dpc-1595	107	8	/	/	SYM
dpc-1595	107	9	bd	bd	PROPN
dpc-1595	107	10	aerosol	aerosol	NOUN
dpc-1595	107	11	foam	foam	NOUN
dpc-1595	107	12	,	,	PUNCT
dpc-1595	107	13	66.2	66.2	NUM
dpc-1595	107	14	%	%	NOUN
dpc-1595	107	15	of	of	ADP
dpc-1595	107	16	the	the	DET
dpc-1595	107	17	patients	patient	NOUN
dpc-1595	107	18	were	be	AUX
dpc-1595	107	19	very	very	ADV
dpc-1595	107	20	satisfied	satisfied	ADJ
dpc-1595	107	21	,	,	PUNCT
dpc-1595	107	22	15.4	15.4	NUM
dpc-1595	107	23	%	%	NOUN
dpc-1595	107	24	was	be	AUX
dpc-1595	107	25	satisfied	satisfied	ADJ
dpc-1595	107	26	,	,	PUNCT
dpc-1595	107	27	10.8	10.8	NUM
dpc-1595	107	28	%	%	NOUN
dpc-1595	107	29	was	be	AUX
dpc-1595	107	30	not	not	PART
dpc-1595	107	31	very	very	ADV
dpc-1595	107	32	satisfied	satisfied	ADJ
dpc-1595	107	33	,	,	PUNCT
dpc-1595	107	34	and	and	CCONJ
dpc-1595	107	35	7.7	7.7	NUM
dpc-1595	107	36	%	%	NOUN
dpc-1595	107	37	was	be	AUX
dpc-1595	107	38	not	not	PART
dpc-1595	107	39	at	at	ADV
dpc-1595	107	40	all	all	ADV
dpc-1595	107	41	satisfied	satisfied	ADJ
dpc-1595	107	42	.	.	PUNCT
dpc-1595	108	1	the	the	DET
dpc-1595	108	2	patients	patient	NOUN
dpc-1595	108	3	reporting	report	VERB
dpc-1595	108	4	little	little	ADJ
dpc-1595	108	5	or	or	CCONJ
dpc-1595	108	6	no	no	PRON
dpc-1595	108	7	satisfaction	satisfaction	NOUN
dpc-1595	108	8	corresponded	correspond	VERB
dpc-1595	108	9	to	to	ADP
dpc-1595	108	10	those	those	PRON
dpc-1595	108	11	in	in	ADP
dpc-1595	108	12	whom	whom	PRON
dpc-1595	108	13	psoriasis	psoriasis	NOUN
dpc-1595	108	14	did	do	AUX
dpc-1595	108	15	not	not	PART
dpc-1595	108	16	improve	improve	VERB
dpc-1595	108	17	with	with	ADP
dpc-1595	108	18	the	the	DET
dpc-1595	108	19	treatment	treatment	NOUN
dpc-1595	108	20	.	.	PUNCT
dpc-1595	109	1	discussion	discussion	NOUN
dpc-1595	109	2	stein	stein	PROPN
dpc-1595	109	3	et	et	PROPN
dpc-1595	109	4	al	al	PROPN
dpc-1595	110	1	[	[	X
dpc-1595	110	2	12	12	NUM
dpc-1595	110	3	]	]	PUNCT
dpc-1595	110	4	,	,	PUNCT
dpc-1595	110	5	among	among	ADP
dpc-1595	110	6	others	other	NOUN
dpc-1595	110	7	,	,	PUNCT
dpc-1595	110	8	reported	report	VERB
dpc-1595	110	9	that	that	SCONJ
dpc-1595	110	10	the	the	DET
dpc-1595	110	11	high	high	ADJ
dpc-1595	110	12	efficacy	efficacy	NOUN
dpc-1595	110	13	of	of	ADP
dpc-1595	110	14	cal	cal	PROPN
dpc-1595	110	15	/	/	SYM
dpc-1595	110	16	bd	bd	PROPN
dpc-1595	110	17	aerosol	aerosol	NOUN
dpc-1595	110	18	foam	foam	NOUN
dpc-1595	110	19	is	be	AUX
dpc-1595	110	20	an	an	DET
dpc-1595	110	21	important	important	ADJ
dpc-1595	110	22	characteristic	characteristic	NOUN
dpc-1595	110	23	in	in	ADP
dpc-1595	110	24	the	the	DET
dpc-1595	110	25	treatment	treatment	NOUN
dpc-1595	110	26	of	of	ADP
dpc-1595	110	27	mild	mild	ADJ
dpc-1595	110	28	-	-	PUNCT
dpc-1595	110	29	moderate	moderate	ADJ
dpc-1595	110	30	plaque	plaque	NOUN
dpc-1595	110	31	psoriasis	psoriasis	NOUN
dpc-1595	110	32	.	.	PUNCT
dpc-1595	111	1	its	its	PRON
dpc-1595	111	2	speed	speed	NOUN
dpc-1595	111	3	of	of	ADP
dpc-1595	111	4	action	action	NOUN
dpc-1595	111	5	,	,	PUNCT
dpc-1595	111	6	in	in	ADP
dpc-1595	111	7	patients	patient	NOUN
dpc-1595	111	8	with	with	ADP
dpc-1595	111	9	mild	mild	ADJ
dpc-1595	111	10	or	or	CCONJ
dpc-1595	111	11	moderate	moderate	ADJ
dpc-1595	111	12	psoriasis	psoriasis	NOUN
dpc-1595	111	13	,	,	PUNCT
dpc-1595	111	14	deserves	deserve	VERB
dpc-1595	111	15	to	to	PART
dpc-1595	111	16	be	be	AUX
dpc-1595	111	17	reviewed	review	VERB
dpc-1595	111	18	[	[	PUNCT
dpc-1595	111	19	13	13	NUM
dpc-1595	111	20	]	]	PUNCT
dpc-1595	111	21	.	.	PUNCT
dpc-1595	112	1	this	this	DET
dpc-1595	112	2	study	study	NOUN
dpc-1595	112	3	evaluated	evaluate	VERB
dpc-1595	112	4	the	the	DET
dpc-1595	112	5	adherence	adherence	NOUN
dpc-1595	112	6	and	and	CCONJ
dpc-1595	112	7	satisfaction	satisfaction	NOUN
dpc-1595	112	8	of	of	ADP
dpc-1595	112	9	patients	patient	NOUN
dpc-1595	112	10	with	with	ADP
dpc-1595	112	11	plaque	plaque	NOUN
dpc-1595	112	12	psoriasis	psoriasis	NOUN
dpc-1595	112	13	on	on	ADP
dpc-1595	112	14	the	the	DET
dpc-1595	112	15	trunk	trunk	NOUN
dpc-1595	112	16	and	and	CCONJ
dpc-1595	112	17	extremities	extremity	NOUN
dpc-1595	112	18	treated	treat	VERB
dpc-1595	112	19	with	with	ADP
dpc-1595	112	20	cal	cal	PROPN
dpc-1595	112	21	/	/	SYM
dpc-1595	112	22	bd	bd	PROPN
dpc-1595	112	23	aerosol	aerosol	NOUN
dpc-1595	112	24	foam	foam	NOUN
dpc-1595	112	25	.	.	PUNCT
dpc-1595	113	1	over	over	ADP
dpc-1595	113	2	a	a	DET
dpc-1595	113	3	4	4	NUM
dpc-1595	113	4	-	-	PUNCT
dpc-1595	113	5	week	week	NOUN
dpc-1595	113	6	period	period	NOUN
dpc-1595	113	7	,	,	PUNCT
dpc-1595	113	8	patients	patient	NOUN
dpc-1595	113	9	treated	treat	VERB
dpc-1595	113	10	with	with	ADP
dpc-1595	113	11	cal	cal	PROPN
dpc-1595	113	12	/	/	SYM
dpc-1595	113	13	bd	bd	PROPN
dpc-1595	113	14	aerosol	aerosol	NOUN
dpc-1595	113	15	foam	foam	NOUN
dpc-1595	113	16	had	have	VERB
dpc-1595	113	17	a	a	DET
dpc-1595	113	18	significant	significant	ADJ
dpc-1595	113	19	improvement	improvement	NOUN
dpc-1595	113	20	in	in	ADP
dpc-1595	113	21	disease	disease	NOUN
dpc-1595	113	22	severity	severity	NOUN
dpc-1595	113	23	that	that	PRON
dpc-1595	113	24	was	be	AUX
dpc-1595	113	25	directly	directly	ADV
dpc-1595	113	26	related	relate	VERB
dpc-1595	113	27	to	to	ADP
dpc-1595	113	28	treatment	treatment	NOUN
dpc-1595	113	29	adherence	adherence	NOUN
dpc-1595	113	30	.	.	PUNCT
dpc-1595	114	1	non	non	ADJ
dpc-1595	114	2	-	-	NOUN
dpc-1595	114	3	compliance	compliance	NOUN
dpc-1595	114	4	with	with	ADP
dpc-1595	114	5	topical	topical	ADJ
dpc-1595	114	6	therapy	therapy	NOUN
dpc-1595	114	7	continues	continue	VERB
dpc-1595	114	8	to	to	PART
dpc-1595	114	9	be	be	AUX
dpc-1595	114	10	a	a	DET
dpc-1595	114	11	challenge	challenge	NOUN
dpc-1595	114	12	in	in	ADP
dpc-1595	114	13	clinical	clinical	ADJ
dpc-1595	114	14	practice	practice	NOUN
dpc-1595	114	15	for	for	ADP
dpc-1595	114	16	patients	patient	NOUN
dpc-1595	114	17	with	with	ADP
dpc-1595	114	18	psoriasis	psoriasis	NOUN
dpc-1595	114	19	,	,	PUNCT
dpc-1595	114	20	and	and	CCONJ
dpc-1595	114	21	constitutes	constitute	VERB
dpc-1595	114	22	a	a	DET
dpc-1595	114	23	key	key	ADJ
dpc-1595	114	24	limiting	limit	VERB
dpc-1595	114	25	factor	factor	NOUN
dpc-1595	114	26	in	in	ADP
dpc-1595	114	27	its	its	PRON
dpc-1595	114	28	effectiveness	effectiveness	NOUN
dpc-1595	114	29	[	[	X
dpc-1595	114	30	14	14	NUM
dpc-1595	114	31	]	]	PUNCT
dpc-1595	114	32	.	.	PUNCT
dpc-1595	115	1	according	accord	VERB
dpc-1595	115	2	to	to	ADP
dpc-1595	115	3	the	the	DET
dpc-1595	115	4	results	result	NOUN
dpc-1595	115	5	obtained	obtain	VERB
dpc-1595	115	6	using	use	VERB
dpc-1595	115	7	the	the	DET
dpc-1595	115	8	morisky	morisky	ADJ
dpc-1595	115	9	-	-	PUNCT
dpc-1595	115	10	greenlevine	greenlevine	NOUN
dpc-1595	115	11	scale	scale	NOUN
dpc-1595	115	12	,	,	PUNCT
dpc-1595	115	13	at	at	ADP
dpc-1595	115	14	12	12	NUM
dpc-1595	115	15	weeks	week	NOUN
dpc-1595	115	16	only	only	ADV
dpc-1595	115	17	73.8	73.8	NUM
dpc-1595	115	18	%	%	NOUN
dpc-1595	115	19	of	of	ADP
dpc-1595	115	20	the	the	DET
dpc-1595	115	21	participants	participant	NOUN
dpc-1595	115	22	were	be	AUX
dpc-1595	115	23	fully	fully	ADV
dpc-1595	115	24	compliant	compliant	ADJ
dpc-1595	115	25	with	with	ADP
dpc-1595	115	26	the	the	DET
dpc-1595	115	27	treatment	treatment	NOUN
dpc-1595	115	28	.	.	PUNCT
dpc-1595	116	1	this	this	DET
dpc-1595	116	2	lack	lack	NOUN
dpc-1595	116	3	of	of	ADP
dpc-1595	116	4	adherence	adherence	NOUN
dpc-1595	116	5	was	be	AUX
dpc-1595	116	6	due	due	ADJ
dpc-1595	116	7	to	to	ADP
dpc-1595	116	8	the	the	DET
dpc-1595	116	9	lack	lack	NOUN
dpc-1595	116	10	of	of	ADP
dpc-1595	116	11	response	response	NOUN
dpc-1595	116	12	to	to	ADP
dpc-1595	116	13	treatment	treatment	NOUN
dpc-1595	116	14	,	,	PUNCT
dpc-1595	116	15	coinciding	coincide	VERB
dpc-1595	116	16	in	in	ADP
dpc-1595	116	17	those	those	DET
dpc-1595	116	18	patients	patient	NOUN
dpc-1595	116	19	with	with	ADP
dpc-1595	116	20	psoriasis	psoriasis	NOUN
dpc-1595	116	21	duration	duration	NOUN
dpc-1595	116	22	of	of	ADP
dpc-1595	116	23	more	more	ADJ
dpc-1595	116	24	than	than	ADP
dpc-1595	116	25	10	10	NUM
dpc-1595	116	26	years	year	NOUN
dpc-1595	116	27	.	.	PUNCT
dpc-1595	117	1	these	these	DET
dpc-1595	117	2	patients	patient	NOUN
dpc-1595	117	3	,	,	PUNCT
dpc-1595	117	4	who	who	PRON
dpc-1595	117	5	previously	previously	ADV
dpc-1595	117	6	had	have	VERB
dpc-1595	117	7	systemic	systemic	ADJ
dpc-1595	117	8	treatment	treatment	NOUN
dpc-1595	117	9	,	,	PUNCT
dpc-1595	117	10	received	receive	VERB
dpc-1595	117	11	treatment	treatment	NOUN
dpc-1595	117	12	with	with	ADP
dpc-1595	117	13	systemic	systemic	ADJ
dpc-1595	117	14	or	or	CCONJ
dpc-1595	117	15	biological	biological	ADJ
dpc-1595	117	16	therapy	therapy	NOUN
dpc-1595	117	17	after	after	SCONJ
dpc-1595	117	18	the	the	DET
dpc-1595	117	19	study	study	NOUN
dpc-1595	117	20	ended	end	VERB
dpc-1595	117	21	.	.	PUNCT
dpc-1595	118	1	the	the	DET
dpc-1595	118	2	reason	reason	NOUN
dpc-1595	118	3	why	why	SCONJ
dpc-1595	118	4	therapeutic	therapeutic	ADJ
dpc-1595	118	5	compliance	compliance	NOUN
dpc-1595	118	6	extends	extend	VERB
dpc-1595	118	7	up	up	ADP
dpc-1595	118	8	to	to	PART
dpc-1595	118	9	12	12	NUM
dpc-1595	118	10	weeks	week	NOUN
dpc-1595	118	11	is	be	AUX
dpc-1595	118	12	directly	directly	ADV
dpc-1595	118	13	related	relate	VERB
dpc-1595	118	14	to	to	ADP
dpc-1595	118	15	the	the	DET
dpc-1595	118	16	effectiveness	effectiveness	NOUN
dpc-1595	118	17	of	of	ADP
dpc-1595	118	18	cal	cal	PROPN
dpc-1595	118	19	/	/	SYM
dpc-1595	118	20	bd	bd	PROPN
dpc-1595	118	21	aerosol	aerosol	NOUN
dpc-1595	118	22	foam	foam	NOUN
dpc-1595	118	23	beyond	beyond	ADP
dpc-1595	118	24	the	the	DET
dpc-1595	118	25	4	4	NUM
dpc-1595	118	26	weeks	week	NOUN
dpc-1595	118	27	indicated	indicate	VERB
dpc-1595	118	28	in	in	ADP
dpc-1595	118	29	the	the	DET
dpc-1595	118	30	datasheet	datasheet	NOUN
dpc-1595	118	31	,	,	PUNCT
dpc-1595	118	32	as	as	SCONJ
dpc-1595	118	33	demonstrated	demonstrate	VERB
dpc-1595	118	34	by	by	ADP
dpc-1595	118	35	paul	paul	PROPN
dpc-1595	118	36	et	et	PROPN
dpc-1595	118	37	al	al	PROPN
dpc-1595	118	38	.	.	PUNCT
dpc-1595	119	1	[	[	X
dpc-1595	119	2	15	15	NUM
dpc-1595	119	3	]	]	PUNCT
dpc-1595	119	4	.	.	PUNCT
dpc-1595	120	1	the	the	DET
dpc-1595	120	2	most	most	ADV
dpc-1595	120	3	frequent	frequent	ADJ
dpc-1595	120	4	difficulties	difficulty	NOUN
dpc-1595	120	5	associated	associate	VERB
dpc-1595	120	6	with	with	ADP
dpc-1595	120	7	non	non	ADJ
dpc-1595	120	8	-	-	NOUN
dpc-1595	120	9	compliance	compliance	NOUN
dpc-1595	120	10	are	be	AUX
dpc-1595	120	11	the	the	DET
dpc-1595	120	12	patients	patient	NOUN
dpc-1595	120	13	’	’	PART
dpc-1595	120	14	perception	perception	NOUN
dpc-1595	120	15	of	of	ADP
dpc-1595	120	16	the	the	DET
dpc-1595	120	17	effectiveness	effectiveness	NOUN
dpc-1595	120	18	of	of	ADP
dpc-1595	120	19	the	the	DET
dpc-1595	120	20	product	product	NOUN
dpc-1595	120	21	and	and	CCONJ
dpc-1595	120	22	the	the	DET
dpc-1595	120	23	discomfort	discomfort	NOUN
dpc-1595	120	24	of	of	ADP
dpc-1595	120	25	the	the	DET
dpc-1595	120	26	administration	administration	NOUN
dpc-1595	120	27	regimen	regiman	NOUN
dpc-1595	120	28	.	.	PUNCT
dpc-1595	121	1	as	as	SCONJ
dpc-1595	121	2	observed	observe	VERB
dpc-1595	121	3	in	in	ADP
dpc-1595	121	4	our	our	PRON
dpc-1595	121	5	study	study	NOUN
dpc-1595	121	6	,	,	PUNCT
dpc-1595	121	7	both	both	DET
dpc-1595	121	8	difficulties	difficulty	NOUN
dpc-1595	121	9	have	have	AUX
dpc-1595	121	10	been	be	AUX
dpc-1595	121	11	overcome	overcome	VERB
dpc-1595	121	12	with	with	ADP
dpc-1595	121	13	this	this	DET
dpc-1595	121	14	new	new	ADJ
dpc-1595	121	15	formulation	formulation	NOUN
dpc-1595	121	16	.	.	PUNCT
dpc-1595	122	1	the	the	DET
dpc-1595	122	2	quick	quick	ADJ
dpc-1595	122	3	and	and	CCONJ
dpc-1595	122	4	effective	effective	ADJ
dpc-1595	122	5	response	response	NOUN
dpc-1595	122	6	to	to	ADP
dpc-1595	122	7	treatment	treatment	NOUN
dpc-1595	122	8	has	have	VERB
dpc-1595	122	9	a	a	DET
dpc-1595	122	10	direct	direct	ADJ
dpc-1595	122	11	impact	impact	NOUN
dpc-1595	122	12	on	on	ADP
dpc-1595	122	13	treatment	treatment	NOUN
dpc-1595	122	14	compliance	compliance	NOUN
dpc-1595	122	15	.	.	PUNCT
dpc-1595	123	1	patient	patient	ADJ
dpc-1595	123	2	expectations	expectation	NOUN
dpc-1595	123	3	are	be	AUX
dpc-1595	123	4	directly	directly	ADV
dpc-1595	123	5	linked	link	VERB
dpc-1595	123	6	to	to	ADP
dpc-1595	123	7	therapeutic	therapeutic	ADJ
dpc-1595	123	8	adherence	adherence	NOUN
dpc-1595	123	9	[	[	X
dpc-1595	123	10	16	16	NUM
dpc-1595	123	11	]	]	PUNCT
dpc-1595	123	12	,	,	PUNCT
dpc-1595	123	13	and	and	CCONJ
dpc-1595	123	14	treatment	treatment	NOUN
dpc-1595	123	15	failure	failure	NOUN
dpc-1595	123	16	plays	play	VERB
dpc-1595	123	17	the	the	DET
dpc-1595	123	18	main	main	ADJ
dpc-1595	123	19	role	role	NOUN
dpc-1595	123	20	in	in	ADP
dpc-1595	123	21	abandoning	abandon	VERB
dpc-1595	123	22	therapy	therapy	NOUN
dpc-1595	123	23	,	,	PUNCT
dpc-1595	123	24	especially	especially	ADV
dpc-1595	123	25	in	in	ADP
dpc-1595	123	26	topical	topical	ADJ
dpc-1595	123	27	treatments	treatment	NOUN
dpc-1595	123	28	.	.	PUNCT
dpc-1595	124	1	the	the	DET
dpc-1595	124	2	secondary	secondary	ADJ
dpc-1595	124	3	objective	objective	NOUN
dpc-1595	124	4	of	of	ADP
dpc-1595	124	5	the	the	DET
dpc-1595	124	6	study	study	NOUN
dpc-1595	124	7	was	be	AUX
dpc-1595	124	8	to	to	PART
dpc-1595	124	9	assess	assess	VERB
dpc-1595	124	10	patient	patient	ADJ
dpc-1595	124	11	satisfaction	satisfaction	NOUN
dpc-1595	124	12	after	after	ADP
dpc-1595	124	13	cal	cal	PROPN
dpc-1595	124	14	/	/	SYM
dpc-1595	124	15	bd	bd	PROPN
dpc-1595	124	16	aerosol	aerosol	VERB
dpc-1595	124	17	foam	foam	NOUN
dpc-1595	124	18	treatment	treatment	NOUN
dpc-1595	124	19	.	.	PUNCT
dpc-1595	125	1	the	the	DET
dpc-1595	125	2	results	result	NOUN
dpc-1595	125	3	show	show	VERB
dpc-1595	125	4	how	how	SCONJ
dpc-1595	125	5	patient	patient	ADJ
dpc-1595	125	6	satisfaction	satisfaction	NOUN
dpc-1595	125	7	after	after	ADP
dpc-1595	125	8	treatment	treatment	NOUN
dpc-1595	125	9	was	be	AUX
dpc-1595	125	10	maintained	maintain	VERB
dpc-1595	125	11	over	over	ADP
dpc-1595	125	12	time	time	NOUN
dpc-1595	125	13	.	.	PUNCT
dpc-1595	126	1	low	low	ADJ
dpc-1595	126	2	satisfaction	satisfaction	NOUN
dpc-1595	126	3	or	or	CCONJ
dpc-1595	126	4	dissatisfaction	dissatisfaction	NOUN
dpc-1595	126	5	with	with	ADP
dpc-1595	126	6	the	the	DET
dpc-1595	126	7	treatment	treatment	NOUN
dpc-1595	126	8	,	,	PUNCT
dpc-1595	126	9	recorded	record	VERB
dpc-1595	126	10	in	in	ADP
dpc-1595	126	11	9	9	NUM
dpc-1595	126	12	patients	patient	NOUN
dpc-1595	126	13	,	,	PUNCT
dpc-1595	126	14	was	be	AUX
dpc-1595	126	15	justified	justify	VERB
dpc-1595	126	16	by	by	ADP
dpc-1595	126	17	their	their	PRON
dpc-1595	126	18	having	have	VERB
dpc-1595	126	19	a	a	DET
dpc-1595	126	20	partial	partial	ADJ
dpc-1595	126	21	or	or	CCONJ
dpc-1595	126	22	no	no	DET
dpc-1595	126	23	response	response	NOUN
dpc-1595	126	24	to	to	ADP
dpc-1595	126	25	the	the	DET
dpc-1595	126	26	treatment	treatment	NOUN
dpc-1595	126	27	.	.	PUNCT
dpc-1595	127	1	however	however	ADV
dpc-1595	127	2	,	,	PUNCT
dpc-1595	127	3	the	the	DET
dpc-1595	127	4	cosmetic	cosmetic	ADJ
dpc-1595	127	5	evaluation	evaluation	NOUN
dpc-1595	127	6	of	of	ADP
dpc-1595	127	7	the	the	DET
dpc-1595	127	8	product	product	NOUN
dpc-1595	127	9	by	by	ADP
dpc-1595	127	10	these	these	DET
dpc-1595	127	11	patients	patient	NOUN
dpc-1595	127	12	was	be	AUX
dpc-1595	127	13	positive	positive	ADJ
dpc-1595	127	14	.	.	PUNCT
dpc-1595	128	1	as	as	SCONJ
dpc-1595	128	2	previously	previously	ADV
dpc-1595	128	3	reported	report	VERB
dpc-1595	128	4	,	,	PUNCT
dpc-1595	128	5	low	low	ADJ
dpc-1595	128	6	adherence	adherence	NOUN
dpc-1595	128	7	to	to	ADP
dpc-1595	128	8	treatment	treatment	NOUN
dpc-1595	128	9	may	may	AUX
dpc-1595	128	10	be	be	AUX
dpc-1595	128	11	justified	justify	VERB
dpc-1595	128	12	by	by	ADP
dpc-1595	128	13	the	the	DET
dpc-1595	128	14	acceptability	acceptability	NOUN
dpc-1595	128	15	of	of	ADP
dpc-1595	128	16	the	the	DET
dpc-1595	128	17	vehicle	vehicle	NOUN
dpc-1595	128	18	and	and	CCONJ
dpc-1595	128	19	its	its	PRON
dpc-1595	128	20	cosmetics	cosmetic	NOUN
dpc-1595	128	21	[	[	X
dpc-1595	128	22	17	17	NUM
dpc-1595	128	23	]	]	PUNCT
dpc-1595	128	24	.	.	PUNCT
dpc-1595	129	1	the	the	DET
dpc-1595	129	2	cal	cal	PROPN
dpc-1595	129	3	/	/	SYM
dpc-1595	129	4	bd	bd	PROPN
dpc-1595	129	5	aerosol	aerosol	NOUN
dpc-1595	129	6	foam	foam	NOUN
dpc-1595	129	7	formula	formula	NOUN
dpc-1595	129	8	was	be	AUX
dpc-1595	129	9	developed	develop	VERB
dpc-1595	129	10	to	to	PART
dpc-1595	129	11	provide	provide	VERB
dpc-1595	129	12	patients	patient	NOUN
dpc-1595	129	13	with	with	ADP
dpc-1595	129	14	comfortable	comfortable	ADJ
dpc-1595	129	15	and	and	CCONJ
dpc-1595	129	16	easy	easy	ADJ
dpc-1595	129	17	topical	topical	ADJ
dpc-1595	129	18	application	application	NOUN
dpc-1595	129	19	.	.	PUNCT
dpc-1595	130	1	this	this	PRON
dpc-1595	130	2	allows	allow	VERB
dpc-1595	130	3	for	for	ADP
dpc-1595	130	4	greater	great	ADJ
dpc-1595	130	5	adherence	adherence	NOUN
dpc-1595	130	6	to	to	ADP
dpc-1595	130	7	treatment	treatment	NOUN
dpc-1595	130	8	compared	compare	VERB
dpc-1595	130	9	with	with	ADP
dpc-1595	130	10	other	other	ADJ
dpc-1595	130	11	topical	topical	ADJ
dpc-1595	130	12	formulations	formulation	NOUN
dpc-1595	130	13	for	for	ADP
dpc-1595	130	14	the	the	DET
dpc-1595	130	15	treatment	treatment	NOUN
dpc-1595	130	16	of	of	ADP
dpc-1595	130	17	psoriasis	psoriasis	NOUN
dpc-1595	130	18	.	.	PUNCT
dpc-1595	131	1	treatment	treatment	NOUN
dpc-1595	131	2	adherence	adherence	NOUN
dpc-1595	131	3	—	—	PUNCT
dpc-1595	131	4	an	an	DET
dpc-1595	131	5	essential	essential	ADJ
dpc-1595	131	6	objective	objective	NOUN
dpc-1595	131	7	in	in	ADP
dpc-1595	131	8	chronic	chronic	ADJ
dpc-1595	131	9	skin	skin	NOUN
dpc-1595	131	10	diseases	disease	NOUN
dpc-1595	131	11	such	such	ADJ
dpc-1595	131	12	as	as	ADP
dpc-1595	131	13	psoriasis	psoriasis	NOUN
dpc-1595	131	14	—	—	PUNCT
dpc-1595	131	15	and	and	CCONJ
dpc-1595	131	16	patient	patient	ADJ
dpc-1595	131	17	satisfaction	satisfaction	NOUN
dpc-1595	131	18	are	be	AUX
dpc-1595	131	19	strongly	strongly	ADV
dpc-1595	131	20	linked	link	VERB
dpc-1595	131	21	,	,	PUNCT
dpc-1595	131	22	as	as	SCONJ
dpc-1595	131	23	we	we	PRON
dpc-1595	131	24	have	have	AUX
dpc-1595	131	25	observed	observe	VERB
dpc-1595	131	26	in	in	ADP
dpc-1595	131	27	our	our	PRON
dpc-1595	131	28	study	study	NOUN
dpc-1595	131	29	.	.	PUNCT
dpc-1595	132	1	high	high	ADJ
dpc-1595	132	2	adherence	adherence	NOUN
dpc-1595	132	3	100	100	NUM
dpc-1595	132	4	80	80	NUM
dpc-1595	132	5	60	60	NUM
dpc-1595	132	6	40	40	NUM
dpc-1595	132	7	20	20	NUM
dpc-1595	132	8	0	0	NUM
dpc-1595	132	9	0	0	NUM
dpc-1595	132	10	4	4	NUM
dpc-1595	132	11	12	12	NUM
dpc-1595	132	12	weeks	week	NOUN
dpc-1595	132	13	ts	ts	ADP
dpc-1595	132	14	q	q	PROPN
dpc-1595	132	15	m	m	PROPN
dpc-1595	132	16	9	9	NUM
dpc-1595	132	17	sc	sc	PROPN
dpc-1595	132	18	o	o	X
dpc-1595	132	19	re	re	X
dpc-1595	132	20	moderate	moderate	ADJ
dpc-1595	132	21	adherence	adherence	NOUN
dpc-1595	132	22	low	low	ADJ
dpc-1595	132	23	or	or	CCONJ
dpc-1595	132	24	no	no	DET
dpc-1595	132	25	adherence	adherence	NOUN
dpc-1595	132	26	figure	figure	NOUN
dpc-1595	132	27	2	2	NUM
dpc-1595	132	28	.	.	PUNCT
dpc-1595	132	29	patient	patient	ADJ
dpc-1595	132	30	satisfaction	satisfaction	NOUN
dpc-1595	132	31	with	with	ADP
dpc-1595	132	32	cal	cal	PROPN
dpc-1595	132	33	/	/	SYM
dpc-1595	132	34	bd	bd	PROPN
dpc-1595	132	35	treatment	treatment	NOUN
dpc-1595	132	36	,	,	PUNCT
dpc-1595	132	37	scored	score	VERB
dpc-1595	132	38	on	on	ADP
dpc-1595	132	39	the	the	DET
dpc-1595	132	40	tsqm-9	tsqm-9	NUM
dpc-1595	132	41	scale	scale	NOUN
dpc-1595	132	42	,	,	PUNCT
dpc-1595	132	43	according	accord	VERB
dpc-1595	132	44	to	to	ADP
dpc-1595	132	45	treatment	treatment	NOUN
dpc-1595	132	46	adherence	adherence	NOUN
dpc-1595	132	47	.	.	PUNCT
dpc-1595	133	1	values	value	NOUN
dpc-1595	133	2	are	be	AUX
dpc-1595	133	3	mean	mean	ADJ
dpc-1595	133	4	and	and	CCONJ
dpc-1595	133	5	sd	sd	ADP
dpc-1595	133	6	6	6	NUM
dpc-1595	133	7	research	research	NOUN
dpc-1595	133	8	|	|	ADV
dpc-1595	133	9	dermatol	dermatol	ADJ
dpc-1595	133	10	pract	pract	NOUN
dpc-1595	133	11	concept	concept	NOUN
dpc-1595	133	12	.	.	PUNCT
dpc-1595	134	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	134	2	another	another	DET
dpc-1595	134	3	variable	variable	NOUN
dpc-1595	134	4	recorded	record	VERB
dpc-1595	134	5	during	during	ADP
dpc-1595	134	6	the	the	DET
dpc-1595	134	7	study	study	NOUN
dpc-1595	134	8	was	be	AUX
dpc-1595	134	9	the	the	DET
dpc-1595	134	10	number	number	NOUN
dpc-1595	134	11	of	of	ADP
dpc-1595	134	12	packages	package	NOUN
dpc-1595	134	13	used	use	VERB
dpc-1595	134	14	during	during	ADP
dpc-1595	134	15	treatment	treatment	NOUN
dpc-1595	134	16	and	and	CCONJ
dpc-1595	134	17	follow	follow	NOUN
dpc-1595	134	18	-	-	PUNCT
dpc-1595	134	19	up	up	NOUN
dpc-1595	134	20	at	at	ADP
dpc-1595	134	21	12	12	NUM
dpc-1595	134	22	weeks	week	NOUN
dpc-1595	134	23	.	.	PUNCT
dpc-1595	135	1	of	of	ADP
dpc-1595	135	2	the	the	DET
dpc-1595	135	3	participants	participant	NOUN
dpc-1595	135	4	,	,	PUNCT
dpc-1595	135	5	87.6	87.6	NUM
dpc-1595	135	6	%	%	NOUN
dpc-1595	135	7	consumed	consume	VERB
dpc-1595	135	8	only	only	ADV
dpc-1595	135	9	2	2	NUM
dpc-1595	135	10	cans	can	NOUN
dpc-1595	135	11	of	of	ADP
dpc-1595	135	12	cal	cal	PROPN
dpc-1595	135	13	/	/	SYM
dpc-1595	135	14	bd	bd	PROPN
dpc-1595	135	15	aerosol	aerosol	NOUN
dpc-1595	135	16	foam	foam	NOUN
dpc-1595	135	17	.	.	PUNCT
dpc-1595	136	1	with	with	ADP
dpc-1595	136	2	these	these	DET
dpc-1595	136	3	data	datum	NOUN
dpc-1595	136	4	we	we	PRON
dpc-1595	136	5	corroborate	corroborate	VERB
dpc-1595	136	6	what	what	PRON
dpc-1595	136	7	was	be	AUX
dpc-1595	136	8	published	publish	VERB
dpc-1595	136	9	by	by	ADP
dpc-1595	136	10	balak	balak	PROPN
dpc-1595	136	11	et	et	PROPN
dpc-1595	136	12	al	al	PROPN
dpc-1595	136	13	.	.	PUNCT
dpc-1595	137	1	[	[	X
dpc-1595	137	2	18	18	NUM
dpc-1595	137	3	]	]	PUNCT
dpc-1595	137	4	and	and	CCONJ
dpc-1595	137	5	duvetorp	duvetorp	PROPN
dpc-1595	137	6	et	et	PROPN
dpc-1595	137	7	al	al	PROPN
dpc-1595	137	8	.	.	PUNCT
dpc-1595	138	1	[	[	X
dpc-1595	138	2	19	19	NUM
dpc-1595	138	3	]	]	PUNCT
dpc-1595	138	4	,	,	PUNCT
dpc-1595	138	5	who	who	PRON
dpc-1595	138	6	considered	consider	VERB
dpc-1595	138	7	this	this	DET
dpc-1595	138	8	medication	medication	NOUN
dpc-1595	138	9	a	a	DET
dpc-1595	138	10	cost	cost	NOUN
dpc-1595	138	11	-	-	PUNCT
dpc-1595	138	12	effective	effective	ADJ
dpc-1595	138	13	treatment	treatment	NOUN
dpc-1595	138	14	for	for	ADP
dpc-1595	138	15	plaque	plaque	NOUN
dpc-1595	138	16	psoriasis	psoriasis	NOUN
dpc-1595	138	17	.	.	PUNCT
dpc-1595	139	1	our	our	PRON
dpc-1595	139	2	results	result	NOUN
dpc-1595	139	3	regarding	regard	VERB
dpc-1595	139	4	treatment	treatment	NOUN
dpc-1595	139	5	adherence	adherence	NOUN
dpc-1595	139	6	,	,	PUNCT
dpc-1595	139	7	effectiveness	effectiveness	NOUN
dpc-1595	139	8	,	,	PUNCT
dpc-1595	139	9	and	and	CCONJ
dpc-1595	139	10	tolerability	tolerability	NOUN
dpc-1595	139	11	of	of	ADP
dpc-1595	139	12	cal	cal	PROPN
dpc-1595	139	13	/	/	SYM
dpc-1595	139	14	bd	bd	PROPN
dpc-1595	139	15	aerosol	aerosol	VERB
dpc-1595	139	16	foam	foam	NOUN
dpc-1595	139	17	support	support	NOUN
dpc-1595	139	18	the	the	DET
dpc-1595	139	19	conclusions	conclusion	NOUN
dpc-1595	139	20	of	of	ADP
dpc-1595	139	21	a	a	DET
dpc-1595	139	22	recent	recent	ADJ
dpc-1595	139	23	review	review	NOUN
dpc-1595	139	24	of	of	ADP
dpc-1595	139	25	studies	study	NOUN
dpc-1595	139	26	on	on	ADP
dpc-1595	139	27	the	the	DET
dpc-1595	139	28	use	use	NOUN
dpc-1595	139	29	of	of	ADP
dpc-1595	139	30	cal/	cal/	PROPN
dpc-1595	139	31	bd	bd	PROPN
dpc-1595	139	32	aerosol	aerosol	VERB
dpc-1595	139	33	foam	foam	NOUN
dpc-1595	139	34	in	in	ADP
dpc-1595	139	35	clinical	clinical	ADJ
dpc-1595	139	36	practice	practice	NOUN
dpc-1595	139	37	[	[	X
dpc-1595	139	38	20	20	NUM
dpc-1595	139	39	]	]	PUNCT
dpc-1595	139	40	.	.	PUNCT
dpc-1595	140	1	the	the	DET
dpc-1595	140	2	safety	safety	NOUN
dpc-1595	140	3	of	of	ADP
dpc-1595	140	4	cal	cal	PROPN
dpc-1595	140	5	/	/	SYM
dpc-1595	140	6	bd	bd	PROPN
dpc-1595	140	7	aerosol	aerosol	NOUN
dpc-1595	140	8	foam	foam	NOUN
dpc-1595	140	9	further	far	ADV
dpc-1595	140	10	strengthens	strengthen	VERB
dpc-1595	140	11	its	its	PRON
dpc-1595	140	12	indication	indication	NOUN
dpc-1595	140	13	as	as	ADP
dpc-1595	140	14	the	the	DET
dpc-1595	140	15	first	first	ADJ
dpc-1595	140	16	line	line	NOUN
dpc-1595	140	17	of	of	ADP
dpc-1595	140	18	therapy	therapy	NOUN
dpc-1595	140	19	in	in	ADP
dpc-1595	140	20	patients	patient	NOUN
dpc-1595	140	21	with	with	ADP
dpc-1595	140	22	mild	mild	ADJ
dpc-1595	140	23	–	–	PUNCT
dpc-1595	140	24	moderate	moderate	ADJ
dpc-1595	140	25	plaque	plaque	NOUN
dpc-1595	140	26	psoriasis	psoriasis	NOUN
dpc-1595	140	27	[	[	X
dpc-1595	140	28	21	21	NUM
dpc-1595	140	29	]	]	PUNCT
dpc-1595	140	30	.	.	PUNCT
dpc-1595	141	1	in	in	ADP
dpc-1595	141	2	a	a	DET
dpc-1595	141	3	study	study	NOUN
dpc-1595	141	4	,	,	PUNCT
dpc-1595	141	5	60	60	NUM
dpc-1595	141	6	%	%	NOUN
dpc-1595	141	7	of	of	ADP
dpc-1595	141	8	participants	participant	NOUN
dpc-1595	141	9	who	who	PRON
dpc-1595	141	10	had	have	AUX
dpc-1595	141	11	previously	previously	ADV
dpc-1595	141	12	used	use	VERB
dpc-1595	141	13	cal	cal	PROPN
dpc-1595	141	14	/	/	SYM
dpc-1595	141	15	bd	bd	PROPN
dpc-1595	141	16	gel	gel	NOUN
dpc-1595	141	17	were	be	AUX
dpc-1595	141	18	asked	ask	VERB
dpc-1595	141	19	to	to	PART
dpc-1595	141	20	compare	compare	VERB
dpc-1595	141	21	the	the	DET
dpc-1595	141	22	two	two	NUM
dpc-1595	141	23	formulations	formulation	NOUN
dpc-1595	141	24	,	,	PUNCT
dpc-1595	141	25	and	and	CCONJ
dpc-1595	141	26	95	95	NUM
dpc-1595	141	27	%	%	NOUN
dpc-1595	141	28	said	say	VERB
dpc-1595	141	29	that	that	SCONJ
dpc-1595	141	30	the	the	DET
dpc-1595	141	31	new	new	ADJ
dpc-1595	141	32	formulation	formulation	NOUN
dpc-1595	141	33	was	be	AUX
dpc-1595	141	34	better	well	ADJ
dpc-1595	141	35	,	,	PUNCT
dpc-1595	141	36	mainly	mainly	ADV
dpc-1595	141	37	due	due	ADP
dpc-1595	141	38	to	to	ADP
dpc-1595	141	39	its	its	PRON
dpc-1595	141	40	efficacy	efficacy	NOUN
dpc-1595	141	41	and	and	CCONJ
dpc-1595	141	42	cosmetics	cosmetic	NOUN
dpc-1595	141	43	(	(	PUNCT
dpc-1595	141	44	non	non	ADJ
dpc-1595	141	45	-	-	ADJ
dpc-1595	141	46	greasy	greasy	ADJ
dpc-1595	141	47	feel	feel	NOUN
dpc-1595	141	48	and	and	CCONJ
dpc-1595	141	49	absence	absence	NOUN
dpc-1595	141	50	of	of	ADP
dpc-1595	141	51	residue	residue	NOUN
dpc-1595	141	52	)	)	PUNCT
dpc-1595	141	53	;	;	PUNCT
dpc-1595	141	54	the	the	DET
dpc-1595	141	55	remaining	remain	VERB
dpc-1595	141	56	5	5	NUM
dpc-1595	141	57	%	%	NOUN
dpc-1595	141	58	considered	consider	VERB
dpc-1595	141	59	the	the	DET
dpc-1595	141	60	gel	gel	NOUN
dpc-1595	141	61	and	and	CCONJ
dpc-1595	141	62	foam	foam	NOUN
dpc-1595	141	63	formulations	formulation	NOUN
dpc-1595	141	64	to	to	PART
dpc-1595	141	65	be	be	AUX
dpc-1595	141	66	similar	similar	ADJ
dpc-1595	141	67	in	in	ADP
dpc-1595	141	68	efficacy	efficacy	NOUN
dpc-1595	141	69	and	and	CCONJ
dpc-1595	141	70	cosmetics	cosmetic	NOUN
dpc-1595	141	71	.	.	PUNCT
dpc-1595	142	1	the	the	DET
dpc-1595	142	2	effectiveness	effectiveness	NOUN
dpc-1595	142	3	of	of	ADP
dpc-1595	142	4	cal	cal	PROPN
dpc-1595	142	5	/	/	SYM
dpc-1595	142	6	bd	bd	PROPN
dpc-1595	142	7	aerosol	aerosol	NOUN
dpc-1595	142	8	foam	foam	NOUN
dpc-1595	142	9	is	be	AUX
dpc-1595	142	10	essential	essential	ADJ
dpc-1595	142	11	for	for	ADP
dpc-1595	142	12	adherence	adherence	NOUN
dpc-1595	142	13	to	to	ADP
dpc-1595	142	14	treatment	treatment	NOUN
dpc-1595	142	15	.	.	PUNCT
dpc-1595	143	1	this	this	DET
dpc-1595	143	2	drug	drug	NOUN
dpc-1595	143	3	combination	combination	NOUN
dpc-1595	143	4	inhibits	inhibit	VERB
dpc-1595	143	5	the	the	DET
dpc-1595	143	6	production	production	NOUN
dpc-1595	143	7	of	of	ADP
dpc-1595	143	8	one	one	NUM
dpc-1595	143	9	of	of	ADP
dpc-1595	143	10	the	the	DET
dpc-1595	143	11	most	most	ADV
dpc-1595	143	12	important	important	ADJ
dpc-1595	143	13	interleukins	interleukin	NOUN
dpc-1595	143	14	in	in	ADP
dpc-1595	143	15	psoriasis	psoriasis	NOUN
dpc-1595	143	16	,	,	PUNCT
dpc-1595	143	17	il-17	il-17	X
dpc-1595	143	18	,	,	PUNCT
dpc-1595	143	19	and	and	CCONJ
dpc-1595	143	20	decreases	decrease	VERB
dpc-1595	143	21	its	its	PRON
dpc-1595	143	22	blood	blood	NOUN
dpc-1595	143	23	level	level	NOUN
dpc-1595	143	24	[	[	X
dpc-1595	143	25	22	22	NUM
dpc-1595	143	26	]	]	PUNCT
dpc-1595	143	27	.	.	PUNCT
dpc-1595	144	1	however	however	ADV
dpc-1595	144	2	,	,	PUNCT
dpc-1595	144	3	the	the	DET
dpc-1595	144	4	vasoconstrictive	vasoconstrictive	ADJ
dpc-1595	144	5	power	power	NOUN
dpc-1595	144	6	of	of	ADP
dpc-1595	144	7	the	the	DET
dpc-1595	144	8	corticosteroid	corticosteroid	NOUN
dpc-1595	144	9	in	in	ADP
dpc-1595	144	10	the	the	DET
dpc-1595	144	11	new	new	ADJ
dpc-1595	144	12	aerosol	aerosol	NOUN
dpc-1595	144	13	foam	foam	NOUN
dpc-1595	144	14	formulation	formulation	NOUN
dpc-1595	144	15	is	be	AUX
dpc-1595	144	16	not	not	PART
dpc-1595	144	17	superior	superior	ADJ
dpc-1595	144	18	to	to	ADP
dpc-1595	144	19	that	that	PRON
dpc-1595	144	20	in	in	ADP
dpc-1595	144	21	the	the	DET
dpc-1595	144	22	gel	gel	NOUN
dpc-1595	144	23	formulation	formulation	NOUN
dpc-1595	144	24	[	[	X
dpc-1595	144	25	23	23	NUM
dpc-1595	144	26	]	]	PUNCT
dpc-1595	144	27	.	.	PUNCT
dpc-1595	145	1	this	this	DET
dpc-1595	145	2	study	study	NOUN
dpc-1595	145	3	has	have	VERB
dpc-1595	145	4	limitations	limitation	NOUN
dpc-1595	145	5	due	due	ADP
dpc-1595	145	6	to	to	ADP
dpc-1595	145	7	the	the	DET
dpc-1595	145	8	small	small	ADJ
dpc-1595	145	9	number	number	NOUN
dpc-1595	145	10	of	of	ADP
dpc-1595	145	11	enrolled	enrol	VERB
dpc-1595	145	12	patients	patient	NOUN
dpc-1595	145	13	.	.	PUNCT
dpc-1595	146	1	a	a	DET
dpc-1595	146	2	multicenter	multicenter	ADJ
dpc-1595	146	3	study	study	NOUN
dpc-1595	146	4	with	with	ADP
dpc-1595	146	5	the	the	DET
dpc-1595	146	6	participation	participation	NOUN
dpc-1595	146	7	of	of	ADP
dpc-1595	146	8	specialized	specialized	ADJ
dpc-1595	146	9	psoriasis	psoriasis	NOUN
dpc-1595	146	10	units	unit	NOUN
dpc-1595	146	11	could	could	AUX
dpc-1595	146	12	increase	increase	VERB
dpc-1595	146	13	the	the	DET
dpc-1595	146	14	number	number	NOUN
dpc-1595	146	15	of	of	ADP
dpc-1595	146	16	patients	patient	NOUN
dpc-1595	146	17	studied	study	VERB
dpc-1595	146	18	.	.	PUNCT
dpc-1595	147	1	high	high	ADJ
dpc-1595	147	2	adherence	adherence	NOUN
dpc-1595	147	3	weeks	week	NOUN
dpc-1595	147	4	1240	1240	NUM
dpc-1595	147	5	15	15	NUM
dpc-1595	147	6	12	12	NUM
dpc-1595	147	7	9	9	NUM
dpc-1595	147	8	6	6	NUM
dpc-1595	147	9	3	3	NUM
dpc-1595	147	10	0	0	NUM
dpc-1595	147	11	moderate	moderate	ADJ
dpc-1595	147	12	adherence	adherence	NOUN
dpc-1595	147	13	low	low	ADJ
dpc-1595	147	14	or	or	CCONJ
dpc-1595	147	15	no	no	DET
dpc-1595	147	16	adherence	adherence	NOUN
dpc-1595	147	17	bs	bs	ADP
dpc-1595	147	18	a	a	DET
dpc-1595	147	19	8	8	NUM
dpc-1595	147	20	6	6	NUM
dpc-1595	147	21	4	4	NUM
dpc-1595	147	22	2	2	NUM
dpc-1595	147	23	sc	sc	NOUN
dpc-1595	147	24	o	o	X
dpc-1595	147	25	re	re	X
dpc-1595	147	26	pasi	pasi	PROPN
dpc-1595	147	27	weeks	weeks	PROPN
dpc-1595	147	28	bsi	bsi	PROPN
dpc-1595	147	29	0	0	NUM
dpc-1595	147	30	0	0	NUM
dpc-1595	147	31	4	4	NUM
dpc-1595	147	32	12	12	NUM
dpc-1595	147	33	figure	figure	NOUN
dpc-1595	147	34	3	3	NUM
dpc-1595	147	35	.	.	PUNCT
dpc-1595	147	36	evolution	evolution	NOUN
dpc-1595	147	37	of	of	ADP
dpc-1595	147	38	psoriasis	psoriasis	NOUN
dpc-1595	147	39	severity	severity	NOUN
dpc-1595	147	40	during	during	ADP
dpc-1595	147	41	cal	cal	PROPN
dpc-1595	147	42	/	/	SYM
dpc-1595	147	43	bd	bd	PROPN
dpc-1595	147	44	treatment	treatment	NOUN
dpc-1595	147	45	.	.	PUNCT
dpc-1595	148	1	values	value	NOUN
dpc-1595	148	2	are	be	AUX
dpc-1595	148	3	mean	mean	ADJ
dpc-1595	148	4	and	and	CCONJ
dpc-1595	148	5	sd	sd	INTJ
dpc-1595	148	6	.	.	PUNCT
dpc-1595	149	1	pasi	pasi	NOUN
dpc-1595	149	2	=	=	SYM
dpc-1595	149	3	psoriasis	psoriasis	NOUN
dpc-1595	149	4	area	area	NOUN
dpc-1595	149	5	and	and	CCONJ
dpc-1595	149	6	severity	severity	NOUN
dpc-1595	149	7	index	index	NOUN
dpc-1595	149	8	;	;	PUNCT
dpc-1595	149	9	bsa	bsa	PROPN
dpc-1595	149	10	=	=	PROPN
dpc-1595	149	11	body	body	PROPN
dpc-1595	149	12	surface	surface	NOUN
dpc-1595	149	13	area	area	NOUN
dpc-1595	149	14	figure	figure	NOUN
dpc-1595	149	15	4	4	NUM
dpc-1595	149	16	.	.	PUNCT
dpc-1595	149	17	evolution	evolution	NOUN
dpc-1595	149	18	of	of	ADP
dpc-1595	149	19	psoriasis	psoriasis	NOUN
dpc-1595	149	20	severity	severity	NOUN
dpc-1595	149	21	(	(	PUNCT
dpc-1595	149	22	bsa	bsa	PROPN
dpc-1595	149	23	)	)	PUNCT
dpc-1595	149	24	according	accord	VERB
dpc-1595	149	25	to	to	ADP
dpc-1595	149	26	treatment	treatment	NOUN
dpc-1595	149	27	adherence	adherence	NOUN
dpc-1595	149	28	.	.	PUNCT
dpc-1595	150	1	values	value	NOUN
dpc-1595	150	2	are	be	AUX
dpc-1595	150	3	mean	mean	ADJ
dpc-1595	150	4	and	and	CCONJ
dpc-1595	150	5	sd	sd	NOUN
dpc-1595	150	6	.	.	PUNCT
dpc-1595	151	1	bsa	bsa	PROPN
dpc-1595	151	2	=	=	PROPN
dpc-1595	151	3	body	body	PROPN
dpc-1595	151	4	surface	surface	NOUN
dpc-1595	151	5	area	area	NOUN
dpc-1595	151	6	research	research	NOUN
dpc-1595	151	7	|	|	ADV
dpc-1595	151	8	dermatol	dermatol	NOUN
dpc-1595	151	9	pract	pract	NOUN
dpc-1595	151	10	concept	concept	NOUN
dpc-1595	151	11	.	.	PUNCT
dpc-1595	152	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	152	2	7	7	NUM
dpc-1595	152	3	ta	ta	SYM
dpc-1595	152	4	b	b	PROPN
dpc-1595	152	5	le	le	X
dpc-1595	152	6	2	2	NUM
dpc-1595	152	7	.	.	PUNCT
dpc-1595	153	1	e	e	PROPN
dpc-1595	153	2	ffi	ffi	PROPN
dpc-1595	153	3	ca	can	AUX
dpc-1595	153	4	cy	cy	VERB
dpc-1595	153	5	o	o	PROPN
dpc-1595	153	6	f	f	PROPN
dpc-1595	153	7	tr	tr	PROPN
dpc-1595	153	8	ea	ea	X
dpc-1595	153	9	tm	tm	PROPN
dpc-1595	153	10	en	en	PROPN
dpc-1595	153	11	t	t	PROPN
dpc-1595	153	12	ac	ac	PROPN
dpc-1595	153	13	co	co	PROPN
dpc-1595	153	14	rd	rd	PROPN
dpc-1595	153	15	in	in	ADP
dpc-1595	153	16	g	g	PROPN
dpc-1595	153	17	to	to	ADP
dpc-1595	153	18	a	a	DET
dpc-1595	153	19	dh	dh	NOUN
dpc-1595	153	20	er	er	INTJ
dpc-1595	153	21	en	en	X
dpc-1595	153	22	ce	ce	PROPN
dpc-1595	153	23	8	8	NUM
dpc-1595	153	24	research	research	NOUN
dpc-1595	153	25	|	|	ADV
dpc-1595	153	26	dermatol	dermatol	ADJ
dpc-1595	153	27	pract	pract	NOUN
dpc-1595	153	28	concept	concept	NOUN
dpc-1595	153	29	.	.	PUNCT
dpc-1595	154	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	154	2	conclusions	conclusion	NOUN
dpc-1595	154	3	this	this	DET
dpc-1595	154	4	12	12	NUM
dpc-1595	154	5	-	-	PUNCT
dpc-1595	154	6	week	week	NOUN
dpc-1595	154	7	study	study	NOUN
dpc-1595	154	8	in	in	ADP
dpc-1595	154	9	patients	patient	NOUN
dpc-1595	154	10	with	with	ADP
dpc-1595	154	11	plaque	plaque	NOUN
dpc-1595	154	12	psoriasis	psoriasis	NOUN
dpc-1595	154	13	on	on	ADP
dpc-1595	154	14	the	the	DET
dpc-1595	154	15	trunk	trunk	NOUN
dpc-1595	154	16	and	and	CCONJ
dpc-1595	154	17	extremities	extremity	NOUN
dpc-1595	154	18	showed	show	VERB
dpc-1595	154	19	that	that	SCONJ
dpc-1595	154	20	cal	cal	PROPN
dpc-1595	154	21	/	/	SYM
dpc-1595	154	22	bd	bd	PROPN
dpc-1595	154	23	aerosol	aerosol	NOUN
dpc-1595	154	24	foam	foam	NOUN
dpc-1595	154	25	provides	provide	VERB
dpc-1595	154	26	a	a	DET
dpc-1595	154	27	significant	significant	ADJ
dpc-1595	154	28	improvement	improvement	NOUN
dpc-1595	154	29	in	in	ADP
dpc-1595	154	30	its	its	PRON
dpc-1595	154	31	treatment	treatment	NOUN
dpc-1595	154	32	,	,	PUNCT
dpc-1595	154	33	with	with	ADP
dpc-1595	154	34	very	very	ADV
dpc-1595	154	35	good	good	ADJ
dpc-1595	154	36	adherence	adherence	NOUN
dpc-1595	154	37	and	and	CCONJ
dpc-1595	154	38	a	a	DET
dpc-1595	154	39	favorable	favorable	ADJ
dpc-1595	154	40	safety	safety	NOUN
dpc-1595	154	41	profile	profile	NOUN
dpc-1595	154	42	.	.	PUNCT
dpc-1595	155	1	the	the	DET
dpc-1595	155	2	high	high	ADJ
dpc-1595	155	3	level	level	NOUN
dpc-1595	155	4	of	of	ADP
dpc-1595	155	5	adherence	adherence	NOUN
dpc-1595	155	6	,	,	PUNCT
dpc-1595	155	7	the	the	DET
dpc-1595	155	8	rapid	rapid	ADJ
dpc-1595	155	9	action	action	NOUN
dpc-1595	155	10	of	of	ADP
dpc-1595	155	11	the	the	DET
dpc-1595	155	12	drug	drug	NOUN
dpc-1595	155	13	,	,	PUNCT
dpc-1595	155	14	and	and	CCONJ
dpc-1595	155	15	the	the	DET
dpc-1595	155	16	adequate	adequate	ADJ
dpc-1595	155	17	cosmetics	cosmetic	NOUN
dpc-1595	155	18	of	of	ADP
dpc-1595	155	19	the	the	DET
dpc-1595	155	20	vehicle	vehicle	NOUN
dpc-1595	155	21	make	make	VERB
dpc-1595	155	22	cal	cal	PROPN
dpc-1595	155	23	/	/	SYM
dpc-1595	155	24	bd	bd	PROPN
dpc-1595	155	25	in	in	ADP
dpc-1595	155	26	aerosol	aerosol	NOUN
dpc-1595	155	27	foam	foam	VERB
dpc-1595	155	28	a	a	DET
dpc-1595	155	29	firstline	firstline	ADJ
dpc-1595	155	30	topical	topical	ADJ
dpc-1595	155	31	treatment	treatment	NOUN
dpc-1595	155	32	in	in	ADP
dpc-1595	155	33	patients	patient	NOUN
dpc-1595	155	34	with	with	ADP
dpc-1595	155	35	plaque	plaque	NOUN
dpc-1595	155	36	psoriasis	psoriasis	NOUN
dpc-1595	155	37	.	.	PUNCT
dpc-1595	156	1	cal/	cal/	PROPN
dpc-1595	156	2	bd	bd	PROPN
dpc-1595	156	3	aerosol	aerosol	NOUN
dpc-1595	156	4	foam	foam	NOUN
dpc-1595	156	5	can	can	AUX
dpc-1595	156	6	be	be	AUX
dpc-1595	156	7	considered	consider	VERB
dpc-1595	156	8	a	a	DET
dpc-1595	156	9	cost	cost	NOUN
dpc-1595	156	10	-	-	PUNCT
dpc-1595	156	11	effective	effective	ADJ
dpc-1595	156	12	drug	drug	NOUN
dpc-1595	156	13	for	for	ADP
dpc-1595	156	14	the	the	DET
dpc-1595	156	15	treatment	treatment	NOUN
dpc-1595	156	16	of	of	ADP
dpc-1595	156	17	plaque	plaque	NOUN
dpc-1595	156	18	psoriasis	psoriasis	NOUN
dpc-1595	156	19	.	.	PUNCT
dpc-1595	157	1	acknowledgments	acknowledgment	NOUN
dpc-1595	157	2	this	this	DET
dpc-1595	157	3	research	research	NOUN
dpc-1595	157	4	was	be	AUX
dpc-1595	157	5	funded	fund	VERB
dpc-1595	157	6	by	by	ADP
dpc-1595	157	7	leo	leo	PROPN
dpc-1595	157	8	pharma	pharma	PROPN
dpc-1595	157	9	.	.	PUNCT
dpc-1595	158	1	the	the	DET
dpc-1595	158	2	sponsor	sponsor	NOUN
dpc-1595	158	3	did	do	AUX
dpc-1595	158	4	not	not	PART
dpc-1595	158	5	influence	influence	VERB
dpc-1595	158	6	the	the	DET
dpc-1595	158	7	study	study	NOUN
dpc-1595	158	8	design	design	NOUN
dpc-1595	158	9	or	or	CCONJ
dpc-1595	158	10	planning	planning	NOUN
dpc-1595	158	11	,	,	PUNCT
dpc-1595	158	12	but	but	CCONJ
dpc-1595	158	13	has	have	AUX
dpc-1595	158	14	contributed	contribute	VERB
dpc-1595	158	15	on	on	ADP
dpc-1595	158	16	the	the	DET
dpc-1595	158	17	statistical	statistical	ADJ
dpc-1595	158	18	analysis	analysis	NOUN
dpc-1595	158	19	support	support	NOUN
dpc-1595	158	20	.	.	PUNCT
dpc-1595	159	1	references	reference	NOUN
dpc-1595	159	2	1	1	NUM
dpc-1595	159	3	.	.	PUNCT
dpc-1595	159	4	parisi	parisi	PROPN
dpc-1595	159	5	r	r	PROPN
dpc-1595	159	6	,	,	PUNCT
dpc-1595	159	7	symmons	symmon	NOUN
dpc-1595	159	8	dp	dp	PROPN
dpc-1595	159	9	,	,	PUNCT
dpc-1595	159	10	griffiths	griffiths	PROPN
dpc-1595	159	11	ce	ce	PROPN
dpc-1595	159	12	,	,	PUNCT
dpc-1595	159	13	ashcroft	ashcroft	PROPN
dpc-1595	159	14	dm	dm	PROPN
dpc-1595	159	15	.	.	PUNCT
dpc-1595	159	16	;	;	PUNCT
dpc-1595	159	17	identification	identification	NOUN
dpc-1595	159	18	and	and	CCONJ
dpc-1595	159	19	management	management	NOUN
dpc-1595	159	20	of	of	ADP
dpc-1595	159	21	psoriasis	psoriasis	NOUN
dpc-1595	159	22	and	and	CCONJ
dpc-1595	159	23	associated	associate	VERB
dpc-1595	159	24	comorbidity	comorbidity	NOUN
dpc-1595	159	25	(	(	PUNCT
dpc-1595	159	26	impact	impact	NOUN
dpc-1595	159	27	)	)	PUNCT
dpc-1595	159	28	project	project	NOUN
dpc-1595	159	29	team	team	NOUN
dpc-1595	159	30	.	.	PUNCT
dpc-1595	160	1	global	global	ADJ
dpc-1595	160	2	epidemiology	epidemiology	NOUN
dpc-1595	160	3	of	of	ADP
dpc-1595	160	4	psoriasis	psoriasis	NOUN
dpc-1595	160	5	:	:	PUNCT
dpc-1595	160	6	a	a	DET
dpc-1595	160	7	systematic	systematic	ADJ
dpc-1595	160	8	review	review	NOUN
dpc-1595	160	9	of	of	ADP
dpc-1595	160	10	incidence	incidence	NOUN
dpc-1595	160	11	and	and	CCONJ
dpc-1595	160	12	prevalence	prevalence	NOUN
dpc-1595	160	13	.	.	PUNCT
dpc-1595	160	14	 	 	SPACE
dpc-1595	161	1	j	j	PROPN
dpc-1595	161	2	invest	invest	VERB
dpc-1595	161	3	dermatol	dermatol	NOUN
dpc-1595	161	4	.	.	PUNCT
dpc-1595	162	1	2013;133(2):377	2013;133(2):377	NUM
dpc-1595	162	2	-	-	SYM
dpc-1595	162	3	385	385	NUM
dpc-1595	162	4	.	.	PUNCT
dpc-1595	163	1	doi	doi	NOUN
dpc-1595	163	2	:	:	PUNCT
dpc-1595	163	3	10.1038	10.1038	NUM
dpc-1595	163	4	/	/	SYM
dpc-1595	163	5	jid.2012.339	jid.2012.339	PROPN
dpc-1595	163	6	.	.	PUNCT
dpc-1595	164	1	pmid	pmid	NOUN
dpc-1595	164	2	:	:	PUNCT
dpc-1595	164	3	23014338	23014338	NUM
dpc-1595	164	4	.	.	PUNCT
dpc-1595	165	1	2	2	X
dpc-1595	165	2	.	.	X
dpc-1595	165	3	boehncke	boehncke	NOUN
dpc-1595	165	4	wh	wh	PROPN
dpc-1595	165	5	,	,	PUNCT
dpc-1595	165	6	schön	schön	PROPN
dpc-1595	165	7	mp	mp	PROPN
dpc-1595	165	8	.	.	PROPN
dpc-1595	165	9	psoriasis	psoriasis	NOUN
dpc-1595	165	10	.	.	PUNCT
dpc-1595	165	11	 	 	SPACE
dpc-1595	166	1	lancet	lancet	PROPN
dpc-1595	166	2	.	.	PUNCT
dpc-1595	167	1	2015;386(9997):983994	2015;386(9997):983994	X
dpc-1595	167	2	.	.	PUNCT
dpc-1595	168	1	doi	doi	NOUN
dpc-1595	168	2	:	:	PUNCT
dpc-1595	168	3	10.1016	10.1016	NUM
dpc-1595	168	4	/	/	SYM
dpc-1595	168	5	s0140	s0140	PROPN
dpc-1595	168	6	-	-	PUNCT
dpc-1595	168	7	6736(14)61909	6736(14)61909	NUM
dpc-1595	168	8	-	-	SYM
dpc-1595	168	9	7	7	NUM
dpc-1595	168	10	.	.	NOUN
dpc-1595	168	11	3	3	NUM
dpc-1595	168	12	.	.	X
dpc-1595	168	13	michalek	michalek	VERB
dpc-1595	169	1	i	i	PRON
dpc-1595	169	2	m	m	PROPN
dpc-1595	169	3	,	,	PUNCT
dpc-1595	169	4	loring	lore	VERB
dpc-1595	169	5	b	b	PROPN
dpc-1595	169	6	,	,	PUNCT
dpc-1595	169	7	john	john	PROPN
dpc-1595	169	8	sm	sm	PROPN
dpc-1595	169	9	.	.	PUNCT
dpc-1595	170	1	a	a	DET
dpc-1595	170	2	systematic	systematic	ADJ
dpc-1595	170	3	review	review	NOUN
dpc-1595	170	4	of	of	ADP
dpc-1595	170	5	worldwide	worldwide	ADJ
dpc-1595	170	6	epidemiology	epidemiology	NOUN
dpc-1595	170	7	of	of	ADP
dpc-1595	170	8	psoriasis	psoriasis	NOUN
dpc-1595	170	9	.	.	PUNCT
dpc-1595	170	10	 	 	SPACE
dpc-1595	171	1	j	j	PROPN
dpc-1595	171	2	eur	eur	PROPN
dpc-1595	171	3	acad	acad	PROPN
dpc-1595	171	4	dermatol	dermatol	NOUN
dpc-1595	171	5	venereol	venereol	NOUN
dpc-1595	171	6	.	.	PUNCT
dpc-1595	172	1	2017;31(2):205	2017;31(2):205	NUM
dpc-1595	172	2	-	-	PUNCT
dpc-1595	172	3	212	212	NUM
dpc-1595	172	4	.	.	PUNCT
dpc-1595	173	1	doi	doi	NOUN
dpc-1595	173	2	:	:	PUNCT
dpc-1595	173	3	10.1111	10.1111	NUM
dpc-1595	173	4	/	/	SYM
dpc-1595	173	5	jdv.13854.pmid	jdv.13854.pmid	NOUN
dpc-1595	173	6	:	:	PUNCT
dpc-1595	173	7	27573025	27573025	NUM
dpc-1595	173	8	.	.	PUNCT
dpc-1595	174	1	4	4	X
dpc-1595	174	2	.	.	X
dpc-1595	174	3	kimball	kimball	PROPN
dpc-1595	174	4	ab	ab	PROPN
dpc-1595	174	5	,	,	PUNCT
dpc-1595	174	6	gieler	gieler	NOUN
dpc-1595	174	7	u	u	PROPN
dpc-1595	174	8	,	,	PUNCT
dpc-1595	174	9	linder	linder	PROPN
dpc-1595	174	10	d	d	PROPN
dpc-1595	174	11	,	,	PUNCT
dpc-1595	174	12	sampogna	sampogna	PROPN
dpc-1595	174	13	f	f	PROPN
dpc-1595	174	14	,	,	PUNCT
dpc-1595	174	15	warren	warren	PROPN
dpc-1595	174	16	rb	rb	PROPN
dpc-1595	174	17	,	,	PUNCT
dpc-1595	174	18	augustin	augustin	PROPN
dpc-1595	174	19	m.	m.	NOUN
dpc-1595	174	20	psoriasis	psoriasis	NOUN
dpc-1595	174	21	:	:	PUNCT
dpc-1595	174	22	is	be	AUX
dpc-1595	174	23	the	the	DET
dpc-1595	174	24	impairment	impairment	NOUN
dpc-1595	174	25	to	to	ADP
dpc-1595	174	26	a	a	DET
dpc-1595	174	27	patient	patient	NOUN
dpc-1595	174	28	’s	’s	PART
dpc-1595	174	29	life	life	NOUN
dpc-1595	174	30	cumulative	cumulative	ADJ
dpc-1595	174	31	?	?	PUNCT
dpc-1595	174	32	 	 	SPACE
dpc-1595	174	33	j	j	PROPN
dpc-1595	174	34	eur	eur	PROPN
dpc-1595	174	35	acad	acad	PROPN
dpc-1595	174	36	dermatol	dermatol	NOUN
dpc-1595	174	37	venereol	venereol	NOUN
dpc-1595	174	38	.	.	PUNCT
dpc-1595	175	1	2010;24(9):989	2010;24(9):989	NUM
dpc-1595	175	2	-	-	SYM
dpc-1595	175	3	1004	1004	NUM
dpc-1595	175	4	.	.	PUNCT
dpc-1595	176	1	doi	doi	NOUN
dpc-1595	176	2	:	:	PUNCT
dpc-1595	176	3	10.1111	10.1111	NUM
dpc-1595	176	4	/	/	SYM
dpc-1595	176	5	j.1.468	j.1.468	NOUN
dpc-1595	176	6	-	-	PUNCT
dpc-1595	176	7	3083.2010.03705.x	3083.2010.03705.x	NOUN
dpc-1595	176	8	.	.	PUNCT
dpc-1595	177	1	pmid	pmid	NOUN
dpc-1595	177	2	:	:	PUNCT
dpc-1595	177	3	20477920	20477920	NUM
dpc-1595	177	4	.	.	PUNCT
dpc-1595	178	1	5	5	X
dpc-1595	178	2	.	.	X
dpc-1595	178	3	lebwohl	lebwohl	PROPN
dpc-1595	178	4	m	m	PROPN
dpc-1595	178	5	,	,	PUNCT
dpc-1595	178	6	ting	ting	PROPN
dpc-1595	178	7	pt	pt	PROPN
dpc-1595	178	8	,	,	PUNCT
dpc-1595	178	9	koo	koo	PROPN
dpc-1595	178	10	jy	jy	PROPN
dpc-1595	178	11	.	.	PUNCT
dpc-1595	179	1	psoriasis	psoriasis	NOUN
dpc-1595	179	2	treatment	treatment	NOUN
dpc-1595	179	3	:	:	PUNCT
dpc-1595	179	4	traditional	traditional	ADJ
dpc-1595	179	5	therapy	therapy	NOUN
dpc-1595	179	6	.	.	PUNCT
dpc-1595	179	7	 	 	SPACE
dpc-1595	180	1	ann	ann	PROPN
dpc-1595	180	2	rheum	rheum	PROPN
dpc-1595	180	3	dis	dis	PROPN
dpc-1595	180	4	.	.	PUNCT
dpc-1595	181	1	2005;64	2005;64	NUM
dpc-1595	181	2	suppl	suppl	PROPN
dpc-1595	181	3	2(suppl	2(suppl	PROPN
dpc-1595	181	4	2):ii83	2):ii83	PROPN
dpc-1595	181	5	-	-	PUNCT
dpc-1595	181	6	ii86	ii86	PROPN
dpc-1595	181	7	.	.	PUNCT
dpc-1595	182	1	doi	doi	PROPN
dpc-1595	182	2	:	:	PUNCT
dpc-1595	182	3	10.1136	10.1136	NUM
dpc-1595	182	4	/	/	SYM
dpc-1595	182	5	ard.2004.030791	ard.2004.030791	PROPN
dpc-1595	182	6	.	.	PUNCT
dpc-1595	183	1	pmid	pmid	NOUN
dpc-1595	183	2	:	:	PUNCT
dpc-1595	183	3	15708945	15708945	NUM
dpc-1595	183	4	.	.	PUNCT
dpc-1595	184	1	6	6	NUM
dpc-1595	184	2	.	.	X
dpc-1595	184	3	bewley	bewley	PROPN
dpc-1595	184	4	ap	ap	PROPN
dpc-1595	184	5	,	,	PUNCT
dpc-1595	184	6	shear	shear	PROPN
dpc-1595	184	7	nh	nh	PROPN
dpc-1595	184	8	,	,	PUNCT
dpc-1595	184	9	calzavara	calzavara	NOUN
dpc-1595	184	10	-	-	PUNCT
dpc-1595	184	11	pinton	pinton	NOUN
dpc-1595	184	12	pg	pg	PROPN
dpc-1595	184	13	,	,	PUNCT
dpc-1595	184	14	hansen	hansen	PROPN
dpc-1595	184	15	jb	jb	PROPN
dpc-1595	184	16	,	,	PUNCT
dpc-1595	184	17	nyeland	nyeland	PROPN
dpc-1595	184	18	me	i	PRON
dpc-1595	184	19	,	,	PUNCT
dpc-1595	184	20	signorovitch	signorovitch	VERB
dpc-1595	184	21	j.	j.	PROPN
dpc-1595	184	22	calcipotriol	calcipotriol	PROPN
dpc-1595	184	23	plus	plus	CCONJ
dpc-1595	184	24	betamethasone	betamethasone	PROPN
dpc-1595	184	25	dipropionate	dipropionate	PROPN
dpc-1595	184	26	aerosol	aerosol	NOUN
dpc-1595	184	27	foam	foam	NOUN
dpc-1595	184	28	vs.	vs.	ADP
dpc-1595	184	29	apremilast	apremilast	NOUN
dpc-1595	184	30	,	,	PUNCT
dpc-1595	184	31	methotrexate	methotrexate	NOUN
dpc-1595	184	32	,	,	PUNCT
dpc-1595	184	33	acitretin	acitretin	NOUN
dpc-1595	184	34	or	or	CCONJ
dpc-1595	184	35	fumaric	fumaric	ADJ
dpc-1595	184	36	acid	acid	NOUN
dpc-1595	184	37	esters	ester	NOUN
dpc-1595	184	38	for	for	ADP
dpc-1595	184	39	the	the	DET
dpc-1595	184	40	treatment	treatment	NOUN
dpc-1595	184	41	of	of	ADP
dpc-1595	184	42	plaque	plaque	NOUN
dpc-1595	184	43	psoriasis	psoriasis	NOUN
dpc-1595	184	44	:	:	PUNCT
dpc-1595	184	45	a	a	DET
dpc-1595	184	46	matching	matching	NOUN
dpc-1595	184	47	-	-	PUNCT
dpc-1595	184	48	adjusted	adjust	VERB
dpc-1595	184	49	indirect	indirect	ADJ
dpc-1595	184	50	comparison	comparison	NOUN
dpc-1595	184	51	.	.	PUNCT
dpc-1595	184	52	 	 	SPACE
dpc-1595	185	1	j	j	PROPN
dpc-1595	185	2	eur	eur	PROPN
dpc-1595	185	3	acad	acad	PROPN
dpc-1595	185	4	dermatol	dermatol	NOUN
dpc-1595	185	5	venereol	venereol	NOUN
dpc-1595	185	6	.	.	PUNCT
dpc-1595	186	1	2019;33(6):1107	2019;33(6):1107	PROPN
dpc-1595	186	2	-	-	PUNCT
dpc-1595	186	3	1115	1115	NUM
dpc-1595	186	4	.	.	PUNCT
dpc-1595	187	1	doi	doi	NOUN
dpc-1595	187	2	:	:	PUNCT
dpc-1595	187	3	10.1111	10.1111	NUM
dpc-1595	187	4	/	/	SYM
dpc-1595	187	5	jdv.15369	jdv.15369	NOUN
dpc-1595	187	6	.	.	PUNCT
dpc-1595	188	1	pmid	pmid	NOUN
dpc-1595	188	2	:	:	PUNCT
dpc-1595	188	3	30472749	30472749	NUM
dpc-1595	188	4	.	.	PUNCT
dpc-1595	189	1	7	7	X
dpc-1595	189	2	.	.	X
dpc-1595	189	3	mason	mason	PROPN
dpc-1595	189	4	ar	ar	PROPN
dpc-1595	189	5	,	,	PUNCT
dpc-1595	189	6	mason	mason	PROPN
dpc-1595	189	7	j	j	PROPN
dpc-1595	189	8	,	,	PUNCT
dpc-1595	189	9	cork	cork	NOUN
dpc-1595	189	10	m	m	NOUN
dpc-1595	189	11	,	,	PUNCT
dpc-1595	189	12	dooley	dooley	PROPN
dpc-1595	189	13	g	g	PROPN
dpc-1595	189	14	,	,	PUNCT
dpc-1595	189	15	hancock	hancock	PROPN
dpc-1595	189	16	h.	h.	PROPN
dpc-1595	189	17	topical	topical	ADJ
dpc-1595	189	18	treatments	treatment	NOUN
dpc-1595	189	19	for	for	ADP
dpc-1595	189	20	chronic	chronic	ADJ
dpc-1595	189	21	plaque	plaque	NOUN
dpc-1595	189	22	psoriasis	psoriasis	NOUN
dpc-1595	189	23	.	.	PUNCT
dpc-1595	189	24	 	 	SPACE
dpc-1595	190	1	cochrane	cochrane	NOUN
dpc-1595	190	2	database	database	PROPN
dpc-1595	190	3	syst	syst	PROPN
dpc-1595	190	4	rev	rev	PROPN
dpc-1595	190	5	.	.	PUNCT
dpc-1595	191	1	2013;cd005028	2013;cd005028	NUM
dpc-1595	191	2	.	.	PUNCT
dpc-1595	192	1	doi	doi	NOUN
dpc-1595	192	2	:	:	PUNCT
dpc-1595	192	3	10.1002/14651858.cd005028	10.1002/14651858.cd005028	NUM
dpc-1595	192	4	.	.	PUNCT
dpc-1595	193	1	pub3	pub3	PROPN
dpc-1595	193	2	.	.	PUNCT
dpc-1595	194	1	pmid	pmid	NOUN
dpc-1595	194	2	:	:	PUNCT
dpc-1595	194	3	23543539	23543539	NUM
dpc-1595	194	4	.	.	PUNCT
dpc-1595	195	1	8	8	X
dpc-1595	195	2	.	.	X
dpc-1595	195	3	basse	basse	PROPN
dpc-1595	195	4	lh	lh	PROPN
dpc-1595	195	5	,	,	PUNCT
dpc-1595	195	6	olesen	olesen	VERB
dpc-1595	195	7	m	m	PROPN
dpc-1595	195	8	,	,	PUNCT
dpc-1595	195	9	lacour	lacour	PROPN
dpc-1595	195	10	jp	jp	PROPN
dpc-1595	195	11	,	,	PUNCT
dpc-1595	195	12	queille	queille	NOUN
dpc-1595	195	13	-	-	PUNCT
dpc-1595	195	14	roussel	roussel	PROPN
dpc-1595	195	15	c.	c.	PROPN
dpc-1595	195	16	enhanced	enhance	VERB
dpc-1595	195	17	in	in	ADP
dpc-1595	195	18	vitro	vitro	X
dpc-1595	195	19	skin	skin	NOUN
dpc-1595	195	20	penetration	penetration	NOUN
dpc-1595	195	21	and	and	CCONJ
dpc-1595	195	22	antipsoriatic	antipsoriatic	ADJ
dpc-1595	195	23	effect	effect	NOUN
dpc-1595	195	24	of	of	ADP
dpc-1595	195	25	fixed	fix	VERB
dpc-1595	195	26	combination	combination	NOUN
dpc-1595	195	27	calcipotriol	calcipotriol	NOUN
dpc-1595	195	28	plus	plus	CCONJ
dpc-1595	195	29	betamethasone	betamethasone	NOUN
dpc-1595	195	30	dipropionate	dipropionate	NOUN
dpc-1595	195	31	in	in	ADP
dpc-1595	195	32	an	an	DET
dpc-1595	195	33	innovative	innovative	ADJ
dpc-1595	195	34	foam	foam	NOUN
dpc-1595	195	35	vehicle	vehicle	NOUN
dpc-1595	195	36	.	.	PUNCT
dpc-1595	196	1	j	j	PROPN
dpc-1595	196	2	invest	invest	VERB
dpc-1595	196	3	dermatol	dermatol	NOUN
dpc-1595	196	4	.	.	PUNCT
dpc-1595	197	1	2014;134	2014;134	NUM
dpc-1595	197	2	:	:	PUNCT
dpc-1595	197	3	s33	s33	X
dpc-1595	197	4	(	(	PUNCT
dpc-1595	197	5	abst	abst	PROPN
dpc-1595	197	6	192	192	NUM
dpc-1595	197	7	)	)	PUNCT
dpc-1595	197	8	.	.	PUNCT
dpc-1595	198	1	9	9	X
dpc-1595	198	2	.	.	X
dpc-1595	198	3	queille	queille	NOUN
dpc-1595	198	4	-	-	PUNCT
dpc-1595	198	5	roussel	roussel	PROPN
dpc-1595	198	6	c	c	PROPN
dpc-1595	198	7	,	,	PUNCT
dpc-1595	198	8	olesen	olesen	VERB
dpc-1595	198	9	m	m	PROPN
dpc-1595	198	10	,	,	PUNCT
dpc-1595	198	11	villumsen	villumsen	PROPN
dpc-1595	198	12	j	j	PROPN
dpc-1595	198	13	,	,	PUNCT
dpc-1595	198	14	lacour	lacour	PROPN
dpc-1595	198	15	jp	jp	NOUN
dpc-1595	198	16	.	.	PUNCT
dpc-1595	198	17	efficacy	efficacy	NOUN
dpc-1595	198	18	of	of	ADP
dpc-1595	198	19	an	an	DET
dpc-1595	198	20	innovative	innovative	ADJ
dpc-1595	198	21	aerosol	aerosol	NOUN
dpc-1595	198	22	foam	foam	NOUN
dpc-1595	198	23	formulation	formulation	NOUN
dpc-1595	198	24	of	of	ADP
dpc-1595	198	25	fixed	fix	VERB
dpc-1595	198	26	combination	combination	NOUN
dpc-1595	198	27	calcipotriol	calcipotriol	NOUN
dpc-1595	198	28	plus	plus	CCONJ
dpc-1595	198	29	betamethasone	betamethasone	NOUN
dpc-1595	198	30	dipropionate	dipropionate	NOUN
dpc-1595	198	31	in	in	ADP
dpc-1595	198	32	patients	patient	NOUN
dpc-1595	198	33	with	with	ADP
dpc-1595	198	34	psoriasis	psoriasis	NOUN
dpc-1595	198	35	vulgaris	vulgaris	NOUN
dpc-1595	198	36	.	.	PUNCT
dpc-1595	198	37	 	 	SPACE
dpc-1595	199	1	clin	clin	PROPN
dpc-1595	199	2	drug	drug	PROPN
dpc-1595	199	3	investig	investig	PROPN
dpc-1595	199	4	.	.	PUNCT
dpc-1595	200	1	2015;35(4):239	2015;35(4):239	NUM
dpc-1595	200	2	-	-	SYM
dpc-1595	200	3	245	245	NUM
dpc-1595	200	4	.	.	PUNCT
dpc-1595	201	1	doi	doi	NOUN
dpc-1595	201	2	:	:	PUNCT
dpc-1595	201	3	10.1007	10.1007	NUM
dpc-1595	201	4	/	/	SYM
dpc-1595	201	5	s40261	s40261	PROPN
dpc-1595	201	6	-	-	PUNCT
dpc-1595	201	7	015	015	NUM
dpc-1595	201	8	-	-	PUNCT
dpc-1595	201	9	0269	0269	NUM
dpc-1595	201	10	-	-	SYM
dpc-1595	201	11	7	7	NUM
dpc-1595	201	12	.	.	PUNCT
dpc-1595	202	1	pmid	pmid	NOUN
dpc-1595	202	2	:	:	PUNCT
dpc-1595	202	3	25708531	25708531	NUM
dpc-1595	202	4	.	.	PUNCT
dpc-1595	203	1	10	10	NUM
dpc-1595	203	2	.	.	PUNCT
dpc-1595	203	3	taraska	taraska	PROPN
dpc-1595	203	4	v	v	NOUN
dpc-1595	203	5	,	,	PUNCT
dpc-1595	203	6	tuppal	tuppal	NOUN
dpc-1595	203	7	r	r	NOUN
dpc-1595	203	8	,	,	PUNCT
dpc-1595	203	9	olesen	olesen	ADP
dpc-1595	203	10	m	m	PROPN
dpc-1595	203	11	,	,	PUNCT
dpc-1595	203	12	bang	bang	PROPN
dpc-1595	203	13	pedersen	pedersen	PROPN
dpc-1595	203	14	c	c	PROPN
dpc-1595	203	15	,	,	PUNCT
dpc-1595	203	16	papp	papp	PROPN
dpc-1595	203	17	k.	k.	PROPN
dpc-1595	204	1	a	a	DET
dpc-1595	204	2	novel	novel	ADJ
dpc-1595	204	3	aerosol	aerosol	NOUN
dpc-1595	204	4	foam	foam	NOUN
dpc-1595	204	5	formulation	formulation	NOUN
dpc-1595	204	6	of	of	ADP
dpc-1595	204	7	calcipotriol	calcipotriol	PROPN
dpc-1595	204	8	and	and	CCONJ
dpc-1595	204	9	betamethasone	betamethasone	PROPN
dpc-1595	204	10	has	have	VERB
dpc-1595	204	11	no	no	DET
dpc-1595	204	12	impact	impact	NOUN
dpc-1595	204	13	on	on	ADP
dpc-1595	204	14	hpa	hpa	NOUN
dpc-1595	204	15	axis	axis	NOUN
dpc-1595	204	16	and	and	CCONJ
dpc-1595	204	17	calcium	calcium	NOUN
dpc-1595	204	18	homeostasis	homeostasis	NOUN
dpc-1595	204	19	in	in	ADP
dpc-1595	204	20	patients	patient	NOUN
dpc-1595	204	21	with	with	ADP
dpc-1595	204	22	extensive	extensive	ADJ
dpc-1595	204	23	psoriasis	psoriasis	NOUN
dpc-1595	204	24	vulgaris	vulgaris	NOUN
dpc-1595	204	25	.	.	PUNCT
dpc-1595	204	26	 	 	SPACE
dpc-1595	205	1	j	j	PROPN
dpc-1595	205	2	cutan	cutan	PROPN
dpc-1595	205	3	med	med	ADJ
dpc-1595	205	4	surg	surg	NOUN
dpc-1595	205	5	.	.	PUNCT
dpc-1595	206	1	2016;20(1):44	2016;20(1):44	NUM
dpc-1595	206	2	-	-	SYM
dpc-1595	206	3	51	51	NUM
dpc-1595	206	4	.	.	PUNCT
dpc-1595	206	5	doi	doi	NOUN
dpc-1595	206	6	:	:	PUNCT
dpc-1595	206	7	10.1177/1203475415597094	10.1177/1203475415597094	NUM
dpc-1595	206	8	.	.	PUNCT
dpc-1595	207	1	pmid	pmid	NOUN
dpc-1595	207	2	:	:	PUNCT
dpc-1595	207	3	26224733	26224733	NUM
dpc-1595	207	4	.	.	PUNCT
dpc-1595	208	1	11	11	NUM
dpc-1595	208	2	.	.	PUNCT
dpc-1595	208	3	leonardi	leonardi	PROPN
dpc-1595	208	4	c	c	PROPN
dpc-1595	208	5	,	,	PUNCT
dpc-1595	208	6	bagel	bagel	PROPN
dpc-1595	208	7	j	j	PROPN
dpc-1595	208	8	,	,	PUNCT
dpc-1595	208	9	yamauchi	yamauchi	PROPN
dpc-1595	208	10	p	p	PROPN
dpc-1595	208	11	,	,	PUNCT
dpc-1595	208	12	et	et	PROPN
dpc-1595	208	13	al	al	PROPN
dpc-1595	208	14	.	.	PUNCT
dpc-1595	209	1	the	the	DET
dpc-1595	209	2	aerosol	aerosol	NOUN
dpc-1595	209	3	foam	foam	NOUN
dpc-1595	209	4	formulation	formulation	NOUN
dpc-1595	209	5	of	of	ADP
dpc-1595	209	6	the	the	DET
dpc-1595	209	7	fixed	fix	VERB
dpc-1595	209	8	combination	combination	NOUN
dpc-1595	209	9	calcipotriene	calcipotriene	NOUN
dpc-1595	209	10	plus	plus	CCONJ
dpc-1595	209	11	betamethasone	betamethasone	NOUN
dpc-1595	209	12	dipropionate	dipropionate	PROPN
dpc-1595	209	13	improves	improve	VERB
dpc-1595	209	14	the	the	DET
dpc-1595	209	15	health	health	NOUN
dpc-1595	209	16	-	-	PUNCT
dpc-1595	209	17	related	relate	VERB
dpc-1595	209	18	quality	quality	NOUN
dpc-1595	209	19	of	of	ADP
dpc-1595	209	20	life	life	NOUN
dpc-1595	209	21	in	in	ADP
dpc-1595	209	22	patients	patient	NOUN
dpc-1595	209	23	with	with	ADP
dpc-1595	209	24	psoriasis	psoriasis	NOUN
dpc-1595	209	25	vulgaris	vulgaris	NOUN
dpc-1595	209	26	:	:	PUNCT
dpc-1595	209	27	results	result	NOUN
dpc-1595	209	28	from	from	ADP
dpc-1595	209	29	the	the	DET
dpc-1595	209	30	randomized	randomized	ADJ
dpc-1595	209	31	pso	pso	NOUN
dpc-1595	209	32	-	-	PUNCT
dpc-1595	209	33	fast	fast	NOUN
dpc-1595	209	34	study	study	NOUN
dpc-1595	209	35	.	.	PUNCT
dpc-1595	209	36	 	 	SPACE
dpc-1595	210	1	j	j	PROPN
dpc-1595	210	2	drugs	drug	NOUN
dpc-1595	210	3	dermatol	dermatol	NOUN
dpc-1595	210	4	.	.	PUNCT
dpc-1595	211	1	2016;15(8):981	2016;15(8):981	NUM
dpc-1595	211	2	-	-	SYM
dpc-1595	211	3	987	987	NUM
dpc-1595	211	4	.	.	PUNCT
dpc-1595	212	1	pmid	pmid	NOUN
dpc-1595	212	2	:	:	PUNCT
dpc-1595	212	3	27537999	27537999	NUM
dpc-1595	212	4	.	.	PUNCT
dpc-1595	213	1	12	12	NUM
dpc-1595	213	2	.	.	PUNCT
dpc-1595	214	1	stein	stein	PROPN
dpc-1595	214	2	gold	gold	PROPN
dpc-1595	214	3	l	l	PROPN
dpc-1595	214	4	,	,	PUNCT
dpc-1595	214	5	lebwohl	lebwohl	PROPN
dpc-1595	214	6	m	m	PROPN
dpc-1595	214	7	,	,	PUNCT
dpc-1595	214	8	menter	menter	X
dpc-1595	214	9	a	a	X
dpc-1595	214	10	,	,	PUNCT
dpc-1595	214	11	villumsen	villumsen	PROPN
dpc-1595	214	12	j	j	PROPN
dpc-1595	214	13	,	,	PUNCT
dpc-1595	214	14	rosen	rosen	PROPN
dpc-1595	214	15	m	m	PROPN
dpc-1595	214	16	,	,	PUNCT
dpc-1595	214	17	koo	koo	PROPN
dpc-1595	214	18	j.	j.	PROPN
dpc-1595	214	19	aerosol	aerosol	PROPN
dpc-1595	214	20	foam	foam	NOUN
dpc-1595	214	21	formulation	formulation	NOUN
dpc-1595	214	22	of	of	ADP
dpc-1595	214	23	fixed	fix	VERB
dpc-1595	214	24	combination	combination	NOUN
dpc-1595	214	25	calcipotriene	calcipotriene	NOUN
dpc-1595	214	26	plus	plus	CCONJ
dpc-1595	214	27	betamethasone	betamethasone	NOUN
dpc-1595	214	28	dipropionate	dipropionate	NOUN
dpc-1595	214	29	is	be	AUX
dpc-1595	214	30	highly	highly	ADV
dpc-1595	214	31	efficacious	efficacious	ADJ
dpc-1595	214	32	in	in	ADP
dpc-1595	214	33	patients	patient	NOUN
dpc-1595	214	34	with	with	ADP
dpc-1595	214	35	psoriasis	psoriasis	NOUN
dpc-1595	214	36	vulgaris	vulgaris	NOUN
dpc-1595	214	37	:	:	PUNCT
dpc-1595	214	38	pooled	pool	VERB
dpc-1595	214	39	data	datum	NOUN
dpc-1595	214	40	from	from	ADP
dpc-1595	214	41	three	three	NUM
dpc-1595	214	42	randomized	randomized	ADJ
dpc-1595	214	43	controlled	control	VERB
dpc-1595	214	44	studies	study	NOUN
dpc-1595	214	45	.	.	PUNCT
dpc-1595	214	46	 	 	SPACE
dpc-1595	215	1	j	j	PROPN
dpc-1595	215	2	drugs	drug	NOUN
dpc-1595	215	3	dermatol	dermatol	NOUN
dpc-1595	215	4	.	.	PUNCT
dpc-1595	216	1	2016;15(8):951	2016;15(8):951	NUM
dpc-1595	216	2	-	-	PUNCT
dpc-1595	216	3	957	957	NUM
dpc-1595	216	4	.	.	PUNCT
dpc-1595	217	1	pmid	pmid	NOUN
dpc-1595	217	2	:	:	PUNCT
dpc-1595	217	3	27537995	27537995	NUM
dpc-1595	217	4	.	.	PUNCT
dpc-1595	218	1	13	13	NUM
dpc-1595	218	2	.	.	X
dpc-1595	219	1	pink	pink	ADJ
dpc-1595	219	2	ae	ae	PROPN
dpc-1595	219	3	,	,	PUNCT
dpc-1595	219	4	jalili	jalili	NOUN
dpc-1595	219	5	a	a	NOUN
dpc-1595	219	6	,	,	PUNCT
dpc-1595	219	7	berg	berg	PROPN
dpc-1595	219	8	p	p	PROPN
dpc-1595	219	9	,	,	PUNCT
dpc-1595	219	10	et	et	PROPN
dpc-1595	219	11	al	al	PROPN
dpc-1595	219	12	.	.	PROPN
dpc-1595	220	1	rapid	rapid	ADJ
dpc-1595	220	2	onset	onset	NOUN
dpc-1595	220	3	of	of	ADP
dpc-1595	220	4	action	action	NOUN
dpc-1595	220	5	of	of	ADP
dpc-1595	220	6	calcipotriol	calcipotriol	PROPN
dpc-1595	220	7	/	/	SYM
dpc-1595	220	8	betamethasone	betamethasone	PROPN
dpc-1595	220	9	dipropionate	dipropionate	VERB
dpc-1595	220	10	cutaneous	cutaneous	ADJ
dpc-1595	220	11	foam	foam	NOUN
dpc-1595	220	12	in	in	ADP
dpc-1595	220	13	psoriasis	psoriasis	NOUN
dpc-1595	220	14	,	,	PUNCT
dpc-1595	220	15	even	even	ADV
dpc-1595	220	16	in	in	ADP
dpc-1595	220	17	patients	patient	NOUN
dpc-1595	220	18	with	with	ADP
dpc-1595	220	19	more	more	ADV
dpc-1595	220	20	severe	severe	ADJ
dpc-1595	220	21	disease	disease	NOUN
dpc-1595	220	22	.	.	PUNCT
dpc-1595	220	23	 	 	SPACE
dpc-1595	221	1	j	j	PROPN
dpc-1595	221	2	eur	eur	PROPN
dpc-1595	221	3	acad	acad	PROPN
dpc-1595	221	4	dermatol	dermatol	NOUN
dpc-1595	221	5	venereol	venereol	NOUN
dpc-1595	221	6	.	.	PUNCT
dpc-1595	222	1	2019;33(6):1116	2019;33(6):1116	NUM
dpc-1595	222	2	-	-	SYM
dpc-1595	222	3	1123	1123	NUM
dpc-1595	222	4	.	.	PUNCT
dpc-1595	223	1	doi	doi	NOUN
dpc-1595	223	2	:	:	PUNCT
dpc-1595	223	3	10.1111	10.1111	NUM
dpc-1595	223	4	/	/	SYM
dpc-1595	223	5	jdv.15398	jdv.15398	PROPN
dpc-1595	223	6	.	.	PUNCT
dpc-1595	224	1	pmid	pmid	NOUN
dpc-1595	224	2	:	:	PUNCT
dpc-1595	224	3	30916417	30916417	NUM
dpc-1595	224	4	.	.	PUNCT
dpc-1595	225	1	14	14	NUM
dpc-1595	225	2	.	.	PUNCT
dpc-1595	226	1	reich	reich	PROPN
dpc-1595	226	2	k	k	PROPN
dpc-1595	226	3	,	,	PUNCT
dpc-1595	226	4	daudén	daudén	PROPN
dpc-1595	226	5	e.	e.	PROPN
dpc-1595	226	6	treatment	treatment	PROPN
dpc-1595	226	7	adherence	adherence	NOUN
dpc-1595	226	8	:	:	PUNCT
dpc-1595	226	9	a	a	DET
dpc-1595	226	10	hurdle	hurdle	NOUN
dpc-1595	226	11	for	for	ADP
dpc-1595	226	12	real	real	ADJ
dpc-1595	226	13	-	-	PUNCT
dpc-1595	226	14	life	life	NOUN
dpc-1595	226	15	effectiveness	effectiveness	NOUN
dpc-1595	226	16	in	in	ADP
dpc-1595	226	17	psoriasis	psoriasis	NOUN
dpc-1595	226	18	?	?	PUNCT
dpc-1595	226	19	 	 	SPACE
dpc-1595	227	1	j	j	PROPN
dpc-1595	227	2	eur	eur	PROPN
dpc-1595	227	3	acad	acad	PROPN
dpc-1595	227	4	dermatol	dermatol	NOUN
dpc-1595	227	5	venereol	venereol	ADV
dpc-1595	227	6	.	.	PUNCT
dpc-1595	228	1	2014;28	2014;28	PROPN
dpc-1595	228	2	suppl	suppl	ADJ
dpc-1595	228	3	2:1	2:1	NUM
dpc-1595	228	4	-	-	SYM
dpc-1595	228	5	3	3	NUM
dpc-1595	228	6	.	.	PUNCT
dpc-1595	228	7	doi	doi	NOUN
dpc-1595	228	8	:	:	PUNCT
dpc-1595	228	9	10.1111	10.1111	NUM
dpc-1595	228	10	/	/	SYM
dpc-1595	228	11	jdv.12442	jdv.12442	PROPN
dpc-1595	228	12	.	.	PUNCT
dpc-1595	229	1	pmid	pmid	NOUN
dpc-1595	229	2	:	:	PUNCT
dpc-1595	229	3	24684737	24684737	NUM
dpc-1595	229	4	.	.	PUNCT
dpc-1595	230	1	15	15	NUM
dpc-1595	230	2	.	.	PUNCT
dpc-1595	231	1	paul	paul	PROPN
dpc-1595	231	2	c	c	PROPN
dpc-1595	231	3	,	,	PUNCT
dpc-1595	231	4	stein	stein	PROPN
dpc-1595	231	5	gold	gold	PROPN
dpc-1595	231	6	l	l	PROPN
dpc-1595	231	7	,	,	PUNCT
dpc-1595	231	8	cambazard	cambazard	PROPN
dpc-1595	231	9	f	f	X
dpc-1595	231	10	,	,	PUNCT
dpc-1595	231	11	et	et	PROPN
dpc-1595	231	12	al	al	PROPN
dpc-1595	231	13	.	.	PROPN
dpc-1595	231	14	calcipotriol	calcipotriol	PROPN
dpc-1595	231	15	plus	plus	CCONJ
dpc-1595	231	16	betamethasone	betamethasone	PROPN
dpc-1595	231	17	dipropionate	dipropionate	PROPN
dpc-1595	231	18	aerosol	aerosol	NOUN
dpc-1595	231	19	foam	foam	NOUN
dpc-1595	231	20	provides	provide	VERB
dpc-1595	231	21	superior	superior	ADJ
dpc-1595	231	22	efficacy	efficacy	NOUN
dpc-1595	231	23	vs.	vs.	ADP
dpc-1595	231	24	gel	gel	NOUN
dpc-1595	231	25	in	in	ADP
dpc-1595	231	26	patients	patient	NOUN
dpc-1595	231	27	with	with	ADP
dpc-1595	231	28	psoriasis	psoriasis	NOUN
dpc-1595	231	29	vulgaris	vulgaris	NOUN
dpc-1595	231	30	:	:	PUNCT
dpc-1595	231	31	randomized	randomize	VERB
dpc-1595	231	32	,	,	PUNCT
dpc-1595	231	33	controlled	control	VERB
dpc-1595	231	34	pso	pso	NOUN
dpc-1595	231	35	-	-	PUNCT
dpc-1595	231	36	able	able	ADJ
dpc-1595	231	37	study	study	NOUN
dpc-1595	231	38	.	.	PUNCT
dpc-1595	231	39	 	 	SPACE
dpc-1595	232	1	j	j	PROPN
dpc-1595	232	2	eur	eur	PROPN
dpc-1595	232	3	acad	acad	PROPN
dpc-1595	232	4	dermatol	dermatol	NOUN
dpc-1595	232	5	venereol	venereol	NOUN
dpc-1595	232	6	.	.	PUNCT
dpc-1595	233	1	2017;31(1):119	2017;31(1):119	NUM
dpc-1595	233	2	-	-	SYM
dpc-1595	233	3	126	126	NUM
dpc-1595	233	4	.	.	PUNCT
dpc-1595	234	1	doi	doi	NOUN
dpc-1595	234	2	:	:	PUNCT
dpc-1595	234	3	10.1111	10.1111	NUM
dpc-1595	234	4	/	/	SYM
dpc-1595	234	5	jdv.13859	jdv.13859	PROPN
dpc-1595	234	6	.	.	PUNCT
dpc-1595	235	1	pmid	pmid	PROPN
dpc-1595	235	2	:	:	PUNCT
dpc-1595	235	3	27531752	27531752	NUM
dpc-1595	235	4	.	.	PUNCT
dpc-1595	236	1	16	16	NUM
dpc-1595	236	2	.	.	PUNCT
dpc-1595	236	3	brown	brown	PROPN
dpc-1595	236	4	kk	kk	PROPN
dpc-1595	236	5	,	,	PUNCT
dpc-1595	236	6	rehmus	rehmus	VERB
dpc-1595	236	7	we	we	PRON
dpc-1595	236	8	,	,	PUNCT
dpc-1595	236	9	kimball	kimball	PROPN
dpc-1595	236	10	ab	ab	PROPN
dpc-1595	236	11	.	.	PUNCT
dpc-1595	237	1	determining	determine	VERB
dpc-1595	237	2	the	the	DET
dpc-1595	237	3	relative	relative	ADJ
dpc-1595	237	4	importance	importance	NOUN
dpc-1595	237	5	of	of	ADP
dpc-1595	237	6	patient	patient	ADJ
dpc-1595	237	7	motivations	motivation	NOUN
dpc-1595	237	8	for	for	ADP
dpc-1595	237	9	nonadherence	nonadherence	NOUN
dpc-1595	237	10	to	to	ADP
dpc-1595	237	11	topical	topical	ADJ
dpc-1595	237	12	corticosteroid	corticosteroid	ADJ
dpc-1595	237	13	therapy	therapy	NOUN
dpc-1595	237	14	in	in	ADP
dpc-1595	237	15	psoriasis	psoriasis	NOUN
dpc-1595	237	16	.	.	PUNCT
dpc-1595	237	17	 	 	SPACE
dpc-1595	238	1	j	j	PROPN
dpc-1595	238	2	am	be	AUX
dpc-1595	238	3	acad	acad	ADJ
dpc-1595	238	4	dermatol	dermatol	NOUN
dpc-1595	238	5	.	.	PUNCT
dpc-1595	239	1	2006;55(4):607	2006;55(4):607	PROPN
dpc-1595	239	2	-	-	PUNCT
dpc-1595	239	3	613	613	PROPN
dpc-1595	239	4	.	.	PUNCT
dpc-1595	239	5	doi	doi	NOUN
dpc-1595	239	6	:	:	PUNCT
dpc-1595	239	7	10.1016	10.1016	NUM
dpc-1595	239	8	/	/	SYM
dpc-1595	239	9	j.jaad.2005.12.021	j.jaad.2005.12.021	PROPN
dpc-1595	239	10	.	.	PUNCT
dpc-1595	240	1	pmid	pmid	NOUN
dpc-1595	240	2	:	:	PUNCT
dpc-1595	240	3	17010739	17010739	NUM
dpc-1595	240	4	.	.	PUNCT
dpc-1595	241	1	17	17	NUM
dpc-1595	241	2	.	.	PUNCT
dpc-1595	241	3	bewley	bewley	PROPN
dpc-1595	241	4	a	a	PRON
dpc-1595	241	5	,	,	PUNCT
dpc-1595	241	6	page	page	NOUN
dpc-1595	241	7	b.	b.	PROPN
dpc-1595	241	8	maximizing	maximize	VERB
dpc-1595	241	9	patient	patient	NOUN
dpc-1595	241	10	adherence	adherence	NOUN
dpc-1595	241	11	for	for	ADP
dpc-1595	241	12	optimal	optimal	ADJ
dpc-1595	241	13	outcomes	outcome	NOUN
dpc-1595	241	14	in	in	ADP
dpc-1595	241	15	psoriasis	psoriasis	NOUN
dpc-1595	241	16	.	.	PUNCT
dpc-1595	241	17	 	 	SPACE
dpc-1595	242	1	j	j	PROPN
dpc-1595	242	2	eur	eur	PROPN
dpc-1595	242	3	acad	acad	PROPN
dpc-1595	242	4	dermatol	dermatol	NOUN
dpc-1595	242	5	venereol	venereol	NOUN
dpc-1595	242	6	.	.	PUNCT
dpc-1595	243	1	2011;25	2011;25	NUM
dpc-1595	243	2	suppl	suppl	PROPN
dpc-1595	243	3	4:9	4:9	NUM
dpc-1595	243	4	-	-	NOUN
dpc-1595	243	5	14	14	NUM
dpc-1595	243	6	.	.	PUNCT
dpc-1595	244	1	doi	doi	NOUN
dpc-1595	244	2	:	:	PUNCT
dpc-1595	244	3	10.1111	10.1111	NUM
dpc-1595	244	4	/	/	SYM
dpc-1595	244	5	j.1468	j.1468	NOUN
dpc-1595	244	6	-	-	PUNCT
dpc-1595	244	7	3083.2011.04060.x	3083.2011.04060.x	NUM
dpc-1595	244	8	.	.	PUNCT
dpc-1595	245	1	pmid	pmid	NOUN
dpc-1595	245	2	:	:	PUNCT
dpc-1595	245	3	21507078	21507078	NUM
dpc-1595	245	4	.	.	PUNCT
dpc-1595	246	1	18	18	NUM
dpc-1595	246	2	.	.	X
dpc-1595	246	3	balak	balak	PROPN
dpc-1595	246	4	dmw	dmw	PROPN
dpc-1595	246	5	,	,	PUNCT
dpc-1595	246	6	carrascosa	carrascosa	PROPN
dpc-1595	246	7	jm	jm	PROPN
dpc-1595	246	8	,	,	PUNCT
dpc-1595	246	9	gregoriou	gregoriou	NOUN
dpc-1595	246	10	s	s	PROPN
dpc-1595	246	11	,	,	PUNCT
dpc-1595	246	12	et	et	PROPN
dpc-1595	246	13	al	al	PROPN
dpc-1595	246	14	.	.	PROPN
dpc-1595	246	15	cost	cost	PROPN
dpc-1595	246	16	per	per	ADP
dpc-1595	246	17	pasi-75	pasi-75	PROPN
dpc-1595	246	18	responder	responder	NOUN
dpc-1595	246	19	of	of	ADP
dpc-1595	246	20	calcipotriol	calcipotriol	PROPN
dpc-1595	246	21	plus	plus	CCONJ
dpc-1595	246	22	betamethasone	betamethasone	NOUN
dpc-1595	246	23	dipropionate	dipropionate	VERB
dpc-1595	246	24	cutaneous	cutaneous	ADJ
dpc-1595	246	25	foam	foam	NOUN
dpc-1595	246	26	versus	versus	ADP
dpc-1595	246	27	nonbiologic	nonbiologic	ADJ
dpc-1595	246	28	systemic	systemic	ADJ
dpc-1595	246	29	therapies	therapy	NOUN
dpc-1595	246	30	for	for	ADP
dpc-1595	246	31	the	the	DET
dpc-1595	246	32	treatment	treatment	NOUN
dpc-1595	246	33	of	of	ADP
dpc-1595	246	34	plaque	plaque	NOUN
dpc-1595	246	35	psoriasis	psoriasis	NOUN
dpc-1595	246	36	in	in	ADP
dpc-1595	246	37	seven	seven	NUM
dpc-1595	246	38	european	european	ADJ
dpc-1595	246	39	countries	country	NOUN
dpc-1595	246	40	.	.	PUNCT
dpc-1595	247	1	j	j	PROPN
dpc-1595	247	2	dermatolog	dermatolog	PROPN
dpc-1595	247	3	treat	treat	NOUN
dpc-1595	247	4	.	.	PUNCT
dpc-1595	248	1	2020	2020	NUM
dpc-1595	248	2	mar	mar	PROPN
dpc-1595	248	3	6;1	6;1	NUM
dpc-1595	248	4	-	-	SYM
dpc-1595	248	5	8	8	NUM
dpc-1595	248	6	.	.	PUNCT
dpc-1595	249	1	doi	doi	NOUN
dpc-1595	249	2	:	:	PUNCT
dpc-1595	249	3	10.1080/09546634.2019.1707754	10.1080/09546634.2019.1707754	NUM
dpc-1595	249	4	.	.	PUNCT
dpc-1595	250	1	pmid	pmid	NOUN
dpc-1595	250	2	:	:	PUNCT
dpc-1595	250	3	31940225	31940225	NUM
dpc-1595	250	4	.	.	PUNCT
dpc-1595	251	1	19	19	NUM
dpc-1595	251	2	.	.	X
dpc-1595	251	3	duvetorp	duvetorp	PROPN
dpc-1595	251	4	a	a	PROPN
dpc-1595	251	5	,	,	PUNCT
dpc-1595	251	6	levin	levin	PROPN
dpc-1595	251	7	lå	lå	PROPN
dpc-1595	251	8	,	,	PUNCT
dpc-1595	251	9	engerstedt	engerstedt	PROPN
dpc-1595	251	10	mattsson	mattsson	PROPN
dpc-1595	251	11	e	e	PROPN
dpc-1595	251	12	,	,	PUNCT
dpc-1595	251	13	ryttig	ryttig	PROPN
dpc-1595	251	14	l.	l.	PROPN
dpc-1595	251	15	a	a	DET
dpc-1595	251	16	cost	cost	NOUN
dpc-1595	251	17	-	-	PUNCT
dpc-1595	251	18	utility	utility	NOUN
dpc-1595	251	19	analysis	analysis	NOUN
dpc-1595	251	20	of	of	ADP
dpc-1595	251	21	calcipotriol	calcipotriol	PROPN
dpc-1595	251	22	/	/	SYM
dpc-1595	251	23	betamethasone	betamethasone	PROPN
dpc-1595	251	24	dipropionate	dipropionate	PROPN
dpc-1595	251	25	aerosol	aerosol	VERB
dpc-1595	251	26	foam	foam	NOUN
dpc-1595	251	27	versus	versus	ADP
dpc-1595	251	28	ointment	ointment	NOUN
dpc-1595	251	29	for	for	ADP
dpc-1595	251	30	the	the	DET
dpc-1595	251	31	topical	topical	ADJ
dpc-1595	251	32	treatment	treatment	NOUN
dpc-1595	251	33	of	of	ADP
dpc-1595	251	34	psoriasis	psoriasis	NOUN
dpc-1595	251	35	vulgaris	vulgaris	NOUN
dpc-1595	251	36	in	in	ADP
dpc-1595	251	37	sweden	sweden	PROPN
dpc-1595	251	38	.	.	PUNCT
dpc-1595	251	39	 	 	SPACE
dpc-1595	252	1	acta	acta	PROPN
dpc-1595	252	2	derm	derm	PROPN
dpc-1595	252	3	venereol	venereol	NOUN
dpc-1595	252	4	.	.	PUNCT
dpc-1595	253	1	2019;99(4):393	2019;99(4):393	NUM
dpc-1595	253	2	-	-	SYM
dpc-1595	253	3	399	399	NUM
dpc-1595	253	4	.	.	PUNCT
dpc-1595	254	1	doi	doi	NOUN
dpc-1595	254	2	:	:	PUNCT
dpc-1595	254	3	10.2340/00015555	10.2340/00015555	NUM
dpc-1595	254	4	-	-	SYM
dpc-1595	254	5	3112	3112	NUM
dpc-1595	254	6	.	.	PUNCT
dpc-1595	255	1	pmid	pmid	NOUN
dpc-1595	255	2	:	:	PUNCT
dpc-1595	255	3	30628631	30628631	NUM
dpc-1595	255	4	.	.	PUNCT
dpc-1595	256	1	20	20	NUM
dpc-1595	256	2	.	.	PUNCT
dpc-1595	257	1	gerdes	gerdes	PROPN
dpc-1595	257	2	s	s	PROPN
dpc-1595	257	3	,	,	PUNCT
dpc-1595	257	4	velasco	velasco	PROPN
dpc-1595	257	5	m	m	PROPN
dpc-1595	257	6	,	,	PUNCT
dpc-1595	257	7	wu	wu	PROPN
dpc-1595	257	8	jj	jj	PROPN
dpc-1595	257	9	,	,	PUNCT
dpc-1595	257	10	hubo	hubo	PROPN
dpc-1595	257	11	m	m	PROPN
dpc-1595	257	12	,	,	PUNCT
dpc-1595	257	13	veverka	veverka	PROPN
dpc-1595	257	14	ka	ka	PROPN
dpc-1595	257	15	.	.	PROPN
dpc-1595	257	16	calcipotriol	calcipotriol	PROPN
dpc-1595	257	17	/	/	SYM
dpc-1595	257	18	betamethasone	betamethasone	PROPN
dpc-1595	257	19	dipropionate	dipropionate	PROPN
dpc-1595	257	20	aerosol	aerosol	NOUN
dpc-1595	257	21	foam	foam	NOUN
dpc-1595	257	22	for	for	ADP
dpc-1595	257	23	the	the	DET
dpc-1595	257	24	treatment	treatment	NOUN
dpc-1595	257	25	of	of	ADP
dpc-1595	257	26	psoriasis	psoriasis	NOUN
dpc-1595	257	27	vulgaris	vulgaris	NOUN
dpc-1595	257	28	:	:	PUNCT
dpc-1595	257	29	a	a	DET
dpc-1595	257	30	review	review	NOUN
dpc-1595	257	31	of	of	ADP
dpc-1595	257	32	real	real	ADJ
dpc-1595	257	33	-	-	PUNCT
dpc-1595	257	34	world	world	NOUN
dpc-1595	257	35	evidence	evidence	NOUN
dpc-1595	257	36	(	(	PUNCT
dpc-1595	257	37	rwe	rwe	PROPN
dpc-1595	257	38	)	)	PUNCT
dpc-1595	257	39	.	.	PUNCT
dpc-1595	258	1	j	j	PROPN
dpc-1595	258	2	dermatolog	dermatolog	PROPN
dpc-1595	258	3	treat	treat	NOUN
dpc-1595	258	4	.	.	PUNCT
dpc-1595	259	1	2020;jan	2020;jan	NUM
dpc-1595	259	2	28;1	28;1	NUM
dpc-1595	259	3	-	-	SYM
dpc-1595	259	4	11	11	NUM
dpc-1595	259	5	.	.	PUNCT
dpc-1595	260	1	doi	doi	NOUN
dpc-1595	260	2	:	:	PUNCT
dpc-1595	260	3	10.1080/09546634.2020.1717417	10.1080/09546634.2020.1717417	NUM
dpc-1595	260	4	.	.	PUNCT
dpc-1595	261	1	pmid	pmid	NOUN
dpc-1595	261	2	:	:	PUNCT
dpc-1595	261	3	31986945	31986945	NUM
dpc-1595	261	4	.	.	PUNCT
dpc-1595	262	1	21	21	NUM
dpc-1595	262	2	.	.	X
dpc-1595	262	3	amat	amat	NOUN
dpc-1595	262	4	-	-	PUNCT
dpc-1595	262	5	samaranch	samaranch	NOUN
dpc-1595	262	6	v	v	NOUN
dpc-1595	262	7	,	,	PUNCT
dpc-1595	262	8	puig	puig	PROPN
dpc-1595	262	9	l.	l.	PROPN
dpc-1595	262	10	safety	safety	PROPN
dpc-1595	262	11	of	of	ADP
dpc-1595	262	12	calcipotriene	calcipotriene	NOUN
dpc-1595	262	13	and	and	CCONJ
dpc-1595	262	14	betamethasone	betamethasone	NOUN
dpc-1595	262	15	dipropionate	dipropionate	PROPN
dpc-1595	262	16	foam	foam	NOUN
dpc-1595	262	17	for	for	ADP
dpc-1595	262	18	the	the	DET
dpc-1595	262	19	treatment	treatment	NOUN
dpc-1595	262	20	of	of	ADP
dpc-1595	262	21	psoriresearch	psoriresearch	NOUN
dpc-1595	262	22	|	|	ADV
dpc-1595	262	23	dermatol	dermatol	ADJ
dpc-1595	262	24	pract	pract	NOUN
dpc-1595	262	25	concept	concept	NOUN
dpc-1595	262	26	.	.	PUNCT
dpc-1595	263	1	2021;11(3):e2021056	2021;11(3):e2021056	NUM
dpc-1595	263	2	9	9	NUM
dpc-1595	263	3	asis	asis	NOUN
dpc-1595	263	4	.	.	PUNCT
dpc-1595	263	5	 	 	SPACE
dpc-1595	263	6	expert	expert	ADJ
dpc-1595	263	7	opin	opin	NOUN
dpc-1595	263	8	drug	drug	NOUN
dpc-1595	263	9	saf	saf	PROPN
dpc-1595	263	10	.	.	PUNCT
dpc-1595	263	11	2020;19(4):423	2020;19(4):423	NUM
dpc-1595	263	12	-	-	PUNCT
dpc-1595	263	13	432	432	NUM
dpc-1595	263	14	.	.	PUNCT
dpc-1595	264	1	doi	doi	NOUN
dpc-1595	264	2	:	:	PUNCT
dpc-1595	264	3	10.1080/14740338.2020.1749594	10.1080/14740338.2020.1749594	NUM
dpc-1595	264	4	.	.	PUNCT
dpc-1595	265	1	pmid	pmid	NOUN
dpc-1595	265	2	:	:	PUNCT
dpc-1595	265	3	32243212	32243212	NUM
dpc-1595	265	4	.	.	PUNCT
dpc-1595	266	1	22	22	NUM
dpc-1595	266	2	.	.	PUNCT
dpc-1595	267	1	røpke	røpke	PROPN
dpc-1595	267	2	m	m	PROPN
dpc-1595	267	3	,	,	PUNCT
dpc-1595	267	4	bulai	bulai	PROPN
dpc-1595	267	5	livideanu	livideanu	VERB
dpc-1595	267	6	c	c	NOUN
dpc-1595	267	7	,	,	PUNCT
dpc-1595	267	8	kaldate	kaldate	ADJ
dpc-1595	267	9	r	r	NOUN
dpc-1595	267	10	,	,	PUNCT
dpc-1595	267	11	snel	snel	PROPN
dpc-1595	267	12	a	a	PROPN
dpc-1595	267	13	,	,	PUNCT
dpc-1595	267	14	paul	paul	PROPN
dpc-1595	267	15	c.	c.	PROPN
dpc-1595	267	16	changes	change	VERB
dpc-1595	267	17	in	in	ADP
dpc-1595	267	18	interleukin-17a	interleukin-17a	PROPN
dpc-1595	267	19	,	,	PUNCT
dpc-1595	267	20	macrophage	macrophage	NOUN
dpc-1595	267	21	-	-	PUNCT
dpc-1595	267	22	derived	derive	VERB
dpc-1595	267	23	chemokine	chemokine	ADJ
dpc-1595	267	24	and	and	CCONJ
dpc-1595	267	25	adiponectin	adiponectin	NOUN
dpc-1595	267	26	following	follow	VERB
dpc-1595	267	27	treatment	treatment	NOUN
dpc-1595	267	28	of	of	ADP
dpc-1595	267	29	psoriasis	psoriasis	NOUN
dpc-1595	267	30	with	with	ADP
dpc-1595	267	31	calcipotriol	calcipotriol	PROPN
dpc-1595	267	32	plus	plus	CCONJ
dpc-1595	267	33	betamethasone	betamethasone	PROPN
dpc-1595	267	34	dipropionate	dipropionate	PROPN
dpc-1595	267	35	aerosol	aerosol	NOUN
dpc-1595	267	36	foam	foam	NOUN
dpc-1595	267	37	:	:	PUNCT
dpc-1595	267	38	results	result	NOUN
dpc-1595	267	39	from	from	ADP
dpc-1595	267	40	the	the	DET
dpc-1595	267	41	psoable	psoable	PROPN
dpc-1595	267	42	study	study	NOUN
dpc-1595	267	43	.	.	PUNCT
dpc-1595	267	44	 	 	SPACE
dpc-1595	268	1	br	br	PROPN
dpc-1595	268	2	j	j	PROPN
dpc-1595	268	3	dermatol	dermatol	NOUN
dpc-1595	268	4	.	.	PUNCT
dpc-1595	269	1	2018;178(1):e33	2018;178(1):e33	NOUN
dpc-1595	269	2	-	-	PUNCT
dpc-1595	269	3	e34	e34	NOUN
dpc-1595	269	4	.	.	PUNCT
dpc-1595	270	1	doi	doi	NOUN
dpc-1595	270	2	:	:	PUNCT
dpc-1595	270	3	10.1111/	10.1111/	NUM
dpc-1595	270	4	bjd.15814	bjd.15814	NOUN
dpc-1595	270	5	.	.	PUNCT
dpc-1595	271	1	pmid	pmid	NOUN
dpc-1595	271	2	:	:	PUNCT
dpc-1595	271	3	28722136	28722136	NUM
dpc-1595	271	4	.	.	PUNCT
dpc-1595	272	1	23	23	NUM
dpc-1595	272	2	.	.	PUNCT
dpc-1595	273	1	queille	queille	NOUN
dpc-1595	273	2	-	-	PUNCT
dpc-1595	273	3	roussel	roussel	PROPN
dpc-1595	273	4	c	c	PROPN
dpc-1595	273	5	,	,	PUNCT
dpc-1595	273	6	nielsen	nielsen	PROPN
dpc-1595	273	7	j	j	PROPN
dpc-1595	273	8	,	,	PUNCT
dpc-1595	273	9	lacour	lacour	PROPN
dpc-1595	273	10	jp	jp	NOUN
dpc-1595	273	11	.	.	PUNCT
dpc-1595	273	12	vasoconstrictor	vasoconstrictor	NOUN
dpc-1595	273	13	potency	potency	NOUN
dpc-1595	273	14	of	of	ADP
dpc-1595	273	15	fixed	fix	VERB
dpc-1595	273	16	-	-	PUNCT
dpc-1595	273	17	dose	dose	NOUN
dpc-1595	273	18	combination	combination	NOUN
dpc-1595	273	19	calcipotriol	calcipotriol	NOUN
dpc-1595	273	20	(	(	PUNCT
dpc-1595	273	21	50	50	NUM
dpc-1595	273	22	μg	μg	PROPN
dpc-1595	273	23	/	/	SYM
dpc-1595	273	24	g	g	NOUN
dpc-1595	273	25	)	)	PUNCT
dpc-1595	273	26	and	and	CCONJ
dpc-1595	273	27	betamethasone	betamethasone	PROPN
dpc-1595	273	28	dipropionate	dipropionate	PROPN
dpc-1595	273	29	(	(	PUNCT
dpc-1595	273	30	0.5	0.5	NUM
dpc-1595	273	31	mg	mg	PROPN
dpc-1595	273	32	/	/	SYM
dpc-1595	273	33	g	g	NOUN
dpc-1595	273	34	)	)	PUNCT
dpc-1595	273	35	cutaneous	cutaneous	ADJ
dpc-1595	273	36	foam	foam	NOUN
dpc-1595	273	37	versus	versus	ADP
dpc-1595	273	38	other	other	ADJ
dpc-1595	273	39	topical	topical	ADJ
dpc-1595	273	40	corticosteroids	corticosteroid	NOUN
dpc-1595	273	41	used	use	VERB
dpc-1595	273	42	to	to	PART
dpc-1595	273	43	treat	treat	VERB
dpc-1595	273	44	psoriasis	psoriasis	NOUN
dpc-1595	273	45	vulgaris	vulgaris	NOUN
dpc-1595	273	46	.	.	PUNCT
dpc-1595	273	47	 	 	SPACE
dpc-1595	274	1	j	j	PROPN
dpc-1595	274	2	dermatolog	dermatolog	NOUN
dpc-1595	274	3	treat	treat	NOUN
dpc-1595	274	4	.	.	PUNCT
dpc-1595	275	1	2019;30(6):529	2019;30(6):529	NUM
dpc-1595	275	2	-	-	SYM
dpc-1595	275	3	533	533	NUM
dpc-1595	275	4	.	.	PUNCT
dpc-1595	275	5	doi	doi	NOUN
dpc-1595	275	6	:	:	PUNCT
dpc-1595	275	7	10.1080/09546634.2018.1529385	10.1080/09546634.2018.1529385	NUM
dpc-1595	275	8	.	.	PUNCT
dpc-1595	276	1	pmid	pmid	NOUN
dpc-1595	276	2	:	:	PUNCT
dpc-1595	276	3	30582717	30582717	NUM
dpc-1595	276	4	.	.	PUNCT